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Summary  
 
Dependent opioid users, especially those who inject heroin, suffer far increased morbidity and 
mortality compared to the general population. Maintenance treatment with long-acting 
opioids, in Norway called medication assisted rehabilitation, is the most widely used 
treatment for opioid dependence in Norway and worldwide. Studies from several countries 
have shown reduced mortality during opioid maintenance treatment (OMT). Systematic 
studies on the impact of OMT on somatic morbidity have, however, been scarce. 
  
In this thesis findings from two cohort studies investigating the size of acute and subacute 
somatic morbidity among dependent opioid users – prior to, during and after interruption of 
OMT – are presented. Disease incidents were divided into three main categories: drug-related, 
non-drug-related and injuries and drug-related incidents were divided into the sub-categories 
overdose, injecting-related and “other”. In Study 1 (Paper 1), comprising 35 OMT patients 
from Gjøvik municipality, the volume of treatment in hospitals, by general practitioners (GPs) 
and in emergency wards while patients were receiving OMT was compared to the out-of-
treatment period. In Study 2 (Paper 2 and Paper 3), comprising 200 OMT patients from the 
counties Hedmark and Oppland, only hospital treatment was assessed, and disease incidents 
before, during and after OMT were compared. How acute somatic morbidity before, during 
and after OMT was influenced by various patient characteristics was also examined in this 
study. 
 
Both studies showed a substantial reduction in acute drug-related treatment episodes during 
OMT compared to the out-of-treatment period. In Study 1 a 62% reduction in total drug-
related incidents leading to treatment in hospitals, emergency wards and by GPs was found, 
while injecting-related episodes were reduced by 70%, both findings were statistically 
significant. Non-drug-related episodes and injuries did not show statistically significant 
changes. Treatment episodes out of OMT were more often related to drug use (62%) than 
during OMT (36%). GPs treated a greater part of the disease incidents while patients were in 
maintenance treatment (40%) than out of treatment (25%). Both these findings were 
statistically significant. 
 
 14 
In Study 2 the out-of-OMT period was divided in time before the first admission to OMT and 
time out of treatment (one or consecutive periods) after the first OMT period. We found a 
76% reduction in total drug-related acute and subacute somatic disease incidents leading to 
hospital treatment during compared to before OMT. The reduction in injecting-related 
incidents was 83%, in overdoses 64% and 81% in other drug-related incidents; all these 
findings were statistically significant. Patients with ongoing drug-taking during OMT showed 
less reduction than those not using drugs, but even among these the reduction was statistically 
significant. Non-drug-related episodes were 35 % more frequent during OMT than before 
(statistically significant) while injuries were unchanged. 
 
Paper 3 focuses on the 25 % of the patients who interrupted their OMT during the observation 
period. 85 % of the interrupters were unstable and taking drugs when leaving OMT, hence the 
great majority of the interrupters in this sample left treatment because of treatment problems. 
The interrupter group showed less reduction than the non-interrupters in drug-related 
treatment episodes during OMT compared to the pre-OMT period, but the reduction was still 
significant. The first year after leaving OMT the interrupters showed a substantial and 
statistically significant increase – both compared to the during-OMT and the prior-to-OMT 
periods – in drug-related disease incidents, especially the first months, and for overdoses 
especially the first four weeks.  
 
Conclusion 
The two studies demonstrate a considerable reduction in drug-related acute and subacute 
somatic disease incidents leading to health service treatment during OMT. This holds not only 
for patients achieving stable social rehabilitation without problem use of drugs and alcohol 
but even for the group with ongoing problem behaviour and drug-taking. This demonstrates 
the overall health-related benefit associated with OMT. Among OMT interrupters acute and 
subacute drug-related somatic morbidity is substantially increased after interruption of 
maintenance treatment, especially the first months. This should have implications for how to 
treat patients not reaching stable drug-free rehabilitation within OMT programs.  
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Sammendrag  
 
Opioidavhengige, særlig de som injiserer heroin, har langt høyere sykelighet og dødelighet 
enn befolkningen som helhet. Substitusjonsbehandling med langtidsvirkende opioider, i 
Norge kalt legemiddelassistert rehabilitering ved opioidavhengighet (LAR), er den mest 
utbredte behandlingsform for opioidavhengighet i Norge og ellers i verden. Studier fra mange 
land har vist at substitusjonsbehandling reduserer dødeligheten. Hvordan LAR påvirker 
sykeligheten er imidlertid lite systematisk studert. 
 
I denne avhandlingen presenteres funn fra to kohortstudier der omfanget av akutte og 
subakutte somatiske sykdomstilfeller hos opioidavhengige før, under og etter avsluttet LAR 
ble studert. Bare sykdomstilfeller som førte til behandling i helsevesenet ble inkludert og de 
ble delt i tre hovedgrupper, rusrelaterte og ikke-rusrelaterte tilfeller og skader. De rusrelaterte 
tilfellene ble delt i undergruppene overdoser, injiseringsrelaterte og ”andre”. I den Studie 1 
(Artikkel 1), som omfattet 35 LAR-pasienter fra Gjøvik kommune, ble behandling i sykehus, 
hos allmennleger og ved legevakter studert og omfang av behandling mens pasientene var i 
LAR ble sammenlignet med tiden de ikke var i LAR.  I Studie 2 (Artikkel 1 og Artikkel 2), 
som omfattet 200 LAR-pasienter fra Oppland og Hedmark fylker, så vi bare på 
sykehusbehandling, og behandling før, under og etter LAR ble sammenlignet. I denne studien 
så vi også på hvordan ulike egenskaper hos pasientene påvirket forekomsten av 
sykdomsepisoder før, under og etter LAR.   
 
I begge studiene ble det påvist en betydelig reduksjon i akutte rusrelaterte sykdomstilfeller 
mens pasientene var i LAR sammenlignet med tiden de ikke mottok LAR-behandling. I 
Studie 1 var den samlede reduksjonen av rusrelaterte tilfeller 62% og reduksjonen i 
injiseringsrelaterte tilfeller var 70%. Begge disse funnene var statistisk signifikante. Tilfeller 
uten relasjon til rus og skader viste ikke signifikant endring. Sykdomstilfeller utenfor LAR 
var oftere rusrelaterte (62%) enn i LAR (36%).  Allmennlegene behandlet en større andel av 
sykdomstilfellene når pasientene var i LAR (40%) enn når de ikke var i LAR (25%). Begge 
disse funnene var statistisk signifikante. 
 
I Studie 2 ble tiden utenfor LAR delt i tid før den første behandlingsperioden i LAR og tid 
utenfor LAR (en eller flere perioder) etter den første LAR-perioden. Reduksjonen i antall 
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akutte og subakutte rusrelaterte somatiske sykdomsepisoder som medførte sykehusbehandling 
var 76% under LAR-behandling sammenlignet med før LAR. Reduksjonen i 
injiseringsrelaterte tilfeller var 83%, i overdoser 64% og i andre rusrelaterte tilfeller 81%. Alle 
disse funnene var statistisk signifikante. Reduksjonen blant pasienter som fortsatte å bruke 
rusmidler mens de var i LAR var mindre enn blant dem som var rusfrie, men reduksjonen var 
likevel statistisk signifikant blant den firedelen som ruset seg mest mens de var i LAR. Ikke-
rusrelaterte sykdomstilfeller økte med 35 % (statistisk signifikant) mens omfanget av skader 
ikke endret seg.     
 
Artikkel 3 har fokus på de 25 % av pasientene som avbrøt behandlingen i løpet av 
observasjonsperioden.  Av disse ble bare 15 % ansett som stabile og rusfrie da de forlot LAR, 
resten var ustabile og brukte rusmidler. For det store flertallet som avbrøt LAR, skyldtes altså 
dette problemer i behandlingen. Ved sammenligning av perioden i LAR med perioden før 
behandling, viste avbruddsgruppen en mindre, men likevel statistisk signifikant, reduksjon i 
rusrelaterte tilfeller enn gruppen uten avbrudd. Det første året etter avbrudd i behandlingen 
opplevde avbruddsgruppen en stor økning i rusrelaterte sykdomstilfeller, særlig de første 
månedene, og for overdoser særlig de første fire ukene.  
 
Konklusjon 
De to studiene som danner grunnlaget for denne avhandlingen, viser at akutt og subakutt 
somatiske sykelighet blir betydelig redusert mens pasientene er i LAR. Dette gjelder ikke bare 
for dem som oppnår stabil sosial rehabilitering og rusfrihet, men også for pasienter med 
vedvarende problematferd og rusmiddelbruk i LAR. Blant dem som avbryter LAR, øker den 
akutte rusrelaterte sykeligheten kraftig etter avbrudd i behandlingen, særlig de første 
månedene. Dette bør ha betydning for hvordan pasienter som ikke oppnår stabil rusfrihet, skal 
behandles i LAR.  
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Page 25 last three lines: “Overdoses due to methadone and buprenorphine show the same age 
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1 Introduction 
1.1 Illicit opioid use – size and consequences 
Although non-medical use of opium has been known for centuries and illicit use of opiates 
like morphine and heroin has been seen for more than a century, the “modern illicit opioid 
problem” mainly related to heroin use has evolved during the last fifty years to become a 
major societal and public health problem worldwide. The global production of heroin has 
more than doubled since 19851. United Nations World Drug Report 2010 estimated that 
between 13 and 22 million people globally used illicit opioids in 2008, i.e. between 0.3% and 
0.5% of the world’s population aged 15 – 64. The overall heroin use and the related health 
problems in Western and Central Europe is assessed as stable2,3. In Norway the number of 
problem heroin users (heroin users complying with the ICD-10 diagnostic criteria for harmful 
opioid use or opioid dependence4) was estimated to about 9 500 in 2008 including about ¼ of 
the patients in the national opioid maintenance treatment (OMT) programme (the rest of the 
OMT patients were not reckoned as present problem heroin users), and about 8 000 of these 
problem users were injecting5. In 2009 the total number of injecting drug users (IDU) in 
Norway was estimated to between 8 700 – 12 3006.  
 
Non-medical use of prescription opioid drugs is also an increasing problem, not least in North 
America7. This alternative path into opioid dependence may be of increasing importance8. 
 
Problem drug users often fail to obtain and sustain an ordinary social life and private 
economy. They often drop out of education, many have minimal occupational experience and 
are unable to stay in ordinary employment and are thus frequently dependent on social 
security benefits or disability pension. World Health Organization (WHO) estimated the size 
of Disability Adjusted Life Years (the number of years lost due to ill-health, disability or early 
death) attributed to illicit drug use to 6.9 millions in 20009, and use of illicit drugs is ranked 
eighth among causes of disease, death and disability in developed regions of the world10. 
Problem drug use is also closely related to criminality and drug trafficking. Expenses for 
addiction treatment and health services related to mental and physical comorbidity are 
substantial. Equally important are the human costs for the individual dependent drug user, 
their families and close networks. 
 
 20 
1.2 Opioid Dependence 
Drug-dependence – general aspects 
Drug dependence is a complex phenomenon involving elements of choice (rational/informed 
or irrational/ill-informed), habit, conditioning and learning11. Specific changes in brain 
functions related to repeated and prolonged use of potentially addictive psychoactive 
substances seem to play a fundamental role in development of drug dependence. In addition to 
specific characteristics associated with single drugs or drug classes (like opioids), addictive 
drugs have in common the ability to activate the mesocorticolimbic system, particularly the 
ventral tegmental area, nucleus accumbens, amygdala and prefrontal cortex mainly via 
dopaminergic pathways. This system constitutes a common pathway through which addictive 
drugs mediate their reinforcing effects often called the “reward circuit of the brain” or the 
“neurocircuitry of addiction”12,13.  
 
In an evolutionary perspective the reward system can be seen as a system that has evolved to 
reinforce behaviours favourable for survival and reproduction14,15. Endogenous opioids, like 
endorphins and enkephalins, activate opioid receptors of dopaminergic neurons in the 
mesocorticolimbic system, leading to perceived pleasure and well-being. During activities, as 
eating, physical exercise or reproductive activities like sex and childcare, the reward system is 
activated by endogenous opioids. Hence, evolutionary favourable activities are rewarded and 
reinforced. However, when the reward system is stimulated, not by natural activities, but by 
drugs acting directly on the mesocorticolimbic system and to which humans are not adapted 
through evolutionary and/or environmental history, this leads to supraphysiological activation 
creating stimuli more salient and powerful than natural environmental stimuli16.  
 
Activation of the “reward circuit” by psychoactive drugs leads to a feeling of pleasure and 
euphoria, referred to as “liking” of the drug. However, according to the incentive sensitization 
theory, repeated drug stimulation of the reward circuit will lead to neuroadaptation and 
tolerance to the drug (decreasing effect of a given dose) with less reward effect12,13,17. 
Simultaneously, the incentive motivation to get the drug (craving) increases, resulting in less 
“liking” and stronger “wanting”18,19. With prolonged sensitization of the reward system, the 
motivational changes are maintained (“learned”) through modifications of transcription 
mechanisms regulating the gene expression in the brain’s reward system. This may have long-
lasting effects even after prolonged abstinence from the drug, which may explain why 
addictive behaviours tend to relapse18-20. 
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The drug dependence syndrome is in ICD-104 defined as “a cluster of behavioural, cognitive, 
and physiological phenomena that develop after repeated substance use and that typically 
include a strong desire to take the drug, difficulties in controlling its use, persisting in its use 
despite harmful consequences, a higher priority given to drug use than to other activities and 
obligations, increased tolerance, and sometimes a physical withdrawal state.” 
 
Addictive drug behaviour is thus characterized by “difficulties in controlling its use, persisting 
in its use despite harmful consequences” and is “fundamentally about compulsive 
behaviour”21. The dependent individual continues drug-taking in spite of awareness of the 
harmful consequences and a desire to stop drug-taking. It is essential to keep this compulsive 
character of addictive drug behaviour in mind in the study of health-related risk-taking and 
drug-related morbidity among problem drug users. 
 
The opioid system 
Opioids constitute a group of substances acting on opioid receptors12,13. Within the opioid 
group are opiates, the natural alkaloids found in the dried latex from the opium poppy 
(Papaver somniferum) called opium; e.g. morphine. Substances synthesized from these 
alkaloids, such as heroin and oxycondone, are sometimes classified as opiates, other times 
simply as semi-synthetic opioids. Substances acting on opioid receptors but not derived from 
opiates are classified as synthetic opioids; this group contains several sub-categories and 
includes a great number of substances with medical use. Finally, the body produces several 
substances acting on the opioid receptors, as endorphins and enkephalins, categorised as 
endogenous opioids22.  
 
Opioid effects  
Opioid receptors are found in the central nervous system (CNS), the peripheral nervous 
system, the gastrointestinal tract and within cells of the immune system22,23. There are three 
main types of opioid receptors (delta (δ), kappa (κ) and mu (μ) with several subtypes) that 
show characteristic patterns of distribution and mediate various biological effects. The μ-
receptor mediates most of the analgesic effects and also contributes to the adverse effects of 
sedation and respiratory depression and plays a key role in development of opioid 
dependence12.  
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Opioids have unique analgesic qualities, which make them indispensable in modern medicine. 
Besides, opioids have a wide range of effects and side-effects24. Among these effects are 
sedation, euphoria, suppression of coughing and an anti-diarrhoea-effect due to reduced GI-
mobility. The most severe adverse effects are respiratory depression, and risk for development 
of tolerance and dependence.  
 
Heroin 
Heroin (diacetylmorphine) is the most frequently used illicit opioid drug. When taken orally, 
it undergoes a first-pass effect and is metabolized into morphine. After systemic 
administration heroin has a very short half-life in blood, less than 10 minutes in humans25 and 
is very quickly metabolized into the active metabolite 6-monoacetylmorphine (6-MAM) with 
a half-life of 30 minutes26 which is further metabolized into morphine and its active 
metabolite morphine-6-glucuronide. Both morphine and 6-MAM pass the blood-brain barrier 
easily, unlike heroin. Heroin thus acts as a prodrug, and its pharmacological effects are 
mediated through its active metabolites 6-MAM and morphine. Both morphine and 6-MAM 
have opioid effects, but recent studies identify 6-MAM as the metabolite mainly responsible 
for the acute heroin effects26,27. Heroin has a very strong ability to induce dependence and 
this, combined with the harmful effects related to respiratory depression (risk of fatal 
overdose) and non-medical injecting, is why heroin, especially when injected, is regarded as 
the most harmful of illicit drugs28. 
 
1.3 Mortality and health problems related to opioid dependence  
Dependent opioid users suffer increased physical and mental health problems29-33, partly 
related to the adverse toxic effects of the drugs, partly to the preparation of drugs and the 
route of administration and partly due to problematic general life conditions34-37. This brief 
survey will focus on the somatic comorbidity of opioid dependence. 
 
Mortality 
Illicit drug use and its related comorbidity may be regarded as an epidemic with specific 
historical and regional characteristics. Mortality rates are heavily influenced by what kind of 
illicit drugs and what route of drug administration are dominating within a country or a 
region. Drug-takers learn their drug habits and preferences from other drug users and the drug 
use patterns within delimited drug cultures are rather resistant to change and tend to stay 
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stable over time38-40. Further, death rates are influenced by characteristic national or regional 
disease patterns among drug takers and in particular among drug injectors. Especially 
prevalence of human immunodeficiency virus (HIV) varies much between parts of the world 
and within regions, e.g. within Europe2,3,41. Finally, the epidemic is characterised by the 
interaction between the epidemic phenomenon (illicit drug use and related problems) and the 
societal and ecological responses. Hence, estimations and interpretations of drug-related 
mortality and comparison between countries and regions within countries are combined with 
considerable methodological challenges and should be interpreted with caution42.  
 
Nevertheless, illicit drug use is indisputably associated with increased mortality43,44. In the 
year 2000, 197 000 persons (74% male) died of causes attributable to illicit drug use9. Based 
on data from the major cohort studies until 2007, the mean age at death was estimated to 
approximately 30 years. Standardized mortality ratios (SMR), i.e. the age-adjusted ratio 
between mortality in a specific group compared to the entire population, vary between 5 and 
30. More men than women develop drug dependence, which is the main reason why men 
dominate among drug-related deaths. Mortality rates among drug dependent males are slightly 
higher than in the similar female group43. The gender specific SMRs, however, are markedly 
higher for dependent women reflecting the lower baseline mortality among women in the 
examined age groups of interest45-48. Predictors of mortality are drug class, injecting drug use, 
polydrug use (especially heavy alcohol use and benzodiazepine use in combination with 
opioids), increasing age, length of illicit drug use, not receiving treatment, poorer somatic and 
mental health and poorer social functioning43,44,49-52. 
 
Problem opioid use and especially injecting of heroin is associated with the highest mortality. 
Cohort studies comparing death rates between drug classes, consistently find higher death 
rates among primary opioid users43,53-57. In a recent meta-analysis based on 58 prospective 
studies reporting mortality rates in opioid-dependent samples Degenhardt and colleagues 
reported a pooled all-cause crude mortality rate (CMR) of 2,1 per 100 patient years (95% 
confidence interval (CI) 1.9 – 2.3) and a SMR of 14.7 (95% CI 12.8 – 16.5). Men had higher 
CMR and lower SMR than women and out-of-treatment periods had higher mortality risk than 
in-treatment periods, with a pooled relative risk of 2.4 (95% CI 1.8 – 3.2). Overdose was the 
most common cause of death and death rates increased with the proportion of sample 
injecting44. 
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In Norway, the majority of problem heroin users inject the drug58. In 2008 it was estimated 
that 67% of all problem heroin users injected only, 15% smoked only and 18% combined 
smoking and injecting5. This is probably one of the main reasons why overdose mortality 
rates are high in Norway. With a peak in 2001 of 405 drug-related deaths, the number has 
stabilized around 250 the last years, still one of the highest drug-related mortality rates in 
Europe59. Crude mortality rate at a HIV test centre for IDUs in Oslo 1985 – 1991 was found 
to be 2.4 per 100 person years, and the standardized mortality ratio was 3160. A 20-year 
prospective study of mortality and causes of death among all hospitalized opioid addicts 
treated for self-poisoning or admitted for voluntary detoxification in Oslo 1980-81 showed an 
overall SMR of 23.6. Fifty-three per cent of the deaths were classified as due to “drug 
dependence”. SMRs were 5.4 for cardiovascular diseases, 4.3 for cancer, 13.2 for accidents, 
10.7 for suicides and 28.6 for other violent deaths showing an increased risk of death also for 
reasons other than overdose. For “other diseases” including drug dependence and overdose 
the SMR was 65.861.  
 
Opioid overdose 
Overdose is the most frequent cause of death among problem opioid users and most overdoses 
are due to heroin.  
 
Mechanism of overdose 
The primary mechanism of death and health damage in opioid overdose is opioid-induced 
respiratory depression leading to hypoxia and death62. Hypoxia may cause fatal ischemic 
damage to the brain and other organs63, and may in non-fatal overdoses cause permanent 
sequelae from the CNS64. Nerve entrapment and ischemic lesions to muscle tissue in the 
limbs, resulting in peripheral paralysis of varying permanence and necrosis of muscle tissue 
(rhabdomyolisis), sometimes accompanied by renal failure, are frequent complications to non-
fatal overdoses65.  
 
Toxicology 
Used as analgesic medications in proper professional settings, opioids are relatively non-toxic. 
It is the way in which dependent opioid users use the drugs that is the main cause of opioid-
related health damage, not the drugs as such.   
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Polydrug use is of great importance in relation to opioid overdose. Alcohol is the most 
common concomitant drug and is found in half or more of the fatal cases43,44,66-69. 
Benzodiazepines are found in up to a quarter of fatal cases50,67,68. Alcohol and 
benzodiazepines are also closely connected to methadone and buprenorphine related deaths69-
71.  
 
Route of drug administration 
Heroin is injected, smoked (“heroin chasing”) or snorted. Overdose risk is greatest when the 
drug is injected due to the intravenous bolus effect to the brain, and considerably less when 
smoked41,72,73. Injecting also plays a significant part in methadone and buprenorphine related 
overdose, and deaths due to these drugs are often related to high concentrations following 
injection of oral preparations of these long-acting opioids70,74-76. 
 
Tolerance  
Opioid tolerance disappears relatively quickly when opioid intake ceases12,13. Several 
observational clinical studies have demonstrated that dependent opioid users temporarily 
abstinent during imprisonment experience increased risk of fatal overdose the first weeks after 
release77-79. A similar situation occurs immediately after opioid detoxification80 or after 
discharge from inpatient non-maintenance addiction treatment68,81-83.  
 
Demography and epidemiology  
Most overdose fatalities occur among heroin users with long-lasting drug careers44 that are not 
in treatment at the time of overdose48,66,67,81,84. About three to five per cent of all heroin 
overdoses are fatal according to Australian estimations85, hence the risk of dying from an 
opioid overdose can partly be seen as dependent on the number of risk situations (non-fatal 
overdoses) a person has encountered, i.e. as a question of cumulative risk. Further, some 
studies measuring morphine concentrations in autopsy hair samples report lower morphine 
concentrations than in persons with ongoing heroin use indicating less frequent heroin use 
prior to the fatal overdose86,87, or periods of opioid abstinence immediately prior to fatal 
overdose68,88. Overdoses due to methadone and buprenorphine show the same age profile and 
most such cases occur among patients not in maintenance treatment at the time of overdose 
indicating diversion from OMT programs66,81,84,89-91.  
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Microbial infections related to problem opioid use  
Problem opioid users, and especially those injecting heroin or dispersed opioid tablets, are 
prone to a wide range of microbial infections – which are among the most common and 
severe complications to problem opioid use23,92,93. A description of specific characteristics 
concerning infections among problem opioid users is given below. 
 
Pathogenesis 
Infections within this group are to a great extent complications to non-medical injecting23,92-95. 
Intravenous injecting is usually preferred and most frequent, but injecting drug users often 
lack veins fit for injecting and consequently inject intramuscularly or subcutaneously (“skin-
popping”). This practise is associated with increased risk of skin infections compared to 
intravenous injecting96. Opioid users lacking superficial veins viable for injecting frequently 
use deep veins in the groin and neck, both sites vulnerable for severe infections97,98.  
 
Among drug users the commensal flora often serves as a reservoir for numerous potential 
pathogens which cause most of the bacterial infections within the group. Common bacteria 
like Staphylococcus aureus and Streptococcus species, especially Group A (GAS) may cause 
local and severe invasive infections and are the most common pathogens, followed by 
anaerobic cocci and Gram negative rods92,93. In countries where meticillin resistant 
Staphylococcus aureus (MRSA) are common, these have been found to cause abscesses as 
well as invasive infections92. Licking of needles or skin before injecting may cause potential 
pathogens in the orodental flora to penetrate the skin and provoke local or systemic 
infections99.  
 
Sharing of needles and syringes is the main route of transmission of bloodborne viral 
infections, such as HIV, hepatitis B and hepatitis C within this group100-102. Common use of 
other forms of paraphernalia such as spoons for cooking and cotton filters may also be of 
importance103.  Not only bloodborne viral infections but also bacterial infections such as 
Staphylococcus aureus/MRSA104 may be transmitted via this route.  
 
Drug concomitants and adulterants 
During the preparation and the distribution process, heroin may be diluted with adulterants 
and/or contaminated with microbial agents. Especially clostridial infections are spread in this 
way and are also associated with “skin popping”93. These are rare conditions, but may be very 
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severe. Tetanus outbreaks among IDUs have been reported from several countries and are 
often associated with poor outcome and have been related to contamination of street heroin by 
tetanus sporesError! Reference source not found.. Several outbreaks of wound botulism 
have been linked to contamination of black tar heroin with botulism spores105-107. Necrotizing 
fasciitis caused by clostridial infection have been reported93,108. An extensive outbreak of 
severe soft tissue infection due to clostridial infection (Clostridium novyi), linked to 
contaminated heroin, occurred in Scotland in 2000, with concurrent outbreaks and spreading 
in other European countries, also Norway109. Cases of anthrax due to heroin contamination 
have occurred, also  in Norway110, and a severe outbreak took place in Scotland in 2009 with 
31 cases and 11 deaths111. 
 
Host susceptibilities 
Marginalized living conditions like homelessness or low-standard and overcrowded housing 
conditions may increase the risk for contagious diseases. Poverty, ongoing drug-taking, poor 
dental health and lack of nutritious food may lead to malnutrition and related health problems. 
Polydrug use and generally high levels of somatic and mental comorbidity together with poor 
living conditions often lead to a reduced general state of health92. The oral cavity may also, 
because of poor dental status, be a specific entry port for systemic bacterial infections in this 
group112. The process of ageing is often accelerated among dependent opioid users and early 
aging increases susceptibility to severe infections113,114. 
 
Increased vulnerability to infections may also be related to specific high-risk lifestyles. 
Having unprotected sex with multiple partners and prostitution may increase the risk for 
sexually transmitted diseases115.  
 
Clinical manifestations 
Local skin infections, especially abscesses, are the most common complication to non-
medical opioid injecting and are caused by pathogens within the commensal skin and oral 
flora92,93. Haematogenous seeding or less often local expansion from delimited superficial 
infections may cause localized infections e.g. in the skeletal system like osteomyelitis and 
intervertebral discitis. Intramedullary abscesses and bacterial/septic arthritis are other 
examples of severe bacterial infections due to septic embolism92. Such severe infections may 
in part be related to injecting in high-risk areas like the jugular and femoral veins.  
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Non-medical injecting in superficial veins is associated with complications due to vein 
damage and extravascular drug administration. This may cause deep venous thrombosis and 
lung embolism as well as endovascular infections. Thrombophlebitis may cause sclerosis of 
superficial veins leading to injecting in deep veins in the groin with increased risk for deep 
venous thrombosis116 and septic thrombophlebitis117 or in jugular veins associated with risk 
for neck and intracerebral complications118. Infective endocarditis, septic thrombophlebitis, 
mycotic aneurysms and sepsis are among the most severe complications to non-medical 
injecting92. Endocarditis may be both right- and left-sided119 and the left-sided variant may 
cause septic embolization leading to abscesses e.g. in the brain and spleen. Infective 
endocarditis related to injecting drug use may be polymicrobial120.  
 
Pneumonia and other deep respiratory infections are common in problem drug users. 
Community acquired pneumonia is most often caused by the same bacteria that causes 
pneumonia in patients not using drugs, like Streptococcus pneumoniae, Hemofilus influenzae 
and Staphylococcus aureus92,94,95. Aspiration pneumonia caused by oropharyngeal flora is 
often related to non-fatal overdoses94,95. Septic embolism may cause pneumonia and lung 
abscesses98,121. Such infections are often severe and necessitate hospitalization. Opportunistic 
pulmonary infections like tuberculosis are often associated with HIV infection and are a 
severe and frequent problem among problem drug users in parts of the world92.  
 
Infections with bloodborne viruses transmitted by sharing of drug paraphernalia are frequent 
among injecting drug users. HIV infection is common among IDUs in many countries, but is 
relatively rare in other countries like Australia and Norway100,122,123 while hepatitis B102 and 
hepatitis C93,124 are common worldwide. In Norway, the hepatitis C virus (HCV) antibody 
prevalence among IDUs is assessed to be about 70-80%125  and about ⅔ of these are HCV 
polymerase chain reaction (PCR) positive126. Systemic fungal and parasitic infections are rare 
but severe complications to injecting drug use in patients with or without coincidental HIV 
infection93,127. 
 
1.4 Effects of opioid maintenance treatment 
Opioid maintenance treatment (OMT) was introduced in the United States of America (US) in 
the mid-sixties128 and is presently the most widely used treatment for opioid dependence 
worldwide129. The rationale behind this treatment is that the opioid system in dependent 
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opioid users may be stabilized by continuous supply of high doses of long-acting opioids like 
methadone and buprenorphine. The neuroadaptation and dependence-related CNS changes are 
maintained130, but with stable high-dose supply of the long-acting opioid, the patient reaches a 
steady state without withdrawal or intoxication symptoms. The craving for opioids diminishes 
and use of illicit opioids will stop or at least decrease. Thus, OMT does not cure the opioid 
dependence but may reduce many of its harmful effects and give patients an opportunity to 
benefit from social rehabilitation measures.  
 
OMT is in Norway called “medication assisted rehabilitation” emphasizing that medication is 
part of a broader rehabilitation programme. OMT was started as a nationwide treatment 
programme in Norway in 1998. From the start the programme was high threshold, with social 
rehabilitation as the explicit goal of treatment. The treatment has been high-dose and 
methadone and buprenorphine are used as maintenance medications. Gradually the aim of the 
treatment has shifted from “primary social rehabilitation” towards a combined rehabilitation 
and harm-reduction goal. In the national OMT guidelines from 2010 this is formulated as 
follows: “to help the patient to achieve his or her optimal functional level”131. Retention in 
treatment is high compared to most other countries, but ongoing use of prescribed and illicit 
benzodiazepines and cannabis is considerable, while use of central stimulants and illicit 
opioids and non-medical injecting is low132,133.  
 
As described above, dependent opioid users and especially those injecting heroin, suffer a 
wide variety of health problems. Moreover, the IDU population is also a risk group and a 
“reservoir” for epidemic diseases like HIV/AIDS and hepatitis B and C. Due to social and 
mental problems dependent opioid users may be hard to reach and consequently often do not 
receive appropriate acute care and follow-up for their health problems134.  
 
How then, does OMT influence these health problems? When compared to no treatment or 
non-substitution treatment, reduced use of illegal opioids and less injecting135,136, reduced 
risk-taking behaviour related to blood-borne viral infections during OMT135 and increased 
retention in treatment136 are established in meta-analyses based on randomised controlled 
trials (RCTs). Reduced mortality and criminal activity during OMT have not been shown in 
meta-analyses based on RCTs. However, in cohort studies from several countries substantial 
reduction in mortality in versus out of treatment has been documented41,50,51,91. In 1996 
Caplehorn and colleagues50 estimated the risk of death to a quarter during OMT treatment 
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compared to out of treatment based on studies from the US, Sweden and Germany. 
Concerning the Norwegian OMT programme, Clausen and colleagues have documented 
reduced mortality during OMT89 and Bukten and colleagues reductions in criminal activity137 
in national cohort studies.  
 
Improved somatic health during OMT has been reported in some studies based on 
interviews138 and clinical assessment139 and reduced inpatient care due to infections during 
maintenance treatment has been found140. Still, few studies have examined OMT-related 
somatic health effects and changes in morbidity patterns141. Especially, the knowledge about 
changes in morbidity and health care consumption when dependent opioid users enter 
maintenance treatment is scarce. As increased health problems are among the most severe 
consequences of opioid dependence and problem opioid use, investigation of health effects 
related to maintenance treatment is strongly warranted.  
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 Objectives 2
2.1 Overall research aims 
The overall aim of this thesis was to investigate the effects of OMT on acute and subacute 
somatic comorbidity among dependent opioid users. The term somatic comorbidity was used 
because the fundamental health problem defining the target group was opioid dependence. In 
Paper 1, all acute and subacute somatic disease incidents leading to inpatient or outpatient 
hospital contact, contact with general practitioners (GPs) or emergency wards were examined. 
The study sample was 35 OMT patients in one Norwegian municipality, Gjøvik. In Paper 2 
and Paper 3, only inpatient and outpatient hospital contacts were considered. The study 
sample was 200 OMT patients from two Norwegian counties, Hedmark and Oppland. The 
focus in both studies was delimited to acute and subacute incidents, chronic somatic diseases 
were not assessed unless they led to acute/subacute incidents. Further, in Paper 2 and Paper 3, 
the impact of patient characteristics on rates of different kinds of disease incidents was 
estimated.  
 
2.2 Objectives for each paper 
Paper 1: The objective was to compare health care utilization due to acute and subacute 
somatic disease during versus out of maintenance treatment in a cohort of OMT-patients. The 
hypothesis was that health care consumption would decrease during OMT due to less 
morbidity as a consequence of reduced illicit drug use and injecting. Additional research 
questions were: if such reduction does occur, is it valid only for patients who stay abstinent 
from illicit drugs during OMT or also for those with ongoing drug-taking? And, is there a 
shift in the relative distribution of drug-related and non-drug-related treatment episodes 
during OMT compared to out of treatment? Finally, does the relative distribution of type of 
health care contacts (GP versus hospital) change between in- and out-of-treatment periods?  
 
Paper 2:  The objective was to investigate how acute/subacute somatic comorbidity varies 
before, during and after maintenance treatment (in the paper and the thesis referred to as OMT 
status). The main hypothesis was that somatic morbidity is reduced during treatment and more 
detailed research questions were: what changes in somatic morbidity are found during OMT 
compared to before and after treatment, and what kinds of disease incidents are reduced? And, 
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how do various patient characteristics influence the effect of OMT-status on somatic 
morbidity?  
 
Paper 3: This paper focused on acute/subacute somatic morbidity after interruption of 
maintenance treatment. Important pre- and during-OMT characteristics were compared 
between patients with and without interruption of maintenance treatment including the pre-
OMT rates of various kinds of acute/subacute hospital-treated disease incidents. Further, the 
distribution of such incidents throughout the post-treatment period was examined. The 
research questions were: Do patients with interruption of OMT differ from non-interrupters 
regarding pre- and during-OMT characteristics, indicating increased risk-taking behaviour? 
And, how does the incidence of acute/subacute somatic health problems vary according to 
OMT status (before, during and after treatment) and especially throughout the post- OMT 
period within the group of OMT interrupters?   
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 Material and methods 3
The thesis consists of two studies. Both studies are observational with a longitudinal cohort 
design. Paper 1 relates to the first study, while Paper 2 and Paper 3 relate to the second study. 
Methods and material for each study is described below. 
 
3.1 Study 1 (Paper 1) 
Sample and setting 
Record information from hospitals and from GPs and emergency wards was gathered 
retrospectively. Information on ongoing drug-taking was drawn from the annual status reports 
within the national OMT programme from 2001 onwards, thus these data were prospective. 
This information was collected with informed consent from all participants.  
 
The cohort was established in 2004-5 and consisted of patients from one municipality 
(Gjøvik) in Oppland County, Norway, who were admitted to OMT for the first time between 
1999 and June 2005. By the end of 2005, all 40 patients who had started OMT were still alive 
and in treatment, and 36 consented to participate. Data were not collected for one person, 
rendering 35 participants and a participation rate of 87.5%.  
    
Data sources 
Interview  
Thirty-two of the 35 participants (92%) were interviewed about somatic disease incidents 
before and during OMT, and during out-of-treatment periods. The first author (IS) performed 
all interviews, which were conducted in a GP centre or in the patients’ homes. 
 
Medical records 
Records from emergency wards and somatic departments in local hospital were gathered for 
all participants. Based on interview information about hospital treatment, records from other 
hospitals where the participants reported to have received medical treatment during the 
observation period were requested and all these records were received. All records underwent 
full-text in-depth examination by IS. Ninety-one per cent of requested records from GPs who 
were or had been the patients’ regular GP during the observation period were collected.  
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Annual status reports from the national OMT programme 
For 31 patients (89%) information about ongoing use of illicit drugs and alcohol during OMT, 
based on urinary testing and clinical assessment, was gathered from the annual reports made 
for each OMT patient in Norway since 2001. The annual report scores overall drug use during 
the last four weeks on a five-point scale. In our study we simplified this to a dichotomized 
score for the entire treatment period, differentiating between “problematic” use with severe 
consequences for psychosocial function and “abstinence and non-problematic use” without 
such consequences. 
 
Outcome measures and observation period 
The outcome measures were incidence rates during the in-OMT and out-of-OMT periods of 
acute and subacute somatic disease incidents documented in records from GPs, emergency 
wards and somatic hospital departments. Observation time before and between treatment 
periods were combined as the out-of-treatment period, referred to as “before OMT” in the 
paper, and was defined as the last five years out of treatment (before the first admittance to 
OMT or between treatment periods). Only three of 35 patients had experienced interruption of 
OMT (in total five years), thus “out-of treatment” time was mainly before OMT. As all 
patients were in maintenance treatment at study end-point, there was no “after-OMT-time”. 
The during-OMT period was defined as the first five years during maintenance treatment in 
one or consecutive periods.  
 
Only incidents documented in records were included. Health care contacts due to follow-up of 
chronic disease were not counted, but acute/subacute incidents caused by an underlying 
chronic disorder were counted as a new incident. An incident registered in several records was 
counted as one incident. One incident could lead to more than one contact. Incidents were 
categorised as drug-related (overdoses, injecting-related or other drug-related) or non-drug-
related (infections, injuries, other). Inpatient treatment days and number of outpatient hospital 
contacts were also registered. 
 
Inter-rater agreement 
Inter-rater agreement was estimated according to Cohen’s kappa. The inter-rater reliability on 
whether hospital treatment episodes were drug-related or not (κ =1) and if drug-related, to 
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which category (overdose, injecting-related or other) each episode belonged (κ = 0.82), was 
good.  
 
Statistics 
Wilcoxon signed rank test was used to compare incidence rates during the in-treatment and 
out-of-treatment periods. Pearson chi-square test was used to examine changes in the relative 
distribution of drug-related and non-drug-related incidents during the in- and out-of-treatment 
periods. Fischer’s exact test was used to assess changes in acute health problems during 
treatment versus ongoing drug- and alcohol use during OMT. Pearson chi-square test was 
used to compare changes in type of health service contact (GPs versus hospital) in versus out 
of treatment. 
 
Ethics 
The study was approved by the Regional Committee for Medical Research Ethics and the 
Norwegian Social Science Data Services.  
 
3.2 Study 2 (Paper 2 and Paper 3) 
Sample and setting 
Record information from hospitals was gathered retrospectively. Information on ongoing 
drug-taking, overdoses during OMT and reasons for OMT interruption was drawn from the 
annual status reports within the national OMT programme. This information was gathered 
with informed consent from all participants. Information on patient characteristics was 
gathered from a structured interview (Appendix 1). 
 
The cohort in Study 2 was established in 2007-8 and consisted of OMT patients from 
Oppland county and parts of Hedmark (the municipalities Ringsaker, Hamar and Stange) 
county. The eligibility criteria were 1) having started OMT for the first time between January 
1998 and the end of June 2007 in this area or continued OMT after having moved into the 
area during this period, and 2) having contact with or being known by local health or social 
services at the time of invitation. Information about eligibility criterion 1) was based on 
register information from the national OMT programme. The identity of patients was 
unknown to the research group until consent was obtained; participants were recruited by 
personnel in local health and social treatment services and pharmacies. 
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Out of a total of 319 persons who had started or continued OMT in this area (criterion 1), 38 
had no contact with and were unknown to local heath or social services (criterion 2) and 
assessed ineligible for the study. Among the 281 eligible, 13 who had died before the study 
was started, were included. Among the 268 eligible alive, 187 consented to participate, 81 did 
not, and hence the cohort consisted of a total of 200 persons. The participation rate was 
71.2%, 68.8% among patients in treatment versus 73.7% among those not in treatment when 
recruited. Fifty-one (25.5%) had experienced interruption of OMT at least once (12 more than 
once), and this subgroup is the focus of Paper 3, while the whole cohort is studied in Paper 2.  
 
Data sources 
Three data sources were used: a structured interview, medical record data and data from the 
annual status report on each patient from the national OMT programme. 
 
Interview  
One-hundred-and-thirty-six out of the 187 participants still alive (73%) underwent a 
structured interview with questions on demographic data and education and employment 
history, former hospital treatment and recent drug taking and drug trajectories (modules from 
the EuropASI questionnaire). The interviews were performed by IS (54%) and three students 
(46%) from the University of Oslo. Eighty-five per cent of the interviews were performed 
face to face; 30% by home visits, 29% in different kinds of public institutions (inpatient 
treatment centres, low-threshold day-care centres for drug users, GP offices, prisons), 26% at 
other meeting points (e.g. outdoors in parks or in cafes) and 15% were interviewed by 
telephone. Fifty-one of the participants were not interviewed, some of these were impossible 
to reach by telephone or home visits, and some did not show up on repeated appointments. 
 
Medical records 
In study 1 (Paper 1) between 80 and 85% of all somatic disease incidents that were 
documented in records and assessed as severe lead to hospital treatment during the in-
treatment as well as out-of-treatment periods. Hence, in Study 2 only records from somatic 
hospital departments were examined and this was assessed as sufficient to evaluate changes 
concerning severe somatic morbidity according to OMT status (before-during-after OMT). 
Records from somatic departments in the local hospitals (Innlandet Hospital, which is a 
hospital trust comprising all the hospitals in the two counties Hedmark and Oppland) were 
gathered for all participants. Based on information from these records and from the interview, 
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records from other hospitals where the participants had received treatment, were requested. 
More than 99% of all requested records were gathered and examined. All records underwent 
full-text in-depth examination by IS. 
 
Annual status reports from the national OMT programme 
Data on ongoing drug-taking during OMT were based on data from the annual status report.  
A combined score for polydrug use (illicit/non-prescribed use of opioids, cannabis, 
benzodiazepines and central stimulants) for the whole during-OMT period was estimated 
based on urine tests and clinical observation. Dates for admission to and exit from OMT were 
also drawn from these reports which were available for 183 participants (92%).  
 
Outcome measure 
The outcome measures in Study 2 were incidence rates of acute/subacute somatic disease 
incidents leading to inpatient or outpatient hospital treatment and rates of inpatient days and 
outpatient hospital treatment contacts. As OMT status is a time varying variable, rates were 
estimated according to OMT status, i.e. before, during and after OMT. In Paper 2 and Paper 3 
the disease incidents are referred to as “hospital-treated episodes”, “treatment episodes” or 
just “episodes”. Only episodes documented in hospital records were included. The number of 
treatment episodes and the number of inpatient days and outpatient hospital contacts due to 
these episodes were recorded. Health care contacts due to chronic disease were only included 
if the disease caused an acute incident. Each incident was only registered once even if it was 
registered in records from several hospitals. Incidents were categorised into three main 
groups: drug-related (overdoses, injecting-related and other drug-related incidents), non-drug-
related (infections and others) and injuries. Injecting-related incidents were divided into the 
subgroups deep venous thrombosis/lung embolism, acute hepatitis B and C, local bacterial 
infections, systemic bacterial infections and other injecting-related incidents. Other drug-
related incidents were divided into the subgroups withdrawal-related, impaired general health 
condition, neuromuscular (e.g. rhabdomyolisis or peripheral neural damage) and any “other 
drug related episode” (not overdose or injecting-related). 
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Predictors (patient characteristics) 
The main focus of Study 2 was to examine the impact of maintenance treatment on the 
incidence rates of hospital-treated acute/subacute somatic disease incidents, i.e. to compare 
rates in the periods prior to, during and after OMT.  
 
In Paper 2 interaction (or effect modification) between OMT status (before versus during and 
after versus during OMT) and the following variables were tested: gender, age at OMT start, 
age at heroin debut, years of opioid dependence before OMT start, years of education, years 
of employment, lifetime number of overdoses, having experienced OMT interruption and 
ongoing use of illicit drugs during OMT.  
 
In Paper 3 the following patient characteristics were tested for interaction with incidence rates 
the first post-OMT year versus the pre-OMT period for the group with interrupted treatment: 
gender, age at OMT start, years of employment and education, overdoses during life and 
during OMT, taking or not taking illicit drugs when leaving OMT, illicit drug-taking during 
OMT and having experienced more than one OMT interruption. 
 
Observation period 
The pre-OMT period was defined as the five years previous to the first admission to OMT and 
the during-OMT period as the first five years during maintenance treatment in one or 
consecutive periods. The post-OMT period was defined as the first five years out of treatment 
after the first OMT admission in one or consecutive periods. In Paper 3 post-OMT treatment 
episodes were registered according to the end of the preceding treatment period and divided 
into different post-OMT periods: month one, months two and three, months four to twelve, 
and year two to five (”later post-OMT period”). The total pre-OMT observation time was 
1000 patient years (255 patient years among participants with interrupted treatment), 813 
patient years during OMT (193 among participants with interrupted treatment) and 91 patient 
years after interruption of treatment. The study end-point for each patient was defined as the 
date when the record from the local hospital was collected during 2008/2009.   
 
Inter-rater agreement 
Inter-rater agreement was established in Study 1 (see above).  In Study 2 IS scrutinized all 
full-text records. Treatment episodes considered problematic to categorise were discussed 
between IS and another physician (co-author ER) until consensus was reached.  
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Statistics 
Incidence rates were analyzed by means of a Poisson regression model. Dependencies in the 
data, due to the fact that each participant is measured repeatedly (before – during – after 
OMT), were handled by Generalized Estimating Equations with unstructured working 
correlation and robust variance estimation. With regard to drug-related hospital treatment 
episodes, the possible influence of different patient characteristics on the effect of OMT was 
investigated by including the interaction between OMT and the characteristic in question in 
the model, one by one. Incidence rate ratios with 95% confidence intervals were estimated. 
The significance level was set to 5%. Pearson Chi-Square test (categorical variables) and 
Independent-Samples T-test (continuous variables) were used to compare patient 
characteristics between patients with and without interruption of OMT. All analyses were 
performed in SPSS (version 15, SPSS, Chicago, Ill., USA). 
 
Ethics 
The study was approved by the Regional Committee for Medical Research Ethics and the 
Norwegian Social Science Data Services. Exemption from professional secrecy duty of 
confidentiality for those dead was given by the Norwegian Directorate of Health.    
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4 Results  
4.1 Paper 1  
Paper 1 focuses on differences in somatic health care utilization and morbidity between 
periods in and out of (before and interruption periods) maintenance treatment in a cohort of 35 
OMT patients.  
 
The gender distribution was typical for illicit opioid users, 63% were male. Age at OMT start 
was high (37 years), treatment was high dosage, predominantly with methadone. Nearly all 
participants had HCV antibodies, reflecting injection as the main heroin administration route. 
None had antibodies against HIV. 
 
Two-hundred-and-seventy-eight disease incidents were registered. There was a reduction in 
the total number of incidents treated in hospitals, by GPs or emergency wards by 35% (p = 
0.004) during OMT. Substance-related incidents were reduced by 62% (p<0.001) and among 
these, injecting-related incidents by 70% (p<0.001), while non-fatal overdoses did not show 
statistically significant reductions (p=0.13). Non-substance-related incidents were unchanged 
(p=0.74). Overall inpatient days were reduced by 76% (p = 0.003) while outpatient hospital 
treatment contacts showed a non-significant reduction of 46% (p = 0.06). Incidents were less 
often related to substance use during OMT, 36% compared to 62% out treatment (p<0.001). 
 
Forty per cent of all disease incidents during OMT were documented exclusively by GPs, 
compared with 25% in the out-of-OMT period (p = 0.02). Around 90% of all hospital 
treatment, out of as well as during OMT, took place at the local hospital in Gjøvik. Between 
80 and 85% of all disease incidents assessed as moderate or severe led to hospital treatment 
and were documented in hospital records during as well as out of maintenance treatment (this 
finding is not referred in the paper). 
 
Changes in rates of treatment episodes between in-treatment and out-of-treatment periods 
were compared for nine patients with and 22 patients without problematic substance use 
during OMT. Reduction in injecting-related incidents did not differ significantly between the 
groups. The overall reduction in substance-related treatment episodes was greater for patients 
without problematic drug use, but the finding was not significant in this small sample (p = 
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0.06). The reduction in overall treatment episodes was significantly greater for patients 
without problematic drug use (p = 0.007).  
 
4.2 Paper 2 
Paper 2 focuses on acute and subacute morbidity before, during and after maintenance 
treatment. Six-hundred-and-five treatment episodes were identified before OMT, 310 during 
and 106 after interruption of maintenance treatment. Patient years at risk were 1000 before, 
813 during and 91 after OMT. 
 
The gender distribution was typical for dependent opioid users, ⅔ being male. The age at 
OMT start was high (37 years) and the long mean duration (12 years) of opioid dependence 
before the first OMT admittance reflects the late start of OMT in Norway, with an 
accumulated need for treatment among older dependent opioid users when the program was 
launched. Sixty-seven per cent started with methadone when included in OMT and methadone 
dosage was high (122 mg). One fourth of both male and female participants had experienced 
interruption of maintenance treatment once or more, 12 more than once. 
 
Total hospital-treated episodes were reduced by 37% during OMT compared to the period 
before the first admission to treatment and doubled after treatment interruption compared to 
the in-treatment period. Inpatient hospital treatment days were 38% lower and outpatient 
hospital treatment contacts 27% lower during compared to before treatment. After treatment 
the rate of inpatient days was 5.1 times higher than during treatment and the rate of outpatient 
treatment contacts were 2.6 times higher. All these findings were statistically significant.  
 
Drug-related episodes were reduced by 76% during versus before treatment, injecting-related 
episodes were reduced by 83% and the rate of overdoses was 64% lower than before OMT. 
Among the injecting-related episodes, local and systemic bacterial infections were the most 
common. The rate of drug-related inpatient days was 84% lower and the rate of outpatient 
contacts 79% lower compared to the pre-treatment period. After treatment interruption drug-
related episodes were eleven times more frequent than during treatment. These findings were 
also statistically significant. 
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Non-drug-related episodes were 35% more frequent during treatment compared to the pre-
OMT period (p=0.02) but did not show significant increase after versus during OMT. Injuries 
did not show significant changes according to OMT status.  
 
Regarding drug-related episodes three variables (having experienced interruption of OMT, 
years of employment and duration of opioid dependence before OMT) showed statistically 
significant interaction (p-value of interaction < 0.05) with OMT status (before versus during 
OMT), while ongoing drug-taking during OMT showed interaction with OMT status of 
borderline significance (p-value of interaction 0.07). Patients without interruption of OMT 
showed greater reduction in drug-related episodes than those with interrupted treatment; 
however, even among the OMT interrupters the reduction was statistically significant (49%, 
p=0.04). After treatment, drug-related episodes were 5.6 times more frequent than during 
OMT among the interrupters.More work experience and longer duration of opioid dependence 
before OMT showed association with greater reduction of drug-related episodes during OMT. 
Ongoing drug-taking during OMT was associated with less reduction in drug-related episodes 
during treatment, even so, the quartile taking most drugs showed a significant reduction. 
 
4.3 Paper 3 
Paper 3 focuses on acute and subacute hospital-treated somatic disease incidents before, 
during, and especially after OMT in the subgroup with interrupted maintenance treatment 
(N=51) within the same cohort (N=200) as in Paper 2. 
 
None of the pre-OMT patient characteristics tested (gender, age at OMT start, age at heroin 
debut, years of opioid dependence before OMT, years of education, years of employment and 
lifetime number of overdoses) differed significantly between the groups with and without 
interruption of OMT. Contrary to this, OMT interrupters scored significantly higher on illicit 
drug-taking and overdoses during treatment, indicating “problems in treatment”. Among the 
interrupters only 15% were assessed as stable and not taking drugs when leaving OMT. Pre-
OMT rates for total drug-related and non-drug-related treatment episodes did not show 
significant differences between patients with and without treatment interruption. 
 
Drug-related treatment episodes were 3.6 times more frequent the first post-OMT year 
compared to the pre-OMT period. Overdoses were 2.9 times, injecting-related episodes 2.6 
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times and other drug-related episodes 7.7 times more frequent. Among the injecting-related 
episodes local skin infections and systemic bacterial infections were most common before 
OMT and also showed the greatest increase after OMT interruption. Among the other (not 
overdoses or injecting-related) drug-related episodes (see Table 1, Paper 2 for definition), 
contacts due to “impaired general health condition” showed the greatest increase. These 
changes were all statistically significant. The overall increase in drug-related treatment 
episodes was greatest the first months after OMT interruption and in overdoses especially the 
first four weeks.  
 
While non-drug-related episodes did not show significant change before versus during OMT, 
they showed a significant increase the first post-OMT year compared to the pre-OMT period. 
With regard to post-OMT years two to five (later post-OMT period), there was no statistically 
significant increase in drug-related or non-drug-related episodes compared to the pre-OMT 
period. Injuries showed stable rates throughout the whole observation period. 
 
The influence of various patient characteristics on increase in drug-related treatment episodes 
the first post-OMT year versus the pre-OMT period was tested. An interaction of borderline 
statistical significance (p=0.06) was found between gender and OMT status, men showing 
greater increase than women (incidence rate ratio (IRR) 5.0 (95% CI 2.8 – 8.9) versus 2.3 
(95% CI 1.1 – 4.6)). Age at OMT start, years of employment, years of education, overdoses 
during lifetime, drug-taking during OMT, overdoses during OMT and having experienced 
more than one OMT interruption during the observation period did not interact significantly 
with OMT status. The 15 per cent who were described as leaving OMT voluntarily and not 
taking drugs at that time did not differ from the rest regarding increase in drug-related 
treatment episodes the first year after treatment.  
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5 Discussion 
5.1 Summary of findings 
Main findings 
• Drug-related acute/subacute somatic disease incidents leading to hospital and other 
health service treatment among dependent opioid users were significantly reduced 
during OMT compared to before treatment. This comprised overdoses, injecting-
related disorders and other drug-related disease incidents.  
• This held not only for patients staying abstinent from psychoactive substances during 
OMT, but also for patients with ongoing drug-taking during treatment as well as for 
patients with interrupted treatment (Study 2).  
• Among patients with interrupted OMT, the incidence of drug-related disease episodes 
increased significantly after interruption of treatment, especially during the first 
months. Non-fatal overdoses were most frequent during the first four weeks after 
interruption of treatment (Study 2). 
 
Other findings 
• Non-drug-related somatic disease incidents leading to hospital treatment showed a 
significant increase during maintenance treatment compared to the pre-treatment 
period (Study 2). Injuries did not show significant change according to OMT status. 
• The proportion of treatment episodes related to drug use was significantly lower 
during OMT compared to out of treatment (Study 1). 
• A significantly greater proportion of health care contacts were by GPs during OMT 
compared to the out-of-treatment period (Study 1).  
 
5.2 How these studies relate to previous knowledge 
The aim of these studies was to examine the impact of OMT on acute and subacute somatic 
morbidity, i.e. changes in morbidity according to the patients’ OMT status (before, during or 
after OMT). Rates of disease incidents and corresponding rates of inpatient days and 
outpatient contacts were regarded as proxy indicators for somatic morbidity. How do these 
studies add to previous knowledge?  
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Research on OMT-related changes in morbidity among problem opioid users is scarce141. 
Improvement in somatic health and reduction in heroin use and overdoses during maintenance 
treatment have been documented in large cohort studies in the US, the United Kingdom and 
Australia based on interviews51,138,142 and a recent metaanalysis documented significant 
reductions in illicit opioid use, injecting and sharing of injecting equipment during OMT135. 
Reduced consumption of inpatient care due to infections other than HIV during methadone 
treatment140 and improved physical health status during the first 12 months in OMT based on 
clinical assessment139 have been documented. However, we could identify no other studies 
using cohort design based on scrutiny of full-text records to explore long-term changes in 
patterns of acute somatic morbidity related to OMT status. Our studies show substantial 
reductions in acute/subacute drug-related morbidity and health care utilization during 
maintenance treatment and this finding is in accordance with the studies referred to above.  
 
Studies from several countries have documented that injection site infections and severe 
complications to these are a major problem among IDUs94,121,143-148 and that they contribute 
substantially to hospital utilization and costs related to illicit drug use94,145,146. In our studies 
we document major reductions in injection-site infections and in systemic bacterial infections 
during compared to before maintenance treatment. After interruption of OMT we found 
substantial increase in injecting-related episodes (which mainly are bacterial infections), 
especially during the first months off maintenance treatment. These infections are often 
successfully treated through intensive and resource-demanding hospital treatment. Our study 
demonstrates the importance and scale of these infections and brings new evidence on the 
extent to which such infections are reduced during maintenance treatment.  
 
In the Australian Treatment Outcome Study (ATOS) Darke and colleagues concluded: 
“Perhaps the most clinical implication to emerge concerned the importance of stable retention 
in treatment as a consistent predictor of superior treatment outcome” and that “the chances of 
successful outcome for these (more dysfunctional) clients, however, improve dramatically the 
longer they can be retained in a stable treatment”138. In Paper 2 we showed that the quartile 
taking most drugs during OMT and probably maintaining the most “addictive” and risk-taking 
lifestyle, still showed significant reduction in drug-related episodes during treatment, though 
less than the quartile not taking drugs at all. This implies that even patients maintaining illicit 
drug use during treatment benefit from OMT. Moreover, even the group with interrupted 
treatment showed significant reduction – though less than those with continuous treatment – 
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during compared to before OMT.  After treatment the interrupters showed great increase in all 
kinds of drug-related episodes, especially the first months. As far as we know, the distribution 
of acute somatic disease incidents throughout the post-treatment period has not been studied 
before. However, as cited above, Darke and colleagues in the ATOS study found that stable 
retention in treatment was associated with “superior treatment outcome”. The very high 
incidence rates of all kinds of drug-related episodes just after leaving treatment in our study, 
are in accordance with these Australian findings. They are also in accordance with the 
conclusion in a review article by Magura and Rosenblum149 concerning experiences on 
leaving methadone treatment: ”Virtually all of these studies (exiting from extended 
methadone detoxification, "abstinence-oriented" methadone programs, and regular methadone 
maintenance programs) document high rates of relapse to opioid use after methadone 
treatment is discontinued. Most of the patients studied left treatment without meeting clinical 
criteria for detoxification, although high relapse rates were also reported for patients who 
completed this program. The detrimental consequences of leaving methadone treatment are 
dramatically indicated by greatly increased death rates following discharge”. 
 
5.3 Treatment implications 
Maintenance treatment in Norway is now regarded as a treatment modality for opioid 
dependence based on high dose opioid substitution with methadone or buprenorphine in a 
time-unlimited maintenance perspective with a combined social rehabilitation and harm 
reduction objective organized within the public health- and social care system131. Before the 
new guidelines were enforced from 2010, contrasting practices had developed in parts of the 
country reflecting opposed attitudes on whether a high-threshold social rehabilitation 
orientation should be the only acceptable basis for treatment or if a harm-reducing perspective 
should be acceptable, allowing patients with ongoing illicit drug-taking to continue in 
treatment150-153. Even if the new guidelines in several ways have concluded this debate, there 
might still be disagreements in how to implement them154. Our findings should have 
implications on some aspects of how to practise maintenance treatment, both in the 
Norwegian and in an international context. 
 
OMT significantly reduces acute and subacute somatic morbidity and should be available to 
dependent opioid users who want to enter the treatment programme. Programmes should be 
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flexible and organized so as to meet the needs of different groups of dependent opioid users, 
comprising both harm-reducing and social rehabilitation goals.  
 
OMT should generally be regarded as a time-unlimited treatment, also for patients not 
reaching stable social rehabilitation. The goal should be to keep patients in treatment, also 
when they are dysfunctional and engage in high-risk activities. Serial discharges and re-
enrolments are particularly unfortunate. Re-inclusion of OMT drop-outs should be prompt 
and non-bureaucratic when patients are ready for it.  
 
Involuntary discharge from OMT should only be an option if continued treatment is regarded 
as unsafe for the patient or others, i.e. if continued treatment is assessed to be a greater health 
risk for the patient than interruption of treatment. The risk for diversion of OMT medications 
should usually be handled by strengthening the control of intake.  
 
Patients who are well rehabilitated outside drug circles and who have not been taking illicit 
drugs for long frequently want to taper off maintenance treatment and finally live without 
substitution medication. But even in this context, coming off the medication is often hard. 
Patients should be informed about risks and difficulties related to exit from maintenance 
treatment. If they uphold the decision to leave OMT, they should be closely followed up and 
assured that they can restart OMT medication rapidly if they relapse.   
 
5.4 Further research 
The effect of maintenance treatment on morbidity is still scarcely studied though OMT is the 
most widely used treatment for opioid dependence and still expanding. Hence, further 
research is demanded and several topics should be addressed. 
 
As OMT is considered as a time-unlimited treatment, the long-term health effects of receiving 
high-dose opioid maintenance should be thoroughly examined in long-range cohort studies.  
 
Mortality is reduced within OMT programmes and patients will live longer. Therefore OMT-
effects on older patients is an important topic. Dependent opioid users tend to suffer increased 
chronic health problems and long-term outcome of chronic diseases among OMT patients 
should be further studied. 
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Prevalence of mental disorders is substantially increased among dependent opioid users 
compared to the general population. Inpatient and outpatient treatment for mental disorders in 
a pre-during-post-OMT perspective is not studied in the thesis and such studies will be of 
interest. 
 
We found highly increased acute/subacute drug-related morbidity after OMT termination, 
especially the first months. While overdoses seemed to stabilize on the pre-OMT level from 
the second post-OMT year on, injecting-related and other drug-related incidents showed a 
tendency, though statistically non-significant, to stay on a higher level than before the first 
OMT entry. However, the overall post-OMT patient years at risk in our study was only 91 in a 
group of 51 patients, and especially the findings from the second year on relates to relatively 
few observed events. Further studies, focusing both on the period soon after treatment 
interruption and on the long-term effects of OMT termination should be carried out. 
 
Well rehabilitated OMT patients frequently consider tapering off OMT medication and go 
after a drug-free life without maintenance treatment. This is understandable, though it may be 
risky, as opioid substitution is “heavy” medication in an unlimited time perspective, and the 
treatment is not without side effects. Thus, further long-range research focusing on health, 
quality of life and relapse prevention especially in well-rehabilitated post-OMT patients is 
therefore important.  
 
The OMT-related changes in health service expenditures in accordance with the changes in 
consumption of health care services and especially hospital treatment have not been addressed 
in this thesis. Studies of OMT-related effects – in a pre-during-post-OMT perspective – on 
health care costs, not only related to acute somatic morbidity, but also to treatment of 
substance-use-related mental and behavioural disorders and various kinds of chronic diseases 
will be of interest. 
 
5.5 Methodological considerations 
Choice of cohort design  
Randomised controlled trials (RCTs) are often considered to be the “gold standard” when 
treatment effects are evaluated155,156. Some RCTs have been conducted comparing methadone 
maintenance treatment with either placebo medication or non-pharmacological treatment for 
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opioid dependence. In a recent metaanalysis136 Mattick and colleagues identified 11 RCTs, 
two were double blind, with a total number of 1969 participants. The authors conclude: 
“Methadone is an effective maintenance therapy intervention for the treatment of heroin 
dependence as it retains patients in treatment and decreases heroin use better than treatments 
that do not utilise opioid replacement therapy. It does not show a statistically significant 
superior effect on criminal activity or mortality”. Morbidity was not an outcome measure in 
this analysis.  
 
However, while RCT design is widely accepted as the best way to study the effect of medical 
(most often pharmacological) treatment for clearly delimited medical conditions, it is not 
necessarily the most appropriate way to evaluate different treatment modalities for opioid 
dependence. The scepticism towards RCT design in addiction research is both technical and 
theoretical157 and RCT design may also raise severe ethical objections by withholding 
treatment for a control group158. Among the technical problems are difficulties to construct a 
properly matched control group159 and problems with covert selection prior to 
randomisation160. Among the theoretical objections is that RCTs focus on internal validity and 
efficacy contrary to external validity and effectiveness under “real world” clinical 
conditions161,162 and that the random allocation of participants in an RCT differs 
fundamentally from the process where patients with complex mixtures of problems through 
active selection enter the kind of treatment they actively seek163,164.  
 
For these reasons RCT design is not necessarily suitable to evaluate OMT effects when 
maintenance treatment is compared to non-medication treatment or no treatment. Current 
knowledge on OMT treatment outcomes is therefore mainly based on observational studies, 
especially longitudinal cohort studies. Unlike what was found in RCTs, reduced mortality 
during maintenance treatment is well established based on findings from several cohort 
studies from various countries41,50,89,91. 
 
When planning this research project, RCT design was no option because of practical and 
ethical reasons. A cohort design with collection of record data on disease incidents back in 
time was chosen and all eligible patients who had started OMT between January 1998 and 
July 2007 were invited. With regard to the date of examination of the records the collection of 
record data was retrospective. However, as the cohort is basically defined by OMT 
participation, the date of OMT inclusion or even five years previous to the first admission to 
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OMT could be regarded as the study starting point. In this perspective data collection could be 
regarded as prospective and the study could be seen as a “historic prospective” study. As data 
on disease incidents and drug-taking during treatment were gathered from health service 
records and the record collection was almost complete, the risk of data loss was minimised. 
 
The cohort consisted of OMT patients and there was no control group. The study objective 
was to study changes in acute/subacute somatic morbidity when dependent opioid users enter 
and exit maintenance treatment. Rates of disease incidents and treatment contacts were 
measured repeatedly in the same individuals before, during and – for those interrupting 
treatment – after treatment interruption.  Hence, the participants were “their own controls”.  
To set up a matching control group – i.e. a sample of dependent opioid users not receiving 
maintenance treatment and presumed not to deviate systematically from the OMT sample on 
other characteristics – would out of practical, theoretical and ethical reasons hardly have been 
possible. Therefore, the chosen ”historic prospective” cohort design, with the patients as their 
own controls, was regarded as the best possible study design.  
 
Poisson regression – estimation of incidence rates and incidence rate ratios   
The incidence rate ratio is the effect estimate in Poisson regression. The incidence rate of the 
kind of event in question is the outcome variable and the incidence rate ratio (IRR) is the ratio 
between the incidence rates of this event in two different states of a predictor variable. 
 
The main focus in Paper 2 and Paper 3 was to examine the impact of changes in OMT status 
(before, during and after OMT) on the incidence rates of different types of hospital-treated 
disease episodes. However, several other patient characteristics (predictors/covariates) could 
theoretically also have an impact on these rates. OMT status is a time varying covariate as 
patients go in and out of treatment. To examine the effect of patient characteristics – other 
than OMT status – with conceivable impact on incidence rates, the observation period was 
split according to OMT status (before, during and after OMT). The impact of each 
characteristic in question on the crude rate of all drug-related episodes was then tested by 
estimating the IRR between different states of each predictor variable, split according to OMT 
status (before, during and after OMT for OMT interrupters, before and during OMT for non-
interrupters) in the Poisson regression model. In addition to OMT status the following patient 
characteristics were tested (this analysis is not in the paper): gender, having experienced 
interruption of OMT, years of employment and education, age at OMT start, age at heroin 
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debut, years of heroin dependence before the first OMT admission, lifetime overdoses and 
illegal drug-taking during OMT. Only OMT status and lifetime number of overdoses showed 
a significant impact on the incidence rate ratio of drug-related incidents. 
 
As the primary interest of Study 2 was to examine the influence of maintenance treatment 
(OMT status) on the incidence rates of hospital treatment episodes, possible interaction 
between OMT status and the patient characteristics listed in the foregoing paragraph was 
tested. The results of the interaction analysis were reported in the Results section. Potential 
confounding was tested for the same variables. No confounding of importance was found, 
which would be expected as the outcome measure (incidence and treatment contact rates) was 
registered repeatedly (before, during, after OMT) in the participants. 
 
Selection bias 
As the participation rate in Study 1 was as high as 87.5% selection bias was of minor 
importance in this study. In Study 2 the participation rate was 71.2%, about the same for 
patients in and out of treatment when invited, and two hundred persons altogether were 
included. Thirty-eight were assessed as not eligible as they had left the treatment programme 
and had no current contact with social services. It is conceivable that “problem patients” 
might be overrepresented in this group and also among the 81 who did not consent to 
participate. However, as the participation rate for those in and out of treatment when invited 
was about the same, it is unlikely that this factor should cause considerable bias. In both 
studies nearly all requested records were obtained. Hence, selection bias was of limited 
importance and the cohort was considered as representative for the OMT patients in the area. 
 
Acute hospital treatment episodes – a proxy for acute morbidity? 
Both studies assessed acute/subacute somatic disease incidents treated by health care services 
and not morbidity as such. A key question is whether changes in incidence and treatment 
contact rates according to OMT status (before, during, after OMT) reflect a change in 
morbidity; in other words whether these rates can be regarded as proxy indicators for 
morbidity. Information on hospital treatment outside the local area was based on patient recall 
and some disease incidents prior to treatment may have been overlooked. In addition, there 
will be a gap between the volume of disease in any patient sample, and what results in health 
service contacts, and this is particularly so in a population of IDUs134. Due to the structure of 
the treatment program, contact with health services was close during OMT, which probably 
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increased patients’ help-seeking resulting in medical treatment for health problems that would 
not have been treated outside OMT. Further, the patients were five years older during OMT 
than in the pre-OMT period, causing an age-dependent increase in morbidity. These three 
factors – recall bias, changed help-seeking behaviour and increasing age – all tend to increase 
the volume of observed hospital-treated episodes during treatment compared to before 
treatment. Despite this, we found significant reduction in treatment episodes during OMT. 
Hence, our findings most probably reflect a true reduction in acute and subacute morbidity 
during compared to before OMT.  
 
Non-drug-related morbidity – a true increase during OMT? 
Non-drug related hospital treatment episodes showed significant increase during compared to 
before OMT in Study 2. Theoretically it is possible that the increase might to some extent be 
due to harmful effects of maintenance medication and treatment. However, very few of the 
episodes were related to adverse effects of methadone or buprenorphine. Most probably this 
increase does not reflect a true increase in non-drug-related morbidity during treatment, but – 
as discussed above – changes in help-seeking behaviour because of closer follow-up.  
 
Post-treatment period – selection effects in OMT cohort studies  
In our study the crude IRR for drug-related episodes between the post- and during-OMT 
periods was 11.1 (95% CI 6.6 – 18.5) for the whole group, while the interaction analysis 
showed a ratio among patients with interrupted OMT of 5.4 (95% CI 3.0 – 9.7). This 
illustrates a general aspect concerning OMT cohort studies: while the pre- and during-
treatment periods comprise the whole cohort, the post-OMT incidence rates refer only to 
those with interruption of treatment. Patients often leave OMT because of problems in 
treatment like ongoing drug-taking and other forms of risk-taking behaviour. Hence, it is 
conceivable that the OMT interrupters as a group differ from those with non-interrupted 
treatment, and that they may have suffered increased risk for drug-related incidents also 
before and during treatment. In our study only 15% of those who left OMT were assessed as 
stable and drug-free when leaving treatment, the rest left OMT because of “problems in 
treatment”. When comparing the interrupter group with those without interruption, we found 
– perhaps surprisingly – no significant differences concerning the pre-OMT characteristics, 
including pre-OMT incidence rates for all drug-related treatment episodes. However, the 
interrupter group scored significantly higher on drug-taking and overdoses during OMT than 
those without interruption of treatment.  
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This phenomenon, the overrepresentation of patients experiencing “problems in treatment” as 
a sign of ongoing risk-taking and upholding of a drug-dominated lifestyle among patients 
with interrupted OMT, is important in the interpretation of post-treatment outcomes in OMT 
cohort studies. This is of special importance concerning events related to illicit drug use. In 
our study – as stated at the beginning of this section – the interaction analysis showed that the 
increase in the crude incidence rate of drug-related episodes after interruption of OMT 
compared to the in-treatment period only partially could be explained by this selection effect.  
 
Estimation of mortality rates after OMT interruption in OMT cohort studies may be 
influenced by similar selection effects. Mortality and morbidity are different phenomena, 
however, there is intuitively a relation, though complex, between morbidity and mortality and 
it is likely that changes in morbidity more or less will mirror changes in mortality. For 
instance, the ratio between fatal and non-fatal heroin overdoses has been estimated to between 
1:20 and 1:3085. We found a significant increase in drug-related episodes after OMT 
interruption within the interrupter group and  this may indirectly shed light on estimations of 
mortality after leaving OMT in OMT cohort studies89,165,166 and strengthen the assumption 
that mortality increases after OMT interruption among patients showing high-risk behaviours 
during OMT. 
 
Sample size 
Study 1 was conducted in 2005/2006 with 35 participants from one municipality. 278 disease 
incidents were registered. There were statistical significant reductions in overall number of 
disease incidents, in substance-related incidents and in injection-related incidents during OMT 
as compared to the out-of-OMT period and there was a non-significant tendency towards 
reduction in non-fatal overdoses.   
 
Considering these results a sample/cohort size of about 200 was estimated as sufficient to 
evaluate whether non-significant tendencies in Study 1 would prove to be significant in a 
larger sample. A cohort from a greater geographical area consisting of municipalities of 
different size and character would also balance possible distinctive qualities concerning the 
municipality in Study 1 (Gjøvik). Further, this was a study based on patient interviews and in-
depth scrutiny of full-text hospital records and thus labour-intensive. With the available 
resources for the study, it would not have been possible to include considerably more patients.  
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The sample in Study 2 included only 51 OMT interrupters and the overall post-OMT patient 
years were limited, especially from post-OMT year two onwards. Thus the number of post-
OMT episodes and in consequence the power of statistical analyses concerning this period, 
was low.  This is exemplified by the number of drug-related treatment episodes where the 
total number of episodes showed a significant reduction during OMT, while when examining 
each specific type of drug-related episodes, no significant reductions were found although the 
estimated effects were equally large. 
 
External validity 
The study was performed within the Norwegian OMT setting. Specific characteristics of 
importance among dependent opioid users in Norway are that HIV prevalence is low and that 
injecting is the dominant route of heroin administration. Further, the study was conducted in 
an area without major cities, and major cities tend to attract socioeconomic deprived and 
marginalized dependent opioid users.  
 
Moreover, the cohort is rather old. When OMT was started in Norway as late as in 1998 there 
was an accumulated group of older dependent opioid users who dominated among patients 
taken into treatment the first years. Besides, during the first years of OMT in Norway, the age 
limit for OMT admittance was 25 years (it is now abolished). These factors account for the 
high mean age of 37 years at OMT entry, and the long mean durability (12 years) of opioid 
dependence before the first admittance to maintenance treatment. The cohort is representative 
for Norwegian OMT patients, but the age distribution is no doubt characterised by these 
specific historical traits of the Norwegian OMT programme, and this might be a potential 
limitation to the external validity of the study. Age at first OMT admittance did not, however, 
influence the before-versus-during-OMT reduction in drug-related episodes, but patients with 
fewer years of opioid dependence before OMT showed less reduction in incidence rates 
during compared to before treatment.  
 
Brief summary of strengths and limitations  
Limitations 
1) The studies assessed acute/subacute somatic disease incidents treated by health care 
services and not morbidity as such. Even so, we assume that changes in treatment episodes are 
principally in accordance with changes in acute morbidity, as discussed above. 
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2) In Study 2 (Paper 2 and Paper 3), only hospital contact was examined. In the previous 
study (Paper 1), GP contacts were registered as well, and between 80 and 85% of all acute 
somatic disease incidents assessed as severe were found to lead to hospital treatment. Study 2 
therefore focused on hospital-treated episodes exclusively and this was considered sufficient 
to evaluate changes in the most severe disease incidents that are potentially life-threatening or 
may cause severe or permanent health damage. Thus Study 2 did not assess less severe 
morbidity not resulting in hospital contact. 
 
3) Both studies focus on acute/subacute morbidity. Problem opioid users, especially those 
injecting, also experience increased chronic morbidity34,167,168 and suffer increased mortality 
due to various kinds of diseases61.  
 
4) The list of categories of disease incidents differentiating between drug-related and non-
drug-related episodes, and injecting-related and non-injecting-related episodes, was not 
validated by external researchers. We could find no appropriate list in the literature. There 
may be uncertainty about these distinctions, e.g. how to determine whether an infection is 
related to drug-use or recent injecting. However, the inter-rater reliability was good. The fact 
that we found great reductions in drug- and injecting-related infections during OMT while 
infections assessed as not related to drug use showed a slight increase, may indicate that the 
distinction, at least to a considerable extent, was valid. 
 
5) In Study 2 out-of-treatment time was split in time prior to the first admittance to OMT and 
time out of treatment after the first interruption of OMT (post-OMT time). There were 
analytical problems due to the fact that the post-OMT period comprised only 91 patient years 
versus 1000 before and 813 during treatment. This imbalance is due to the very high retention 
in OMT in Norway and would have persisted even with increased sample size.  
 
6) The number of OMT interrupters was low and in consequence the power of statistical 
analyses concerning the post-OMT period was low. 
 
7) The external validity may be influenced by specific traits of the Norwegian OMT 
programme, as discussed above. 
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Strengths 
1) High participation rate among patients in as well as out of OMT when invited.  
 
2) The Norwegian OMT programme has a catchment area organisation and is part of the 
public hospital system, parallel to the organisation of the public somatic hospitals. This 
simplified the collection of data and made it possible to trace almost all hospital contacts.  
 
3) In-depth examination of all full-text records made it possible to collect data that were more 
detailed and robust than interview data (that may lack exactness because of recall bias and 
patients’ interpretations) and register data alone.  
 
4) A long observation period comprising both pre-, during and after OMT time. 
 
5) Key rehabilitation data on all OMT patients are registered annually within the OMT 
programme since 2001 and data on drug taking during treatment could be gathered from this 
register. 
 
6) Although data were collected retrospectively (after inclusion), all data on treatment 
episodes, treatment interruption and drug-taking during OMT were gathered from hospital 
records and registers and because of this “historic prospective” design, loss to follow-up was 
no problem.   
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6 Conclusion 
 
The two studies included in this thesis demonstrate a considerable reduction in acute and 
subacute somatic disease incidents leading to health service treatment during OMT as 
compared to the pre-OMT period. This finding holds even for patients taking illicit drugs 
during OMT. Among OMT interrupters acute and subacute drug-related somatic morbidity is 
substantially increased after interruption of maintenance treatment, especially the first 
months. These findings should have implications on how to treat unstable and dysfunctional 
patients within OMT programs.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 58 
 
 
 
 
 
 
 
 
 
 59 
References 
 
 
1. WHO. Management of substance abuse - Opiates, 
<http://www.who.int/substance_abuse/facts/opiates/en/index.html (loaded August 
25th 2011)> (2011). 
 
2. EMCDDA. The state of the drugs problem in Europe. Annual report 2010. Report No. 
doi:10.2810/33349, (European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), Lisbon, 2010). 
 
3. United Nations Office on Drugs and Crime, U. World Drug Report 2010. (Vienna, 
2010). 
 
4. WHO. International Classification of Diseases (ICD) - 10, 
<http://www.who.int/classifications/icd/en/ (loaded May 5th 2012)> (2010). 
 
5. Amundsen, E. Problem drug use, in The Drug Situation in Norway 2009 - Annual 
report to the European Monitoring Centre for Drugs and Drug Addiction – EMCDDA. 
(Norwegian Institute for Alcohol and Drug Research, SIRUS Oslo, 2009). 
 
6. Norwegian Institute for Alcohol and Drug Research, S. The Drug Situation in Norway 
2010 - Annual report to the European Monitoring Centre for Drugs and Drug 
Addiction – EMCDDA. (Norwegian Institute for Alcohol and Drug Research 
(SIRUS), Oslo, 2010). 
 
7. National Institute on Drug Abuse, N. Epidemiological Trends in Drug Abuse, 
Proceedings of the Community Epidemiology Work Group, Highlights and Executive 
Summary, January 2009., (U.S. DEPARTMENT OF HEALTH AND HUMAN 
SERVICES NATIONAL INSTITUTES OF HEALTH, Bethesda, 2009). 
 
8. Fischer, B. & Rehm, J. Illicit opioid use in the 21st century: witnessing a paradigm 
shift? Addiction 102, 499-501 (2007). 
 
9. Degenhardt Louisa, H. W., Warner-Smith Matthew, Lynskey Michael Illicit drug use, 
in Comparative Quantification of Health Risks: Global and Regional Burden of 
Disease Attributable to Selected Major Risk Factors. (WHO, Geneva, 2004). 
 
10. Babor T. F., C. J., Edwards G., Fischer B., Foxcroft D., Humphreys K. et al. Drug 
Policy and the Public Good  (Oxford UP, 2010). 
 
11. West, R. Theory of addiction  (Blackwell Publishing, 2006). 
 
12. Christie, M. J. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and 
addiction. Br J Pharmacol 154, 384-396 (2008). 
 
13. Feltenstein, M. W. & See, R. E. The neurocircuitry of addiction: an overview. Br J 
Pharmacol 154, 261-274 (2008). 
 
 06 
14. Durrant, R., Adamson, S., Todd, F. & Sellman, D. Drug use and addiction: 
evolutionary perspective. Aust N Z J Psychiatry 43, 1049-1056 (2009). 
 
15. Nesse, R. M. & Berridge, K. C. Psychoactive drug use in evolutionary perspective. 
Science 278, 63-66 (1997). 
 
16. Volkow, N. D., Fowler, J. S., Wang, G. J. & Swanson, J. M. Dopamine in drug abuse 
and addiction: results from imaging studies and treatment implications. Mol 
Psychiatry 9, 557-569 (2004). 
 
17. Dole, V. P., Nyswander, M. E. & Kreek, M. J. Narcotic blockade--a medical technique 
for stopping heroin use by addicts. Trans Assoc Am Physicians 79, 122-136 (1966). 
 
18. Robinson, T. E. & Berridge, K. C. The neural basis of drug craving: an incentive-
sensitization theory of addiction. Brain Res Brain Res Rev 18, 247-291 (1993). 
 
19. Robinson, T. E. & Berridge, K. C. Review. The incentive sensitization theory of 
addiction: some current issues. Philos Trans R Soc Lond B Biol Sci 363, 3137-3146 
(2008). 
 
20. Nestler, E. J. Review. Transcriptional mechanisms of addiction: role of DeltaFosB. 
Philos Trans R Soc Lond B Biol Sci 363, 3245-3255 (2008). 
 
21. Sellman, D. The 10 most important things known about addiction. Addiction 105, 6-13 
(2009). 
 
22. Corbett, A. D., Henderson, G., McKnight, A. T. & Paterson, S. J. 75 years of opioid 
research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147 Suppl 1, 
S153-162 (2006). 
 
23. Friedman, H., Pross, S. & Klein, T. W. Addictive drugs and their relationship with 
infectious diseases. FEMS Immunol Med Microbiol 47, 330-342 (2006). 
 
24. Stein, C., Schafer, M. & Machelska, H. Attacking pain at its source: new perspectives 
on opioids. Nat Med 9, 1003-1008 (2003). 
 
25. Rook, E. J. et al. Pharmacokinetics and pharmacodynamics of high doses of 
pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-
dependent patients. Basic Clin Pharmacol Toxicol 98, 86-96 (2006). 
 
26. Boix, F., Andersen, J. M. & Morland, J. Pharmacokinetic modeling of subcutaneous 
heroin and its metabolites in blood and brain of mice. Addict Biol (2011). 
 
27. Andersen, J. M., Ripel, A., Boix, F., Normann, P. T. & Morland, J. Increased 
locomotor activity induced by heroin in mice: pharmacokinetic demonstration of 
heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. J 
Pharmacol Exp Ther 331, 153-161 (2009). 
 
28. Nutt, D., King, L. A., Saulsbury, W. & Blakemore, C. Development of a rational scale 
to assess the harm of drugs of potential misuse. Lancet 369, 1047-1053 (2007). 
 
 61 
 
29. Fischer, B. et al. Illicit opioid use in Canada: comparing social, health, and drug use 
characteristics of untreated users in five cities (OPICAN study). J Urban Health 82, 
250-266 (2005). 
 
30. Kielland, K. Personer med samtidig alvorlig psykisk lidelse og omfattende 
rusmisbruk. (Norwegian Board of Health Supervision, Oslo, 2000). 
 
31. Landheim, A. S., Bakken, K. & Vaglum, P. Impact of comorbid psychiatric disorders 
on the outcome of substance abusers: a six year prospective follow-up in two 
Norwegian counties. BMC Psychiatry 6, 44 (2006). 
 
32. Regier, D. A. et al. Comorbidity of mental disorders with alcohol and other drug 
abuse. Results from the Epidemiologic Catchment Area (ECA) Study. Jama 264, 
2511-2518 (1990). 
 
33. Warner, L. A., Kessler, R. C., Hughes, M., Anthony, J. C. & Nelson, C. B. Prevalence 
and correlates of drug use and dependence in the United States. Results from the 
National Comorbidity Survey. Arch Gen Psychiatry 52, 219-229 (1995). 
 
34. Cullen, W., O'Brien, S., O'Carroll, A., O'Kelly, F. D. & Bury, G. Chronic illness and 
multimorbidity among problem drug users: a comparative cross sectional pilot study in 
primary care. BMC Fam Pract 10, 25 (2009). 
 
35. Gjeruldsen, S. R., Myrvang, B. & Opjordsmoen, S. A 25-year follow-up study of drug 
addicts hospitalised for acute hepatitis: present and past morbidity. Eur Addict Res 9, 
80-86 (2003). 
 
36. Gossop, M. et al. Substance use, health and social problems of service users at 54 drug 
treatment agencies. Intake data from the National Treatment Outcome Research Study. 
Br J Psychiatry 173, 166-171 (1998). 
 
37. Ross, J. et al. The characteristics of heroin users entering treatment: findings from the 
Australian treatment outcome study (ATOS). Drug Alcohol Rev 24, 411-418 (2005). 
 
38. de la Fuente, L., Barrio, G., Royuela, L. & Bravo, M. J. The transition from injecting 
to smoking heroin in three Spanish cities. The Spanish Group for the Study of the 
Route of Heroin Administration. Addiction 92, 1749-1763 (1997). 
 
39. Gossop, M., Marsden, J., Stewart, D. & Treacy, S. Routes of drug administration and 
multiple drug misuse: regional variations among clients seeking treatment at 
programmes throughout England. Addiction 95, 1197-1206 (2000). 
 
40. Robertson, R. & Richardson, A. Heroin injecting and the introduction of HIV/AIDS 
into a Scottish city. J R Soc Med 100, 491-494 (2007). 
 
41. Brugal, M. T. et al. Evaluating the impact of methadone maintenance programmes on 
mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 100, 
981-989 (2005). 
 
 26 
42. Waal, H. & Gossop, M. Overdose mortality and drug policy. Submitted (2011). 
 
43. Darke, S., Degenhardt, L. & Mattick, R. Mortality Amongst Illicit Drug Users: 
Epidemiology, Causes and Intervention (Cambridge University Press, 2007). 
 
44. Degenhardt, L. et al. Mortality among regular or dependent users of heroin and other 
opioids: a systematic review and meta-analysis of cohort studies. Addiction 106, 32-51 
(2011). 
 
45. Bargagli, A. M., Sperati, A., Davoli, M., Forastiere, F. & Perucci, C. A. Mortality 
among problem drug users in Rome: an 18-year follow-up study, 1980-97. Addiction 
96, 1455-1463 (2001). 
 
46. Eskild, A., Magnus, P., Samuelsen, S. O., Sohlberg, C. & Kittelsen, P. Differences in 
mortality rates and causes of death between HIV positive and HIV negative 
intravenous drug users. Int J Epidemiol 22, 315-320 (1993). 
 
47. Goldstein, A. & Herrera, J. Heroin addicts and methadone treatment in Albuquerque: a 
22-year follow-up. Drug Alcohol Depend 40, 139-150 (1995). 
 
48. Perucci, C. A., Davoli, M., Rapiti, E., Abeni, D. D. & Forastiere, F. Mortality of 
intravenous drug users in Rome: a cohort study. Am J Public Health 81, 1307-1310 
(1991). 
 
49. van Ameijden, E. J. et al. Pre-AIDS mortality and morbidity among injection drug 
users in Amsterdam and Baltimore: an ecological comparison. Subst Use Misuse 34, 
845-865 (1999). 
 
50. Caplehorn, J. R., Dalton, M. S., Haldar, F., Petrenas, A. M. & Nisbet, J. G. Methadone 
maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 31, 177-196 
(1996). 
 
51. Gossop, M., Marsden, J., Stewart, D. & Treacy, S. Change and stability of change 
after treatment of drug misuse: 2-year outcomes from the National Treatment 
Outcome Research Study (UK). Addict Behav 27, 155-166 (2002). 
 
52. van Haastrecht, H. J. et al. Predictors of mortality in the Amsterdam cohort of human 
immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 
143, 380-391 (1996). 
 
53. Bartu, A., Freeman, N. C., Gawthorne, G. S., Codde, J. P. & Holman, C. D. Mortality 
in a cohort of opiate and amphetamine users in Perth, Western Australia. Addiction 99, 
53-60 (2004). 
 
54. Engstrom, A., Adamsson, C., Allebeck, P. & Rydberg, U. Mortality in patients with 
substance abuse: a follow-up in Stockholm County, 1973-1984. Int J Addict 26, 91-
106 (1991). 
 
 
 63 
55. Fugelstad, A., Annell, A., Rajs, J. & Agren, G. Mortality and causes and manner of 
death among drug addicts in Stockholm during the period 1981-1992. Acta Psychiatr 
Scand 96, 169-175 (1997). 
 
56. Tunving, K. Fatal outcome in drug addiction. Acta Psychiatr Scand 77, 551-566 
(1988). 
 
57. Wahren, C. A., Brandt, L. & Allebeck, P. Has mortality in drug addicts increased? A 
comparison between two hospitalized cohorts in Stockholm. Int J Epidemiol 26, 1219-
1226 (1997). 
 
58. Bretteville-Jensen, A. & Amundsen, E. Omfang av sprøytemisbruk i Norge. (Statens 
institutt for rusmiddelforskning, Oslo, 2006). 
 
59. Waal, H., Clausen, T., Håseth, A. & Lillevold, P. SERAF RAPPORT 1/2010 (revidert 
utgave), Siste år med gamle retningslinjer, Statusrapport 2009. (Norwegian Centre for 
Addiction Research, Oslo, 2010). 
 
60. Eskild, A., Magnus, P., Samuelsen, S. O., Sohlberg, C. & Kittelsen, P. [Mortality and 
causes of death among intravenous drug addicts in Oslo]. Tidsskr Nor Laegeforen 113, 
1331-1333 (1993). 
 
61. Bjornaas, M. A. et al. A 20-year prospective study of mortality and causes of death 
among hospitalized opioid addicts in Oslo. BMC Psychiatry 8, 8 (2008). 
 
62. White, J. M. & Irvine, R. J. Mechanisms of fatal opioid overdose. Addiction 94, 961-
972 (1999). 
 
63. Melandri, R. et al. Myocardial damage and rhabdomyolysis associated with prolonged 
hypoxic coma following opiate overdose. J Toxicol Clin Toxicol 34, 199-203 (1996). 
 
64. Pascual Calvet, J., Pou, A., Pedro-Botet, J. & Gutierrez Cebollada, J. [Non-infective 
neurologic complications associated to heroin use]. Arch Neurobiol (Madr) 52 Suppl 
1, 155-161 (1989). 
 
65. Sahni, V., Garg, D., Garg, S., Agarwal, S. K. & Singh, N. P. Unusual complications of 
heroin abuse: transverse myelitis, rhabdomyolysis, compartment syndrome, and ARF. 
Clin Toxicol (Phila) 46, 153-155 (2008). 
 
66. Darke, S., Ross, J., Zador, D. & Sunjic, S. Heroin-related deaths in New South Wales, 
Australia, 1992-1996. Drug Alcohol Depend 60, 141-150 (2000). 
 
67. Davidson, P. J. et al. Fatal heroin-related overdose in San Francisco, 1997-2000: a 
case for targeted intervention. J Urban Health 80, 261-273 (2003). 
 
68. Fugelstad, A. et al. Use of morphine and 6-monoacetylmorphine in blood for the 
evaluation of possible risk factors for sudden death in 192 heroin users. Addiction 98, 
463-470 (2003). 
 
 46 
69. Hickman, M. et al. Trends in drug overdose deaths in England and Wales 1993-98: 
methadone does not kill more people than heroin. Addiction 98, 419-425 (2003). 
 
70. Boyd, J., Randell, T., Luurila, H. & Kuisma, M. Serious overdoses involving 
buprenorphine in Helsinki. Acta Anaesthesiol Scand 47, 1031-1033 (2003). 
 
71. Bryant, W. K. et al. Overdose deaths attributed to methadone and heroin in New York 
City, 1990-1998. Addiction 99, 846-854 (2004). 
 
72. Carpenter, M. J., Chutuape, M. A. & Stitzer, M. L. Heroin snorters versus injectors: 
comparison on drug use and treatment outcome in age-matched samples. Drug 
Alcohol Depend 53, 11-15 (1998). 
 
73. Darke, S., Ross, J. & Teesson, M. Twelve-month outcomes for heroin dependence 
treatments: does route of administration matter? Drug Alcohol Rev 24, 165-171 
(2005). 
 
74. Kintz, P. Deaths involving buprenorphine: a compendium of French cases. Forensic 
Sci Int 121, 65-69 (2001). 
 
75. Perret, G., Deglon, J. J., Kreek, M. J., Ho, A. & La Harpe, R. Lethal methadone 
intoxications in Geneva, Switzerland, from 1994 to 1998. Addiction 95, 1647-1653 
(2000). 
 
76. Pirnay, S. et al. A critical review of the causes of death among post-mortem 
toxicological investigations: analysis of 34 buprenorphine-associated and 35 
methadone-associated deaths. Addiction 99, 978-988 (2004). 
 
77. Merrall, E. L. et al. Meta-analysis of drug-related deaths soon after release from 
prison. Addiction 105, 1545-1554 (2010). 
 
78. Seaman, S. R., Brettle, R. P. & Gore, S. M. Mortality from overdose among injecting 
drug users recently released from prison: database linkage study. Bmj 316, 426-428 
(1998). 
 
79. Seymour, A., Oliver, J. S. & Black, M. Drug-related deaths among recently released 
prisoners in the Strathclyde Region of Scotland. J Forensic Sci 45, 649-654 (2000). 
 
80. Strang, J. et al. Loss of tolerance and overdose mortality after inpatient opiate 
detoxification: follow up study. Bmj 326, 959-960 (2003). 
 
81. Davoli, M. et al. Risk factors for overdose mortality: a case-control study within a 
cohort of intravenous drug users. Int J Epidemiol 22, 273-277 (1993). 
 
82. Gronbladh, L., Ohlund, L. S. & Gunne, L. M. Mortality in heroin addiction: impact of 
methadone treatment. Acta Psychiatr Scand 82, 223-227 (1990). 
 
83. Ravndal, E. & Amundsen, E. J. Mortality among drug users after discharge from 
inpatient treatment: an 8-year prospective study. Drug Alcohol Depend 108, 65-69 
(2010). 
 
 65 
 
84. Fugelstad, A., Rajs, J., Bottiger, M. & Gerhardsson de Verdier, M. Mortality among 
HIV-infected intravenous drug addicts in Stockholm in relation to methadone 
treatment. Addiction 90, 711-716 (1995). 
 
85. Darke, S., Mattick, R. P. & Degenhardt, L. The ratio of non-fatal to fatal heroin 
overdose. Addiction 98, 1169-1171 (2003). 
 
86. Darke, S., Hall, W., Kaye, S., Ross, J. & Duflou, J. Hair morphine concentrations of 
fatal heroin overdose cases and living heroin users. Addiction 97, 977-984 (2002). 
 
87. Tagliaro, F., De Battisti, Z., Smith, F. P. & Marigo, M. Death from heroin overdose: 
findings from hair analysis. Lancet 351, 1923-1925 (1998). 
 
88. Kronstrand, R., Grundin, R. & Jonsson, J. Incidence of opiates, amphetamines, and 
cocaine in hair and blood in fatal cases of heroin overdose. Forensic Sci Int 92, 29-38 
(1998). 
 
89. Clausen, T., Anchersen, K. & Waal, H. Mortality prior to, during and after opioid 
maintenance treatment (OMT): a national prospective cross-registry study. Drug 
Alcohol Depend 94, 151-157 (2008). 
 
90. Davoli, M. et al. Risk of fatal overdose during and after specialist drug treatment: the 
VEdeTTE study, a national multi-site prospective cohort study. Addiction 102, 1954-
1959 (2007). 
 
91. Fugelstad, A., Stenbacka, M., Leifman, A., Nylander, M. & Thiblin, I. Methadone 
maintenance treatment: the balance between life-saving treatment and fatal 
poisonings. Addiction 102, 406-412 (2007). 
 
92. Gordon, R. J. & Lowy, F. D. Bacterial infections in drug users. N Engl J Med 353, 
1945-1954 (2005). 
 
93. Kaushik, K. S., Kapila, K. & Praharaj, A. K. Shooting up: the interface of microbial 
infections and drug abuse. J Med Microbiol 60, 408-422 (2011). 
 
94. Palepu, A. et al. Hospital utilization and costs in a cohort of injection drug users. Cmaj 
165, 415-420 (2001). 
 
95. Scheidegger, C. & Zimmerli, W. Infectious complications in drug addicts: seven-year 
review of 269 hospitalized narcotics abusers in Switzerland. Rev Infect Dis 11, 486-
493 (1989). 
 
96. Binswanger, I. A., Kral, A. H., Bluthenthal, R. N., Rybold, D. J. & Edlin, B. R. High 
prevalence of abscesses and cellulitis among community-recruited injection drug users 
in San Francisco. Clin Infect Dis 30, 579-581 (2000). 
 
97. Chandrasekar, P. H. & Narula, A. P. Bone and joint infections in intravenous drug 
abusers. Rev Infect Dis 8, 904-911 (1986). 
 
 66 
98. Stein, M. D. Medical complications of intravenous drug use. J Gen Intern Med 5, 249-
257 (1990). 
 
99. Deutscher, M. & Perlman, D. C. Why some injection drug users lick their needles: a 
preliminary survey. Int J Drug Policy 19, 342-345 (2008). 
 
100. Strathdee, S. A. & Stockman, J. K. Epidemiology of HIV among injecting and non-
injecting drug users: current trends and implications for interventions. Curr HIV/AIDS 
Rep 7, 99-106 (2010). 
 
101. Hagan, H. et al. Attribution of hepatitis C virus seroconversion risk in young injection 
drug users in 5 US cities. J Infect Dis 201, 378-385 (2010). 
 
102. van Houdt, R. et al. Two decades of hepatitis B infections among drug users in 
Amsterdam: are they still a high-risk group? J Med Virol 81, 1163-1169 (2009). 
 
103. Shah, S. M. et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and 
washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir 
Immune Defic Syndr Hum Retrovirol 11, 301-306 (1996). 
 
104. Levine, D. P., Crane, L. R. & Zervos, M. J. Bacteremia in narcotic addicts at the 
Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. 
Rev Infect Dis 8, 374-396 (1986). 
 
105. Barry, J. et al. Botulism in injecting drug users, Dublin, Ireland, November-December 
2008. Euro Surveill 14 (2009). 
 
106. Brett, M. M., Hallas, G. & Mpamugo, O. Wound botulism in the UK and Ireland. J 
Med Microbiol 53, 555-561 (2004). 
 
107. Passaro, D. J., Werner, S. B., McGee, J., Mac Kenzie, W. R. & Vugia, D. J. Wound 
botulism associated with black tar heroin among injecting drug users. Jama 279, 859-
863 (1998). 
 
108. Dunbar, N. M. & Harruff, R. C. Necrotizing fasciitis: manifestations, microbiology 
and connection with black tar heroin. J Forensic Sci 52, 920-923 (2007). 
 
109. McGuigan, C. C. et al. Lethal outbreak of infection with Clostridium novyi type A and 
other spore-forming organisms in Scottish injecting drug users. J Med Microbiol 51, 
971-977 (2002). 
 
110. Ringertz, S. H. et al. Injectional anthrax in a heroin skin-popper. Lancet 356, 1574-
1575 (2000). 
 
111. Booth, M. G., Hood, J., Brooks, T. J. & Hart, A. Anthrax infection in drug users. 
Lancet 375, 1345-1346 (2010). 
 
112. Que, Y. A. & Moreillon, P. Infective endocarditis. Nat Rev Cardiol 8, 322-336 (2011). 
 
 
 67 
113. Darke, S. et al. The ageing heroin user: career length, clinical profile and outcomes 
across 36 months. Drug Alcohol Rev 28, 243-249 (2009). 
 
114. Torres, L., Kaplan, C. & Valdez, D. Health Consequences of Long-Term Injection 
Heroin Use Among Aging Mexican American Men. Journal of Aging and Health 
23(6) 912–932 (2011). 
 
115. Nelson, K. E. et al. Sexually transmitted diseases in a population of intravenous drug 
users: association with seropositivity to the human immunodeficiency virus (HIV). J 
Infect Dis 164, 457-463 (1991). 
 
116. Mackenzie, A. R., Laing, R. B., Douglas, J. G., Greaves, M. & Smith, C. C. High 
prevalence of iliofemoral venous thrombosis with severe groin infection among 
injecting drug users in North East Scotland: successful use of low molecular weight 
heparin with antibiotics. Postgrad Med J 76, 561-565 (2000). 
 
117. Manekeller, S. et al. [Analysis of vascular complications in intra-venous drug addicts 
after puncture of femoral vessels]. Zentralbl Chir 129, 21-28 (2004). 
 
118. Boedeker, C. C. et al. [Etiology and therapy of the internal jugular vein thrombosis]. 
Laryngorhinootologie 83, 743-749 (2004). 
 
119. Starakis, I. & Mazokopakis, E. E. Injecting illicit substances epidemic and infective 
endocarditis. Infect Disord Drug Targets 10, 22-26 (2010). 
 
120. Hecht, S. R. & Berger, M. Right-sided endocarditis in intravenous drug users. 
Prognostic features in 102 episodes. Ann Intern Med 117, 560-566 (1992). 
 
121. Cherubin, C. E. & Sapira, J. D. The medical complications of drug addiction and the 
medical assessment of the intravenous drug user: 25 years later. Ann Intern Med 119, 
1017-1028 (1993). 
 
122. Lawrinson, P. et al. Key findings from the WHO collaborative study on substitution 
therapy for opioid dependence and HIV/AIDS. Addiction 103, 1484-1492 (2008). 
 
123. The Norwegian Institute of Public Health. Hiv-situasjonen i Norge per 31.desember 
2010. (The Norwegian Institute of Public Health, Oslo, 2011). 
 
124. Reimer, J. et al. Multiple viral hepatitis in injection drug users and associated risk 
factors. J Gastroenterol Hepatol 22, 80-85 (2007). 
 
125. Hiv-situasjonen i Norge pr.  31. desember 2006. (The Norwegian Institute of Public 
Health, Oslo, 2007). 
 
126. Egeland, A. in 7th International Hepatitis C Conference, Edinburgh. 
 
127. Leen, C. L. & Brettle, R. P. Fungal infections in drug users. J Antimicrob Chemother 
28 Suppl A, 83-96 (1991). 
 
 86 
128. Dole, V. P. & Nyswander, M. A Medical Treatment for Diacetylmorphine (Heroin) 
Addiction. a Clinical Trial with Methadone Hydrochloride. Jama 193, 646-650 
(1965). 
 
129. WHO. Guidelines for the Psychosocially Assisted Pharmacological Treatment of 
Opioid Dependence  (World Health Organization, 2009). 
 
130. Mørland, J. in Føleleser og fornuft   (ed J. Bramness) Ch. 8, 121 - 138 (SERAF, 
2010). 
 
131. Norwegian Directorate of Health. Nasjonal retningslinje for legemiddelassistert 
rehabilitering ved opioidavhengighet (National guideline for medication assisted 
rehabiliation of opioid dependence), 
<http://www.helsedirektoratet.no/publikasjoner/nasjonale_faglige_retningslinjer/nasjo
nal_retningslinje_for_legemiddelassistert_rehabilitering_ved_opioidavhengighet_671
814 (loaded Nov 30 2011)> (2010). 
 
132. Waal  Helge, C. T., Håseth Atle, Lillevold Pål H. Statusrapport 2010 - Første år med 
nye retningslinjer. Report No. 4/2011, (SERAF - Norwegian Centre for Addiction 
Research, Oslo, 2011). 
 
133. Waal, H. Merits and problems in high-threshold methadone maintenance treatment. 
Evaluation of medication-assisted rehabilitation in norway 1998-2004. Eur Addict Res 
13, 66-73 (2007). 
 
134. Gargiulo, M. in Maintenance Treatment of Heroin Addiction   (ed H Waal, Haga, E) 
Ch. 6, 214-220 (Cappelen Akademisk, 2003). 
 
135. Gowing, L., Farrell, M., Bornemann, R., Sullivan, L. & Ali, R. Substitution treatment 
of injecting opioid users for prevention of HIV infection. Cochrane Database Syst 
Rev, CD004145 (2008). 
 
136. Mattick, R. P., Breen, C., Kimber, J. & Davoli, M. Methadone maintenance therapy 
versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst 
Rev, CD002209 (2009). 
 
137. Bukten, A. et al. Engagement with opioid maintenance treatment and reductions in 
crime: a longitudinal national cohort study. Addiction (2011). 
 
138. Darke, S., Ross, J. & Teesson, M. The Australian Treatment Outcome Study (ATOS): 
what have we learnt about treatment for heroin dependence? Drug Alcohol Rev 26, 49-
54 (2007). 
 
139. Wittchen, H. U. et al. Feasibility and outcome of substitution treatment of heroin-
dependent patients in specialized substitution centers and primary care facilities in 
Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend 95, 245-257 
(2008). 
 
 
 69 
140. Stenbacka, M., Leifman, A. & Romelsjo, A. The impact of methadone on 
consumption of inpatient care and mortality, with special reference to HIV status. 
Subst Use Misuse 33, 2819-2834 (1998). 
 
141. Fischer, B., Rehm, J., Kim, G. & Kirst, M. Eyes wide shut?--A conceptual and 
empirical critique of methadone maintenance treatment. Eur Addict Res 11, 1-9; 
discussion 10-14 (2005). 
 
142. Hubbard, R. L., Craddock, S. G., Flynn, P. M., Anderson, J. & Etheridge, R. M. 
Overview of 1-year follow-up outcomes in the Drug Abuse Treatment Outcome Study 
(DATOS). Psychology of Addictive Behaviors 11, 261-278 (1997). 
 
143. Darke, S., Ross, J. & Kaye, S. Physical injecting sites among injecting drug users in 
Sydney, Australia. Drug Alcohol Depend 62, 77-82 (2001). 
 
144. Del Giudice, P. Cutaneous complications of intravenous drug abuse. Br J Dermatol 
150, 1-10 (2004). 
 
145. Hope, V. D., Marongiu, A., Parry, J. V. & Ncube, F. The extent of injection site 
infection in injecting drug users: findings from a national surveillance study. 
Epidemiol Infect 138, 1510-1518 (2010). 
 
146. Kerr, T. et al. High rates of primary care and emergency department use among 
injection drug users in Vancouver. J Public Health (Oxf) 27, 62-66 (2005). 
 
147. Lloyd-Smith, E. et al. Prevalence and correlates of abscesses among a cohort of 
injection drug users. Harm Reduct J 2, 24 (2005). 
 
148. Takahashi, T. A., Merrill, J. O., Boyko, E. J. & Bradley, K. A. Type and location of 
injection drug use-related soft tissue infections predict hospitalization. J Urban Health 
80, 127-136 (2003). 
 
149. Magura, S. & Rosenblum, A. Leaving methadone treatment: lessons learned, lessons 
forgotten, lessons ignored. Mt Sinai J Med 68, 62-74 (2001). 
 
150. Hansen, M., Kornør, H. & Waal, H. SKR-rapport nr 7/2004 Bidrag til evaluering av 
Legemiddelassistert rehabilitering i Norge (Contributions to evaluation of medication 
assisted rehabilitation in Norway). (Seksjon for kliniske rusmiddelproblemer, 
Universitet i Oslo (Unit for Addiction Medicine, University of Oslo), Oslo, 2004). 
 
151. Skeie, I. [Between medicine, moral and moralism]. Tidsskr Nor Laegeforen 124, 2797 
(2004). 
 
152. Skeie, I., Brekke, M., Lindbaek, M. & Waal, H. [General practitioners can take 
responsibility for medication-based rehabilitation]. Tidsskr Nor Laegeforen 127, 296-
297 (2007). 
 
153. Vindedal, B., Steen, L.-E., Larsen, B. & Knoff, R. Evaluering av legemiddelassistert 
rehabilitering. Rapport til Sosial- og helsedirektoratet (Evaluation of medication 
 07 
assisted rehabilitation. Report to the Directorate of Health and Social Welfare). 
(Sosial- og helsedirektoratet (Directorate of Health and Social Welfare), Oslo, 2004). 
 
154. Nordstrand, B. in 8. nasjonale konferanse - Legemiddelassistert rehabilitering    
(Oslo, 2010). 
 
155. Sackett, D. in Clinical Epidemiology - How to Do Clinical Practice Research Ch. 4, 
59-65 (Lippincott Williams & Wilkins, 2006). 
 
156. Thelle, D. & Laake, P. in Forskningsmetode i medisin og biofag   (eds HB Benestad & 
P Laake) Ch. 8, 242-282 (Gyldendal Akademisk, 2004). 
 
157. Gossop, M. in Maintenance Treatment and Heroin Addiction. Evidence at the 
Crossroads. (ed H Waal, Haga, E) Ch. 3, 91-105 (Cappelen Akademisk Forlag, 2003). 
 
158. Gunne, L. M. & Gronbladh, L. The Swedish methadone maintenance program: a 
controlled study. Drug Alcohol Depend 7, 249-256 (1981). 
 
159. De Leon, G., Inciardi, J. A. & Martin, S. S. Residential drug abuse treatment research: 
are conventional control designs appropriate for assessing treatment effectiveness? J 
Psychoactive Drugs 27, 85-91 (1995). 
 
160. Finney, J. W., Hahn, A. C. & Moos, R. H. The effectiveness of inpatient and 
outpatient treatment for alcohol abuse: the need to focus on mediators and moderators 
of setting effects. Addiction 91, 1773-1796; discussion 1803-1720 (1996). 
 
161. Gilbody, S., Wahlbeck, K. & Adams, C. Randomized controlled trials in 
schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand 105, 243-
251 (2002). 
 
162. Orford, J. Future research directions: a commentary on Project MATCH. Addiction 94, 
62-66 (1999). 
 
163. Seligman, M. E. The effectiveness of psychotherapy. The Consumer Reports study. 
Am Psychol 50, 965-974 (1995). 
 
164. McLellan, A. T. et al. Supplemental social services improve outcomes in public 
addiction treatment. Addiction 93, 1489-1499 (1998). 
 
165. Cornish, R., Macleod, J., Strang, J., Vickerman, P. & Hickman, M. Risk of death 
during and after opiate substitution treatment in primary care: prospective 
observational study in UK General Practice Research Database. Bmj 341, c5475 
(2010). 
 
166. Degenhardt, L. et al. Mortality among clients of a state-wide opioid pharmacotherapy 
program over 20 years: risk factors and lives saved. Drug Alcohol Depend 105, 9-15 
(2009). 
 
167. Millson, P. et al. Determinants of health-related quality of life of opiate users at entry 
to low-threshold methadone programs. Eur Addict Res 12, 74-82 (2006). 
 
 71 
 
168. Puigdollers, E. et al. Characteristics of heroin addicts entering methadone maintenance 
treatment: quality of life and gender. Subst Use Misuse 39, 1353-1368 (2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 72 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73  
 
 
74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75  
Appendix 
 
Somatisk helse blant opioidavhengige før, under og etter legemiddelassistert rehabilitering 
(LAR) 
 
Intervjuskjema 
 
 
Inndeling 
 
A Opplysninger om intervjuet  
B Demografiske data 
C LAR-historie 
D Spesifikk helse – akutte somatiske sykdomsepisoder  
E Spesifikk helse – kroniske somatiske sykdommer  
F Egen oppfatning av helse- og livskvalitet (5-delte skalaer) 
G Egen oppfatning av forhold til helsevesenet (sykehus, legevakt, fastlege), (5-delte skalaer) 
H Mental helse siste to uker 
I Bruk av rusmidler siste 30 dager 
J Bruk av medikamenter siste 30 dager 
K Intervjuers vurdering av informant og informasjon 
 
 
Først vil jeg takke deg for at du har sagt deg villig til å delta i denne undersøkelsen. Det er viktig å studere 
hvordan LAR virker inn på ulike sider av pasientens liv, både for behandlingsapparatet, og ikke minst for 
pasientene. Dette er en studie av de helsemessige effektene av LAR, og jeg vil stille deg en del spørsmål om 
helse og sykdommer du har hatt og om dine erfaringer med helsevesenet. Jeg vil igjen understreke at de 
opplysningene du gir er strengt konfidensielle, og bare vil bli brukt i dette forskningsprosjektet. De vil ikke være 
tilgjengelige for behandlere i LAR eller andre behandlere. 
 
 
A Opplysninger om intervjuet  
 
1 Løpenummer  ______________________________ 
 
2 Kommunenummer: ______________________________ 
 
3 Dato fullført intervju:  ______________________________ 
 
4 Type intervju:  
 
1  Personlig på kontor-institusjon  _____ 
2  Personlig hjemme hos pasient  _____    
3  Personlig annet sted   _____     
4  Telefon     _____ 
 
5 Hvem har gjennomført intervjuet: ________ 
 
 
 
 
B Demografiske data  
 
1 Kjønn: 1 
1 Mann: ______ 
 2  Kvinne: ______ 
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2 Nasjonalitet (statsborgerskap):  
1 Norsk:      _______ 
2 Vesten: Vest-Europa-USA-Canada- Australia-NZ: _______ 
3  Øst-Europa:     _______ 
4 Utenfor Europa/Vesten):    _______ 
5 Ukjent:      _______ 
9 Ubesvart 
 
3 Fødeland pasient: 
1 Norsk:      ________ 
2 Vesten: Vest-Europa-USA-Canada- Australia-NZ: ________ 
3  Øst-Europa:     ________ 
4 Utenfor Europa/Vesten:    ________ 
5 Ukjent:      ________ 
9 Ubesvart:     ________ 
 
4 Alder ved intervju (år):   ________ 
 
5 Sivilstatus nå:  
  1 Gift/partnerskap:   _______ 
2 Samboer:   _______ 
3 Skilt/separert, ikke samboer: _______ 
4  Enslig:    _______ 
5 Annen:    _______ 
6 Ukjent:    _______ 
9 Ubesvart:   _______ 
  
 6 Antall egne barn:    _______ 
 
 7 Antall barn under 18 år som du har omsorgsansvaret for: _______ 
 
8 Høyeste gjennomførte utdanning: 
   1 Ikke fullført grunnskole (7-9 år):   _______ 
  2 Fullført grunnskole:    _______ 
3 Fullført videregående skole (12 år):  _______ 
4 Høyskole-universitet:    _______  
5 Ukjent:      _______ 
6 Ubesvart:     _______ 
 
 
9 Hvor lenge har du vært i vanlig, lønnet arbeid (ikke gjennom sosialkontor, Aetat eller 
trygdekontor og ikke ”svart” arbeid): 
1 <1år: _____ 
2 1-5 år: _____ 
3 > 5år: _____ 
 
10 Hvor har du bodd de siste 30 dager: 
1 Hjemme, i min vanlige bolig   _______ 
2 I behandlingsinstitusjon eller sykehus  _______ 
3 I fengsel     _______ 
4 Hos venner/familie    _______ 
5 Annet      _______ 
6 Ukjent      _______ 
9 Ubesvart     _______ 
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C LAR-historie (Spørsmål 1-8 besvares ut fra journalopplysninger i LAR-Øst, 9-11 i intervjuet) 
 
  
1 LAR-start mnd/år:       __________ 
 
2 Alder ved LAR-start (år + mnd.):      __________  
 
3 LAR-slutt mnd/år : __________, evt. flere: 
 
4 Evt. re-inntak i LAR, mnd./år: __________, evt. flere: 
 
5 Årsak LAR-slutt (første gang, evt ved senere avslutninger): 
1 Ekskludert pga. brudd på behandlingsavtale (”aktiv utskrivning”):  ___ 
2 Utskrevet pga ikke hentet LAR-medikament over tid (”passiv utskrivning”): ___ 
3 Frivillig rusfri:        ___ 
4 Frivillig ikke rusfri:       ___ 
5 Død:         ___ 
6 Annet:         ___ 
 
6 Måneder i LAR:    __________ 
 
7 Måneder mellom LAR-perioder:  __________ 
 
8 Måneder etter LAR:   __________ 
 
9 LAR-medikament ved start: 
1 Metadon:   ___  
2 Subutex:   ___ 
3 Suboxone:   ___ 
 
10 Skifte av LAR-medikament (til hva/når/evt. flere ganger): 
 
____________________________________________________________ 
 
11 LAR-medikament og dose ved intervju  
1 Metadon:   ___ dose:  __________  
2 Subutex:   ___   __________   
3 Suboxone:   ___   __________ 
 
 
 
 
D Spesifikk helse – akutte sykdomsepisoder  
 
Formålet med denne studien er å studere helsetilstanden til personer som er eller har vært med i LAR – 
før, mens og evt. etter at de har vært med i LAR. Vi er først og fremst interessert i mer alvorlige 
kroppslige sykdomstilfeller som du er blitt behandlet for ved somatiske sykehus, evt. legevakter. Etter 
intervjuet vil vi gjennomgå journaler fra sykehus og andre steder du har fått behandling.  
 
Jeg vil derfor nå stille noen spørsmål om hvilke sykdommer du har hatt og ved hvilke somatiske 
sykehus du har fått behandling tidligere i livet, og spesielt de siste 5 år før du startet i LAR, de første 5 
år du var i LAR og evt. i tida etter at du sluttet i LAR. (Noter også episoder som kan være lenger tilbake 
enn 5 år før LAR). 
 
Har du vært innlagt eller fått behandling ved noen av disse sykehusene de siste fem år før LAR eller 
senere og kan du huske omtrent når, og hva som feilte deg? 
(Når episoder nevnes, også føre dem inn under avsnittet om episoder registrert etter diagnosegruppe 
nedenfor, slik at man slipper å spørre/registrere dobbelt). 
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Gjøvik: 
 
 
Lillehammer: 
 
 
Hamar: 
 
 
Elverum: 
 
 
Tynset: 
 
 
Kongsvinger: 
 
 
Hønefoss: 
 
 
Har du vært innlagt på eller fått behandling ved sykehus utenfor Oppland og Hedmark? 
 
Oslo: 
 
 
Andre steder: 
 
 
 
Har du fått behandling ved legevakt eller ambulansetjeneste de siste 5 år før LAR eller senere: 
 
 
 
For alle: 
 
Hvilke allmennleger/legesenter har du brukt de siste 5 år før LAR eller senere: 
 
 
 
 
For alle: 
 
Har du hatt følgende sykdommer/skader?  
 
(Spørre om innleggelser/behandling i sykehus/legevakter som evt. ikke ble husket i forrige del, ikke 
gjenta episoder som det alt er opplyst om): Kan du si omtrent når du hadde sykdommen? Dersom du 
fikk behandling for sykdommen, hvor (sykehus/legevakt/legekontor...) fikk du behandling.  
       
For de aktuelle sykdommer spørres: Har du hatt: Ja/nei? Fått behandling (ja/nei) ? Behandling: 
Hvor? Når? 
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Rusrelatert sykdom 
 
1 Overdoser/forgiftninger (tilstand der du pga. rusmidler ble bevisstløs eller ikke i stand til å ta 
vare på deg selv) Antall overdoser med bevisstløshet gjennom hele livet: (Ring rundt rett 
alternativ). 
1) 0   2)   1-2  3)   3-10  4) >10   
 
1b) Overdoser i LAR-perioden: 
1) 0  2) 1-5  3) >5 
 
Sykdom relatert til injisering – Jeg vil nå spørre om en del sykdommer som ofte har sammenheng 
med bruk av sprøyter: 
 
 
2 Blodpropp i armer, bein eller lunger (dyp venetrombose i armer/bein og lungeemboli): 
  
 
 
3 Akutte virusinfeksjoner som kan smitte ved sprøytedeling 
 
(Akutt Hiv-infeksjon. Akutt hepatitt B- eller Hepatitt C-infeksjon, spørr etter ”gulsott” ): 
 
 
4 Lokal infeksjoner i hud og underhud, abscess (byll), erysipelas (rosen), flegmone: 
 
 
5 Alvorlige infeksjoner som spres i kroppen (blodforgiftning, infeksjon i hjerteklaffer, beinvev, 
mellomvirvelskiver, dype og alvorlige bløtvevsinfeksjoner som nekrotiserende fasciitt eller 
annen alvorlig infeksjon): 
 
 
6 Annen sykdom relatert til injisering: 
 
 
 
Annen sykdom relatert til bruk av rusmiddel: 
  
Jeg vil nå spørre om en del andre sykdommer som ofte har sammenheng med rusmiddelbruk: 
 
7 Kraftig abstinensreaksjon med eller uten delirium eller kramper: 
 
 
8 Akutt episode relatert til underernæring, utmattelse eller alvorlig nedsatt allmenntilstand som 
har medført innleggelse/behandling: 
  
 
9 Nyreskade eller nerve-/muskelskader etter langvarig bevisstløshet i forbindelse med 
rusmiddelbruk (nyresvikt, drophand/dropfoot, forbigående eller varige 
lammelser/nerve/muskel-skader): 
 
 
10 Annen akutt sykdom med sammenheng til rusmiddelbruk: 
 
 
 
 Ikke rusrelatert sykdom:  
 
Jeg vil nå spørre om en del andre sykdommer som ofte ikke har sammenheng med bruk av rusmidler: 
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11 Infeksjoner: Luftveier – lungebetennelse, andre betydelige infeksjon (ikke bagateller – 
forkjølelse mm.), Urinveier: Nyrebekkenbetennelse, andre urinveisiinfeksjoner , Annet. 
 
 
 
 
12 Kreft: 
 
 
13 Annen akutt sykdom (hjerte/kar, fordøyelsessystem, nevrologi mm.): 
 
 
 
 
Skader:  
 
Jeg vil nå spørre om skader, jeg tenker da på større skader som har ført til behandling ved sykehus, 
poliklinikker eller legevakter. 
 
14 Hode/ansikt skader (ikke kutt- eller skuddskade): 
 
 
15 Brudd (ikke hode/ansikt): 
 
 
16 Bløtdelsskade (ikke hode/ansikt og ikke kutt/skudd): 
 
  
17 Kuttskade: 
 
 
18 Skuddskade: 
 
 
19 Annen skade: 
 
 
 
  
 
 
E Kroniske sykdommer   
   
Jeg vil nå spørre om du har betydelige kroniske sykdommer/helseproblemer, om du er under behandling for dette 
og om du bruker medisiner for det.  
 
(For hver kategori spørres har/har ikke – hvilken sykdom – behandling/ikke behandling – hvor behandling – og 
medisiner). 
 
1 HIV:  
1 Ja:  ___ 
2 Nei:  ___ 
3 Vet ikke: ___ 
  4 Ikke besvart: ___ 
 
2 Kronisk hepatitt B (”smitteførende”):  
  1 Ja:  ___ 
2 Nei:  ___ 
3 Vet ikke: ___ 
  4 Ikke besvart: ___ 
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3 Hepatitt C: 
  1 Nei, ikke smittet 
  2 Nei, gjennomført behandling, ikke tilbakefall 
  3 Ja, gjennomført behandling, men tilbakefall     
  4 Ja, antistoff positiv, negativ PCR (”ikke påvist virus i blodet”):  ___ 
  5 Ja, antistoff positiv, positiv PCR positiv (”påvist virus i blodet”):  ___ 
  6 Ja, antistoff positiv, ukjent PCR (”ukjent om virus i blodet”):   ___ 
  7 Vet ikke:        ___ 
  8 Ikke besvart:        ___ 
 
    
4 Kreft/ondartet sykdom 
  1 Ja:  ___ 
2 Nei:  ___ 
3 Vet ikke: ___ 
  4 Ikke besvart: ___ 
 
 
5 Annen sykdom 
  1 Ja:  ___  
2 Nei:  ___ 
3 Ikke besvart: ___ 
 
 
 
 
 
 
F Egen oppfatning av helse- og livskvalitet  
 
 
Mange har fått et bedre liv i LAR, mens andre har hatt mer problemer. Jeg vil nå stille noen spørsmål om 
hvordan du mener LAR har virket inn på helsa di og livskvaliteten din. Du skal angi ett svaralternativ på hvert 
spørsmål. 
 
Ring rundt valgt alternativ: 
 
For alle: 
 
1 Hvordan har den fysiske helsa di vært i LAR-perioden sammenlignet med de siste 5 år før 
LAR? 
 
1 Mye dårligere     
2  Litt dårligere 
              3  Uendret 
4 Litt bedre 
5 Mye bedre 
 
 
2 Hvordan har den psykiske helsa di vært i LAR-perioden sammenlignet med de siste 5 år før 
LAR? 
 
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
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3 Hvordan har livet ditt (livskvaliteten) – i det store og hele - vært i LAR-perioden sammenlignet 
med de siste 5 år før LAR? 
 
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
 
 
Bare for dem som svarer litt/mye dårligere livskvalitet i spm. 3: 
 
4 Du synes livskvaliteten din er blitt dårligere etter at du startet i LAR. Kan du angi de viktigste 
årsakene til at livskvaliteten har blitt dårligere? (Spørsmålet stilles åpent, noter inntil to 
stikkord, spør også spesifikt om den viktigste årsaken, som noteres som nr. 1. Noter 
formuleringer mest mulig ordrett). 
 
Stikkord: 
 
1, viktigst: 
 
 
 
2: 
 
 
 
 
Bare for dem som svarer litt/mye bedre livskvalitet i spm. 3: 
 
5 Du synes livskvaliteten din er blitt bedre etter at du startet i LAR Kan du angi de viktigste 
årsakene til at livskvaliteten er blitt bedre? (Spørsmålet stilles åpent, noter inntil to stikkord, 
spør også spesifikt om den viktigste årsaken, som noteres som nr. 1. Noter gjerne 
formuleringer mest mulig ordrett). 
 
Stikkord/formuleringer: 
 
1, viktigst: 
 
 
 
2: 
 
 
 
 
Bare for dem som har avsluttet LAR: 
 
  
6 Hvordan har den fysiske (kroppslige) helsa di vært etter LAR-perioden sammenlignet med tida 
i LAR? 
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
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7 Hvordan har den psykiske helsa di vært etter LAR-perioden sammenlignet med tida i LAR?
  
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
 
8 Hvordan har livet ditt (livskvaliteten) – i det store og hele - vært etter LAR-perioden 
sammenlignet med tida i LAR? 
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
 
 
G Egen oppfatning av forhold til helsevesenet (sykehus, legevakt, allmennlege) 
 
For mange rusmiddelavhengige er forholdet til helsevesenet vanskelig. Dette fører til at mange 
rusmiddelavhengige ikke får tilstrekkelig medisinsk behandling. Jeg vil derfor nå stille noen spørsmål om 
hvordan LAR har virket inn på ditt forhold til helsevesenet. Du skal angi ett svaralternativ for hvert spørsmål. 
 
Ring rundt valgt alternativ: 
 
 
For alle: 
 
 
1 Når du sammenligner tida før du startet i LAR – gjerne de siste fem årene – med perioden i 
LAR, har du da i større eller mindre grad fått hjelp for dine helseplager i tida du har vært med i 
LAR i forhold til tida før LAR? 
 
1  I mye mindre grad     
2  I litt mindre grad 
3 Uendret 
4 I litt større grad 
5 I mye større grad 
      
 
For dem som svarer at de har fått mindre hjelp for helseplager i LAR (alt., 1-2) i spm. 1: 
 
2 Hva oppfatter du som den viktigste årsaken til at du har fått mindre hjelp til 
helseproblemer i LAR? (Spørsmålet stilles åpent, noter inntil to stikkord, og marker så 
alternativ nedenfor som passer best med stikkordene. Spør også spesifikt om den 
viktigste årsaken, som noteres som nr. 1. Noter gjerne formuleringer mest mulig 
ordrett). 
 
Stikkord: 
 
1, viktigst: 
 
 
 
2: 
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For dem som svarer at de har fått mer hjelp for helseplager i LAR (alt. 5-6-7) i spm. 1: 
 
3 Hva oppfatter du som den viktigste årsaken til at du har fått mer hjelp til helseproblemer i 
LAR? (Spørsmålet stilles åpent, noter inntil to stikkord, og marker så alternativ nedenfor som 
passer best med stikkordene. Spør også spesifikt om den viktigste årsaken, som noteres som nr. 
1. Noter gjerne formuleringer mest mulig ordrett). 
 
Stikkord: 
 
1, viktigst: 
 
 
 
2: 
 
 
 
 
 
For alle: 
 
4 Hvordan oppfatter du den hjelpen du har fått spesielt fra allmennlegene i tida du har vært med i 
LAR i forhold til tida før LAR? 
 
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
    
 
5 I den grad du har hatt konflikter med allmennlegene du har brukt, har det vært mer eller mindre 
konflikt i tida du har vært med i LAR i forhold til tida før LAR? 
 
1 Mye mer konflikt    
2  Litt mer konflikt 
              3  Uendret 
4 Litt mindre konflikt 
5  Mye mindre konflikt 
      
Bare for dem som har avsluttet LAR: 
 
6      Har du i større eller mindre grad fått hjelp for dine helseplager i tida etter LAR i forhold til tida 
du var med i LAR? 
 
1  I mye mindre grad     
2  I litt mindre grad 
3 Uendret 
4 I litt større grad 
5 I mye større grad 
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7 Hvordan oppfatter du den hjelpen du har fått fra allmennlegene spesielt i tida etter LAR i 
forhold til tida du var med i LAR? 
  
1 Mye dårligere     
2 Litt dårligere 
3  Uendret 
4 Litt bedre 
5 Mye bedre 
 
 
8 I den grad du har hatt konflikter med allmennlegene du har brukt, har det vært mer eller mindre 
konflikt i tida etter LAR i forhold til tida før LAR? 
 
1 Mye mer konflikt    
2  Litt mer konflikt 
              3  Uendret 
4 Litt mindre konflikt 
5  Mye mindre konflikt 
  
  
 
  
H Mental helse siste to uker 
 
 Jeg vil nå stille fem spørsmål om hvordan du har hatt det psykisk den senere tid. 
 
 Har du i løpet av de siste to ukene var plaget av noe av det følgende? 
 
     Ikke plaget      Litt plaget      Ganske mye Veldig mye 
         Plaget  plaget 
 
 
1 Vært stadig redd 
eller engstelig  ___  ___  ___  ___ 
 
2 Følt deg anspent 
  eller urolig  ___  ___  ___  ___ 
   
  3        Følt håpløshet  
med hensyn til 
framtida   ___  ___  ___  ___ 
 
4 Følt deg nedfor 
eller trist  ___  ___  ___  ___ 
 
 5 Bekymret deg 
  for mye om 
  forskjellige ting  ___  ___  ___  ___ 
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I Bruk av rusmidler  
  
Jeg vil nå stille noen spørsmål om bruk av rusmidler. Hvor mange av de siste 30 dager har du brukt 
følgende rusmidler? 
 
          Dager 
 
1 Alkohol, ikke til beruselse      _____ 
 
 2 Alkohol, til beruselse      _____ 
 
3 Nikotin        _____ 
  
4 Heroin        _____ 
 
5 Andre opiater, smertestillende preparater ikke forskrevet av lege _____ 
 
6 Dempende medisin (benzodiazepiner, andre beroligende, sovemedisin.), 
  
   ikke forskrevet av lege      _____ 
 
7 Kokain        _____ 
 
8 Amfetaminer       _____ 
 
9 Cannabis       _____ 
 
10 Tatt rusmiddel med sprøyte     _____ 
 
 
Jeg vil nå spørre om rusmiddelbruk tidligere i livet. Hvor gammel var du første gang du brukte hvert av disse 
stoffene (alder i år), og hvor mange år har du til sammen brukt dem (hele tall)? (Det spørres om antall år med 
enhver bruk, også sporadisk (>1 gang pr. år), og om antall år med avhengighetspreget bruk (daglig eller flere 
ganger i uka) dersom middelet er tilgjengelig). 
 
Debut? Antall år  Antall år  
  all bruk?  brukt flere ganger  
ukentlig til daglig?  
  
11  Alkohol      _____ _____ _____ 
 
12  Nikotin       _____ _____ _____ 
 
13 Heroin      _____ _____ _____ 
 
14 Andre opiater, smertestillende preparater  _____ _____ _____ 
 
15 Dempende medisin (benzo, andre beroligende, sovemed.)  
 
_____ _____ _____ 
 
16 Kokain      _____  _____ _____ 
 
17 Amfetaminer     _____ _____ _____ 
 
18 Cannabis     _____ _____ _____ 
 
19 Tatt rusmiddel med sprøyte   _____ _____ _____ 
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J Bruk av medikamenter 
 
Hvor mange av de siste 30 dager har du brukt følgende medikamenter forskrevet av lege? 
 
1 Rivotril/Xanor/Flunipam – hvilke/dager:      
   
  _________________________          _____  
 
  _________________________          _____  
 
 
 
 
 
2 Andre benzodiazepiner (Vival, Valium, Stesolid, Sobril, Alopam, Mogadon o. a.) –  
hvilke/dager: 
 
  _________________________          _____  
 
_________________________          _____ 
 
 
 
3 Benzodiazepinlignende sovemedisiner (Imovane, Stilnoct)  
 
– hvilke/dager:          
   
  _________________________          _____ 
 
 
4            Opioidholdige smertestillende eller hostestillende medisin  
 
– hvilke/dager:        
 
_________________________          _____ 
   
5            ADHD-medisin (Strattera, Ritalin, Concerta) –  
 
hvilke/dose:     
 
  _________________________          _____ 
 
 
K Intervjuers vurdering av informant og informasjon 
 
  Ring rundt valgt alternativ: 
 
1 Klinisk ruspåvirket:  
1 Nei 
2 Lett grad 
3 Betydelig grad 
4 Ukjent 
 
2 Holdning til intervjuer/intervjuet:  
1 Positiv/vennlig 
2 Negativ/fiendtlig 
3 Ukjent 
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3 Virker informasjonen i intervjuet troverdig: 
1  Ja 
2 Nei 
3 Usikker 
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Abstract
Background: The long-term impact of opioid maintenance treatment (OMT) on morbidity and health care
utilization among heroin addicts has been insufficiently studied. The objective of this study was to investigate
whether health care utilization due to somatic disease decreased during OMT, and if so, whether the reduction
included all kinds of diseases and whether a reduction was related to abstinence from drug use.
Methods: Cohort study with retrospective registration of somatic disease incidents (health problems, acute or
sub-acute, or acute problems related to chronic disease, resulting in a health care contact). Medical record data
were collected from hospitals, Outpatients' Departments, emergency wards and from general practitioners (GPs)
and prospective data on substance use during OMT were available from 2001 onwards. The observation period
was five years before and up to five years during OMT. The cohort consisted of 35 out of 40 patients who received
OMT between April 1999 and January 2005 in a Norwegian district town. Statistical significance concerning
changes in number of incidents and inpatient and outpatient days during OMT compared with the pre OMT
period was calculated according to Wilcoxon signed rank test. Significance concerning pre/during OMT changes
in disease incidents by relation to the type of health service contacts, as well as the impact of ongoing substance
use during OMT on the volume of contacts, was calculated according to Pearson chi-square and Fisher's exact
tests.
Results: 278 disease incidents were registered. There was a reduction in all incidents by 35% (p = 0.004), in
substance-related incidents by 62% (p < 0.001) and in injection-related incidents by 70% (p < 0.001). There was
an insignificant reduction in non-fatal overdose incidents by 44% (p = 0.127) and an insignificant increase in non-
substance-related incidents by 13% (p = 0.741). Inpatient and outpatient days were reduced by 76% (p = 0.003)
and 46% (p = 0.060), respectively. The disease incidents were less often drug-related during OMT (p < 0.001).
Patients experienced a reduction in substance-related disease incidents regardless of ongoing substance use,
however there was a trend towards greater reductions in those without ongoing abuse.
Conclusion: Although as few as 35 patients were included, this study demonstrates a significant reduction in
health care utilization due to somatic disease incidents during OMT. The reduction was most pronounced for
incidents related to substance use and injection. Inpatient and outpatient days were reduced. Most probably these
findings reflect somatic health improvement among heroin addicts during OMT.
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Background
Opioid addicts, especially injecting heroin users, suffer
increased health problems [1-3] and reduced health
related quality of life (HRQOL) [4-7] as well as increased
mortality, compared to the general population [8-10].
This is particularly related to overdoses [11-14], injuries
[9], human immunodeficiency virus (HIV)-infection
[9,11], viral hepatitis B (HBV) [15,16] and viral hepatitis
C (HCV) [16,17] with end-state liver disease and other
infections like endocarditis [9], osteomyelitis [18] and
others [19,20]. Several studies and case reports demon-
strate vulnerability among injecting drug users (IDUs) to
rare infectious diseases like tetanus [21], botulism [22,23]
and gas gangrene due to Clostridium [21,24-27].
Increased prevalence of various psychiatric diseases
among substance users is well documented in population
surveys and among persons entering opioid maintenance
treatment (OMT) [28-33].
In spite of considerable morbidity, drug users frequently
neglect their health problems, and diseases may remain
untreated. Several studies describe that patients with
extensive drug use cause problems in hospitals [34] and
are difficult to treat in ordinary general practice. Yet some
studies based on central health registers show increased
health care utilization, in particular due to intoxications/
overdoses, infections related to illicit drug use and injuries
[35].
OMT leads to reduced illegal opioid use and injection [36-
39] which probably reduces overdoses and infections. It is
also likely that OMT improves nutritional status and gen-
eral health. Moreover, OMT patients may become more
motivated to seek medical help, and OMT may remove or
at least reduce tension between patients and health service
providers, thus leading to improved health care follow-
up. It is therefore reasonable to assume that over time
OMT will reduce morbidity and mortality. Reduction in
mortality during OMT has been shown in observational
studies [11], but in two recent meta-analyzes of ran-
domised controlled trials (RCTs) mortality reduction
could not be documented [36,38]. However, this might be
due to problems applying RCT design in studies on OMT
effects versus placebo or no treatment [40]. Some studies
have shown improved psychological well-being, reduced
frequency of self-reported physical health problems, and
improved self-perceived HRQOL during OMT [37,41].
Except for this, documentation of OMT-induced health
effects is poor [42]. Consequently observational studies
with careful design might increase the understanding of
OMT effects on health care utilization and also on mor-
bidity.
With a national OMT program implemented during a
short time span and a well documented and severe illicit
drug problem [39], Norway is well suited for such studies.
The number of IDUs in Norway is estimated to 8 200 – 12
500 persons out of a population of 4.7 millions in 2005
[43]. The number of OMT patients December 31th 2005
was 3 614 [44]. Although heroin is usually injected [45]
the prevalence of HIV among heroin users is as low as 1–
2% [46]. The cumulative number of IDUs infected with
HIV from the early 1980s until 2006 is 528 [46]. The anti-
HCV antibody prevalence among IDUs is 70–80% [47]
and approximately 2/3 of these are Polymerase Chain
Reaction (PCR) positive [48]. The death rate among drug
users has been estimated to about 1–2% per year [45]. The
number of registered overdose deaths has been high with
a peak of 405 in 2001 falling to 231 in 2004 [45]. Severe
psychiatric co-morbidity ("double-diagnosis") is docu-
mented in about 1/3 of IDUs [49].
The national OMT program keeps overall surveillance of
patients entering and leaving. Entrance depends on spe-
cific criteria [39]: patients should be at least 25 years old,
have been dependent on opioids for "several" years and
have undergone abstinence-oriented treatment. Treat-
ment is ended if patients fail to pick up the medication
over time, and may be involuntary terminated if patients
show continued illicit drug use, sell the OMT-medication
or illegal drugs, act threatening or violent towards treat-
ment personnel or show severe lack of willingness to fulfil
the program regulations. Authorized regional centres
cooperate with municipal social service and GPs. Only
methadone and buprenorphine are accepted as substitu-
tion medication and the average dosage level is high: 114
mg and 18 mg respectively in 2005 [44]. Retention in
treatment – which means the proportion of patients who
stay in the program over time – is high, compared to most
other countries [39].
The systematic collection of information on all partici-
pants in the OMT-program as well as computer-based
record systems in primary health care and hospitals make
Norway suitable for detailed studies of OMT related
health effects. The objective of this study was to investi-
gate health care utilization due to somatic disease before
versus during OMT in a cohort of OMT-patients. The
hypothesis was that such health care contact would
decrease during OMT, mainly due to reduced health prob-
lems related to illicit drug use and injection. Further, we
wanted to investigate whether such possible reduction
would occur only in patients who stayed abstinent from
illicit drug use or also among those with ongoing abuse.
Methods
Our study compares health care utilization due to somatic
disease before versus during OMT using a retrospective
cohort design.
BMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
Page 3 of 8
(page number not for citation purposes)
Study population
The study was carried out in Gjoevik, a district town with
28 000 inhabitants and with considerable drug problems.
OMT was started locally in 1999, according to the guide-
lines of the national program. However, over the years the
GPs have come to play a more important role than is typ-
ical for OMT in Norway. Further, very few patients, even
among those with ongoing substance use, have had their
treatment involuntarily terminated, rather they have
received increased follow-up by GPs and social workers.
Outcome concerning social rehabilitation and continued
substance use during OMT has been close to national
average [50]. By the end of 2005, all 40 patients who had
started OMT were still in treatment, and 36 consented to
participate in the study. Data were not collected for one
person, rendering 35 participants (87.5%). Key character-
istics of the study population are summarized in Table 1.
The observation period was five years prior to and up to
five years during OMT; the mean observation period dur-
ing OMT was 35 months. Three patients temporarily ter-
minated OMT and then restarted. Disease incidents and
health care utilization that occurred while the three
patients were between OMT periods (in total five years)
were counted as pre-OMT.
Data sources
Thirty-two of the participants were interviewed about dis-
ease incidents during OMT and the years prior to OMT.
One of the authors (IS, physician) performed all inter-
views, which took place in a primary care centre or in the
patient's home. As no validated questionnaire suitable for
collecting this information was available, a list of relevant
diagnoses (Table 2) was used, as well as Time-line Follow-
back procedures, in order to facilitate remembering dis-
ease incidents and treatment.
Based upon the information obtained in the interviews,
records from hospitals, emergency wards and GPs were
collected. For the three persons not interviewed, hospital
records were collected based upon information in their
GPs' records. All requested records concerning inpatient
treatment, treatment in Outpatients' Departments (in
Norway these are hospital units), emergency wards (in
Norway these are part of the primary health care and
staffed by GPs), and 75 out of 82 records from solo GPs
and GP groups (in Norway most GPs work together in
groups of 3–5 sharing a joint record system) were received
and scrutinized. Data collection was concluded in June
2005. All data on diagnosis and health care utilization
presented in the study originate from these records.
Admissions and health care visits mentioned by patients
which could not be verified from records were not
included. Records from hospitals and GPs which had not
been specified by the participants were not requested.
Measures
A "disease incident" was defined as a health problem,
acute or sub-acute, resulting in a health care contact. Only
somatic incidents were counted, psychiatric illness was
only considered if it caused a somatic incident, e.g. an
injury due to self harm. A disease incident could be an iso-
lated case, for instance an overdose, an infection or an
injury, or a new incident due to an underlying chronic dis-
ease, for instance an asthma attack. Even if a disease inci-
dent lead to more than one health care visit, e.g. follow-
up visits for a fracture, it was registered as one incident.
Routine hospital or GP check ups for chronic diseases or
repeated treatment visits for a chronic disease, e.g. hepati-
tis C, were not included. Disease incidents documented in
several records, e.g. from a hospital and a GP, were only
counted once. We also counted number of inpatient treat-
ment days (inpatient days) and treatment days in hospi-
tals' Outpatients' Departments (outpatient days) due to
the disease incidents we registered.
The full-text records were scrutinized by one of the
authors (IS). ICD-10 [51] diagnoses from hospitals and
ICPC [52] diagnoses from GPs were registered. Based on
record information the disease incidents were categorized
Table 1: Cohort characteristics
Male Female
Gender, n (%) 22 (63) 13 (37)
Age at OMT-start, years, mean (range) 37.3 (29.4 – 50.5) 37.5 (27.3 – 50.3)
OMT medication, methadone, n 19 11
OMT medication, buprenorphine, n 3 2
Methadone dosage mg, median (range) 132.5 (100 – 220) 145 (100 – 170)*
Buprenorphine dosage mg, median (range) 22(16 – 32) 22 (20 – 24)
HCV antibody positive, n (%) 21 (95.5) 13 (100)
Receiving anti HCV treatment during OMT, n 1 0
HIV antibody positive, n 0 0
Died during OMT, n 0 0
*One outlier, 580 mg
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by mean of a diagnosis list developed for this study (Table
2). The list differentiates between drug related incidents
and others. Drug related incidents were categorized as
overdoses, injection related incidents and "others", like
rhabdomyolysis and related neuro-muscular damage
related to non-fatal overdoses, severe withdrawal reac-
tions, inpatient treatment because of severe exhaustion,
malnutrition and poor general condition due to drug use,
severe sub-acute dental health problems and several oth-
ers. The incidents not related to drug use were divided into
infections, injuries and "others", the latter including all
incidents not fitting into the specific categories.
Inter-rater agreement on relation to substance use and
diagnostic categories was estimated for 22 disease inci-
dents in six patients by two independent investigators (IS
and another physician). Agreement regarding relation to
substance use was perfect with a kappa value () of 1.
When diagnostic groups were considered,  was 0.82.
Information about ongoing use of illicit drugs and alco-
hol during OMT, based on urinary testing and clinical
assessment, was gathered from the annual reports made
for each OMT patient in Norway since 2001 [39]. For four
patients the treatment period was too short or provided
insufficient information on substance use; thus rendering
such information for 31 patients. The annual report scores
overall drug use during the last four weeks on a five-point
scale. In our study we simplified this to a dichotomized
score for the entire treatment period, differentiating
between "problematic" use with severe consequences for
psychosocial function versus "abstinence or non-prob-
lematic use" without such consequences.
Statistics and ethics
Wilcoxon signed rank test was used to compare changes in
rates of episodes before versus during OMT. Pearson chi-
square and Fisher's exact test were used to evaluate the
changes in the proportion of incidents related to sub-
stance use as well as assessment of health improvement
versus ongoing use of illegal drugs and alcohol during
OMT. Inter-rater agreement was estimated according to
Cohen's kappa. All statistical calculations were performed
in SPSS 14.0.
Table 2: Before/during OMT changes in disease incidents and inpatient and outpatient days. Number of somatic disease incidents* and 
inpatient and outpatient days* per 100 patient years before and during opioid maintenance treatment (OMT) in 35 patients.
Before OMT During OMT Reduction % Increase % P-value**
Incidents/treatment days per 
100 patient ears
Incidents/treatment days per 
100 patient years
Substance-related incidents
Overdoses (non-fatal) 17.7 9.9 44 0.127
Injection-related incidents, total*** 40.6 11.8 70 <0.001
Acute thromboembolic incidents 4.6 0.0
Acute hepatitis 1.7 0.0
Acute local infection 32.6 10.9
Acute/sub-acute general infection 1.7 1.0
Other substance-related incidents 21.7 8.9 59 0.087
Total 80.0 30.6 62 <0.001
Non-substance-related incidents
Infections 10.3 8.9 14 0.849
Injuries 20.6 19.7 4 0.832
Other incidents 12.6 20.7 64 0.375
Total 43.5 49.3 13 0.741
All incidents 123.5 79.9 35 0.004
Treatment days
Inpatient days 257.0 61.0 76 0.003
Outpatient days 59.0 32.0 45 0.060
*Definition of disease incident and treatment days, see text
**Wilcoxon signed rank test
***Overdoses not included, subcategories of incidents in italic
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The Regional Committee for Research Ethics approved the
study.
Results
Table 1 gives a summary of basic demographic and treat-
ment characteristics for the patient sample. The gender
distribution is typical for IDUs and mean age at OMT start
is 37 years. Treatment is high dosage, dominantly with
methadone as agonist. Nearly all patients are HCV-anti-
body positive, reflecting the dominant injecting drug use
pattern.
Altogether, 278 disease incidents were registered during
the observation period, 197 before and 81 during OMT.
Table 2 presents findings on health care utilization before
and during OMT. The overall reduction in disease inci-
dents was 35% (p = 0,004). There was a reduction of 62%
in substance-related incidents (p < 0.001), a 70% reduc-
tion in injection related incidents (p < 0.001), and an
insignificant reduction of 44 and 59% respectively in
overdoses and other substance-related incidents. There
was an insignificant increase of 13% in non-substance-
related disease incidents, exclusively in the group "other",
while infections and injuries showed minor change. Inpa-
tient and outpatient days due to somatic disease incidents
were reduced by 76% (p = 0.003) and 46% (p = 0.060)
respectively.
Table 3 shows the pre/during OMT shift in the distribu-
tion of disease incidents by relation to substance use.
Before OMT 62% of the incidents were related to sub-
stance use, compared to 36% during OMT (p < 0.001).
Table 4 displays health service contacts made during the
278 disease incidents. Forty per cent of all disease inci-
dents during OMT were documented exclusively by GPs,
compared with 25% before OMT (p = 0.02). Around 90%
of all hospital treatment, before as well as during OMT,
took place at the local hospital in Gjoevik.
Table 5 shows changes in disease incidents in nine
patients with and 22 patients without problematic sub-
stance use during OMT. Regarding injection-related inci-
dents, there was no difference between the groups, both
showing improvement. The reduction in all substance-
related incidents was greater for patients without prob-
lematic drug use, but the difference was not statistically
significant (p = 0.06). The reduction in the total number
of incidents was significantly greater for patients without
problematic drug use (p = 0.007).
Discussion
The primary goal of this study was to investigate how
OMT influences health service utilization in heroin
addicts. The study demonstrates a significant reduction in
health care contacts due to somatic disease incidents dur-
ing the five first years of OMT compared to the five previ-
ous years. This is a significant finding. Even if several
studies have shown severe morbidity among heroin
addicts, and some have found health improvement dur-
ing maintenance treatment [37,41], we have not been
able to find any study systematically comparing somatic
morbidity before OMT with morbidity during treatment,
based on record information.
The key question regarding the interpretation of our find-
ings is whether the observed reduction in health care uti-
lization can be seen as an indicator of health
improvement during OMT compared to the period
before. Firstly, how complete was the registration of
admissions and health care visits? The study cohort
includes nearly all OMT-patients in a defined area; hence
selection bias was not a problem. Recall bias could be a
problem, greater the further back we go. The patients'
information turned out to be chiefly correct, when con-
trolled against the records, regarding type of disease or
injury and where treatment had been received, but more
imprecise regarding the point of time. Each patient had on
average been treated at two GP centres, and approximately
90% of all hospital treatment had taken place at the local
hospital which shows a high degree of stability in the rela-
tion between treatment services and the patient group in
Table 4: Changes in type of health service contact. Before/during 
OMT changes in distribution of somatic disease incidents 
separated by type of health service contact. N = 278
Number of incidents (%)
GP* Hosp+**
Before OMT 49 (25) 148 (75)
During OMT 32 (40) 49 (60)
P-value 0.015***
*General practitioner
**Hospital/outpatient clinic/emergency ward
*** Pearson chi-square test
Table 3: Distribution of somatic disease incidents before and 
during OMT by relation to substance use. N = 278.
Relation to substance use* Before OMT (%) During OMT (%) P-value**
Related 123 (62) 29 (36)
Not related 74 (38) 52 (64)
Total 197 (100) 81 (100) <0.001
* Inter-rater agreement  = 1.00
**Pearson chi-square test
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Gjoevik. The study thus comprises the majority of health
service contacts due to somatic disease incidents during
the study period.
Secondly, there will be a gap between the volume of dis-
ease in any patient sample, and what results in health
service contacts, and this is particularly so in a population
of IDUs [34]. Due to the structure of the treatment pro-
gram, contact between patients and the health services
was close during OMT, probably leading to increased
help-seeking and better medical follow-up and tending to
reduce the proportion of disease incidents not resulting in
a health service contact. Thirdly, the patients were five
years older during the OMT period, leading to increased
somatic morbidity. These factors all tend to increase the
volume of registered health care contacts during OMT.
Hence, when our study still shows a decline in utilization
of health services, this most probably is a proxy for an
improvement in somatic health status, and moreover, the
OMT-induced improvement is probably more extensive
than our findings indicate.
Even six out of nine patients with ongoing problematic
substance use during OMT experienced a reduction in
drug related disease incidents. The most likely explana-
tion is that they stop or at least reduce injecting drugs.
However, due to the increase in non-substance-related
disease incidents, the majority of patients with problem-
atic substance-use showed an increase in the total number
of incidents during OMT. This could be a consequence of
changed help-seeking behaviour and better medical fol-
low-up during OMT. If so, this finding reflects improved
follow-up and not a true rise in morbidity. On the other
hand, it is conceivable that patients with ongoing drug
abuse during OMT are more exposed to disease than those
without. However, because of the small number of
patients, and some uncertainty concerning the differenti-
ation between patients with and without ongoing prob-
lematic substance abuse, these results and their
significance should be interpreted with caution.
OMT is often evaluated primarily by its effect on social
rehabilitation and continued substance use. According to
our findings, this is not sufficient. Drug related disease
incidents were reduced even among patients with ongoing
abuse, though to a lesser degree. This might question
involuntary termination of OMT in patients who still take
illegal drugs.
The study has some weaknesses. The cohort is small and
limited to one local community. The research instru-
ments, especially the diagnosis categorisation system,
have not been validated by other researchers. In addition,
it is not always obvious whether a disease incident is
related to substance use or not. However, the high level of
inter-rater agreement on whether incidents were sub-
stance related or not ( = 1) implies that this is possible to
differentiate.
In spite of these weaknesses, our study of a small patient
cohort showed a significant reduction in health care con-
tacts caused by somatic disease incidents during OMT
compared to the five years prior to treatment. These find-
ings ought to be further investigated in an enlarged study.
Table 5: Health care utilization versus ongoing illicit drug use during OMT. Number of patients with reduced, unchanged or increased 
rates of all, substance-related and injection-related somatic disease incidents respectively, in 22 patients with and 9 patients without 
problematic* illicit drug use during OMT
Diagnose group Change in incidents during versus before OMT, number of patients
Illicit drug use Reduction Unchanged Increase Total P value**
All incidents 0.007
Abstinence or non-problematic 18 1*** 3 22
Problematic 3 0 6 9
All substance-related incidents 0.063
Abstinence or non-problematic 18 3**** 1 22
Problematic 6 0 3 9
Injection-related incidents 0.503
Abstinence or non-problematic 15 6*** 1 22
Problematic 6 2*** 1 9
* Definition of problematic drug use, see text
**Chi-square Fisher's exact test: number of patients with increased versus reduced/unchanged rates of all, substance-related and injection-related 
incidents respectively, versus illicit drug use during OMT
*** Patients had zero episodes during both time periods
****Two of the three patients had zero episodes
BMC Public Health 2008, 8:43 http://www.biomedcentral.com/1471-2458/8/43
Page 7 of 8
(page number not for citation purposes)
This could bring information about factors influencing
somatic health status changes during OMT, like psychiat-
ric co-morbidity or living in a larger city. The design cho-
sen appears suitable for investigating OMT-related
changes in somatic morbidity among heroin addicts in
Norway.
Conclusion
Even with as few as 35 patients included, this study dem-
onstrates a significant decrease in health care contacts due
to somatic disease incidents during OMT compared to the
five years before entering treatment. This reduction was
most striking for incidents related to substance use, and
drug injection in particular. Inpatient treatment days and
treatment days in hospitals' Outpatients' Departments
were reduced during OMT. These findings most probably
reflect an improvement in somatic health status for drug
abusers undergoing OMT compared to the period before
entering treatment.
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Changes in somatic disease incidents
during opioid maintenance treatment:
results from a Norwegian cohort study
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ABSTRACT
Objectives: To examine the effect of opioid
maintenance treatment (OMT) on somatic morbidity in
a cohort of OMT patients.
Design: Retrospective cohort study.
Setting: OMT programme in two Norwegian counties.
Participants: 200 OMT patients, participation rate
71.2%.
Main outcome measures: Incidence rates (IR)
before, during and after OMT for acute/subacute
hospital-treated somatic disease incidents (drug-
related, non-drug-related, injuries) and rates for
inpatient days and outpatient treatment contacts.
Results: IR for drug-related hospital treatment
episodes were 76% lower during compared to before
OMT (before versus during incidence rate ratio (IRR)
4.2 (95% CI 2.9 to 6.2), p<0.001) and 11 times higher
after compared to during OMT (after versus during IRR
11.1 (6.6 to 18.5), p<0.001). For non-drug-related
treatment episodes, IR were 35% higher during than
before OMT (before versus during IRR 0.7 (0.6 to 1.0),
p¼0.02) and 32% higher after compared to during OMT
(IRR 1.4 (0.9 to 2.2), p¼0.15), while injuries showed
little change according to OMT status. Although patients
with on-going drug-taking during OMT showed less
reduction in drug-related hospital-treated incidents
during treatment than patients not using illicit drugs, the
quartile with most drug-taking showed a signiﬁcant
reduction (before versus during IRR 3.6 (2.4 to 5.3)).
Patients who had experienced cessation of OMT
showed a signiﬁcant reduction in drug-related
treatment episodes during OMT (before versus during
IRR 1.7 (1.0 to 2.9)), although less than patients without
OMT interruptions (before versus during IRR 6.1 (3.6 to
10.6)), and a signiﬁcant increase after OMT cessation
compared with during OMT (IRR 5.4 (3.0 to 9.7)).
Conclusion: Acute/subacute drug-related somatic
morbidity is reduced during compared to before OMT.
This was also found for patients with on-going drug-
taking during OMT. However, acute drug-related health
problems show an increase after OMT cessation, and
this is a matter of concern. Further studies on somatic
morbidity after OMT cessation should be carried out.
INTRODUCTION
Dependent opioid users, especially those
injecting heroin, have increased somatic1e3
and psychological morbidity3e6 and reduced
health-related quality of life.7 8 Injecting drug
users are prone to chronic bloodborne viral
infections, especially HIV/AIDS9 10 and
chronic hepatitis B11 and hepatitis C,11 12 as
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ARTICLE SUMMARY
Article focus
- Opioid maintenance treatment (OMT) is the most
widely used treatment for opioid dependence, but
the effects of OMT on physical health problems
have received relatively little attention.
- This study investigates how acute somatic
morbidity (drug-related, non-drug-related,
injuries) varies according to OMT status
(before, during, after OMT) in a cohort of 200
OMT patients.
- The research questions were: Is somatic
morbidity reduced during OMT compared to
before and after treatment? If so, what types of
disease incidents are reduced? How is the effect
of OMT status on somatic morbidity inﬂuenced
by various patient characteristics?
Key messages
- Acute drug-related somatic morbidity (overdoses,
injecting-related, other) is substantially reduced
during compared to before OMT.
- This was also found for ‘problem patients’ with
on-going drug-taking during OMT, but to a lesser
degree than for patients not using illicit drugs.
Strengths and limitations of this study
Strengths
- Participation rate was high, selection bias limited,
observation period long and the evaluation of
morbidity changes was based on assessment of
full-text hospital records.
Limitations
- The study focused on acute health problems
treated in hospital, but elective hospital contact
due to chronic health problems and primary
healthcare contacts were not included.
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well as acute and subacute bacterial infections and other
complications related to injecting.13 Opioid dependence
is associated with social marginalisation, criminality and
socioeconomic deprivation accompanied by malnutrition,
chronic diseases and generally impaired health as well as
exposure to overdoses and trauma.1 Mortality among
injecting drug users is much greater than in the general
population, with a standardised mortality ratio ranging
from 5 to 30 in studies from several countries.10 14 The
main causes of death (in descending order) are overdose,
diseases, trauma and suicide.10
Maintenance treatment, hereafter called opioid
maintenance treatment (OMT), has been the most
widely used treatment for opioid dependence for the last
number of decades.15 The speciﬁc changes in physical
and mental health that occur during OMT have received
surprisingly little detailed research attention.16 Mainte-
nance treatment leads to reduced use of illegal opioids
and less injection.17 18 It also induces tolerance to
opioids,19 20 and a corresponding decline in drug-
related morbidity including overdoses should be
expected. Some studies report improved somatic health
during OMT based on interviews,17 clinical assessment21
and reduced consumption of inpatient care due to
infections,22 23 but relatively few studies have investi-
gated OMT-related somatic health effects and morbidity
patterns. In a previous study we found reductions in
somatic disease incidents treated in hospital or by
general practitioners during OMT compared to ‘not in
treatment’.24 Drug-related incidents were reduced by
about two thirds, but non-drug-related incidents showed
a non-signiﬁcant increase (possibly due to closer contact
with health services) and injuries showed no change
during treatment. These ﬁndings were, however, based
upon a small sample of patients from one municipality.
In order to evaluate the effects of maintenance treat-
ment, it is necessary to study morbidity prior to, during
and after OMT. Such studies are scarce, and very few
include long-term follow-up.
The present study investigates how somatic
co-morbidity varies according to OMT status (before,
during and after OMT) in a group of 200 patients. The
main hypothesis to be tested was that somatic morbidity
is reduced during OMT. More detailed research ques-
tions were: (1) What changes in somatic morbidity are
found during OMT compared to before and after
treatment, and what types of disease incidents are
reduced? and (2) How is the effect of OMT status on
somatic morbidity inﬂuenced by various patient charac-
teristics?
MATERIALS AND METHODS
Design, sample and setting
Methadone and buprenorphine are used as substitution
medications in the national Norwegian OMT
programme, which began in 1998. On 13 December
2009, 5383 people were in treatment, and 55.7% were
receiving methadone and 44.3% buprenorphine.25
Norway has a population of 4.9 million and the target
group for OMT is estimated to be about 10 000.25
The study has a retrospective cohort design. The
cohort was established in 2007e8 and consists of those
admitted to OMT from 1998 until the end of June 2007
in two counties (Hedmark and Oppland) in Norway
(ﬁgure 1). The participants were recruited through their
treatment contacts. Out of a total of 319 patients who
started OMT, 38 had no contact with local health or
social services at the time of invitation and were
regarded as ineligible for this study. Of the remaining
281, 13 who died after their ﬁrst OMT entry were
included. Among the 268 eligible subjects still alive, 187
consented to participate and 81 did not, and so the
cohort consisted of 200 persons. The participation rate
was 71.2%, 68.8% among patients in treatment versus
73.7% among those not in treatment when invited.
Measures
A somatic disease incident was deﬁned as any acute or
subacute health problem leading to inpatient or outpa-
tient hospital treatment, henceforth called hospital
treatment episodes, treatment episodes or just episodes.
The numbers of hospital treatment episodes, inpatient
days and outpatient hospital contacts were recorded.
Incidence rates and rates of inpatient days and outpa-
tient contacts for the periods before, during and after
OMTwere calculated. Incidence rate ratios before versus
during treatment and after versus during treatment were
estimated. Only records from somatic departments were
examined. Psychiatric disease incidents were only
considered if they caused a somatic condition, for
example due to self-harm. Hospital contacts for chronic
somatic disorders were not included, but acute treat-
ment episodes caused by an underlying chronic disease
were assessed. One episode could lead to more than one
contact, for instance follow-up of a fracture or an
abscess. One episode documented in records from
several hospitals was only counted once. Episodes were
Figure 1 Participants: patients starting opioid maintenance
treatment between 1998 and June 2007. The studied cohort
consists of the 200 included patients.
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categorised as drug-related (overdoses, injecting-related,
other), non-drug-related (infection, other) or injuries.
Data
One hundred and thirty-six of the 187 alive participants
(73%) underwent structured interviews which collected
information on personal data, former hospital contacts
and drug history as well as education and employment
history.
Records from somatic departments in local hospitals
were examined for all participants. Based on interview
information, records from other hospitals were collected
and more than 99% of all requested records were
examined. Only incidents of somatic disease docu-
mented in hospital records were included and records
for all 200 participants were examined.
Data were also drawn from annual status reports on
each patient in the national OMT programme with
information about ongoing drug-taking during OMT
based on urine tests and clinical assessment. A combined
score based on use of illicit opioids, cannabis, benzodi-
azepines and central stimulants during OMT was calcu-
lated for each patient. Data were obtained for 183
participants (91.5%).
Observation period
Data were studied for the 5 years before ﬁrst admittance
to maintenance treatment, up to the ﬁrst 5 years during
OMT (one or consecutive periods), and up to the ﬁrst
5 years out of treatment (one or consecutive periods)
after ﬁrst admittance to OMT. Thus, the post-OMT
period was deﬁned as the sum of the time between
treatment periods and time after the last treatment
period. The total observation period was 1000 patient-
years before, 813 during and 91 after OMT. The date of
collection of their record from the local hospital (during
2008e9) was deﬁned as the study end-point for each
patient.
Inter-rater agreement
Inter-rater agreement was established in the pilot
study.24 We found high inter-rater reliability for whether
hospital treatment episodes were drug-related (k¼1)
and for categories among drug-related treatment
episodes (overdose, injecting-related or other, k¼0.82).
In this study, IS (the ﬁrst author) ﬁrst scrutinised all
full-text records. Treatment episodes considered difﬁcult
to categorise were discussed between IS and another
physician (the co-author ER) until consensus was
reached.
Statistical analyses
Incidence rates were analysed by means of a Poisson
regression model. Dependencies in the data, due to the
fact that each participant was measured repeatedly
(before, during and after OMT), were handled by
generalised estimating equations with unstructured
working correlation and robust variance estimation.
With regard to drug-related treatment episodes, we
investigated the possible inﬂuence of different patient
characteristics on the effect of OMT by including the
interaction between OMT and the characteristic in
question in the model, one by one. Incidence rate ratios
with 95% CIs were estimated. The signiﬁcance level was
set to 5%. All analyses were performed in SPSS v 15.
The study was approved by the Regional Committee
for Medical Research Ethics and the Norwegian Data
Inspectorate. Exemption from the duty of conﬁdentiality
and professional secrecy for those who had died was
granted by the Norwegian Directorate of Health.
RESULTS
Cohort characteristics
Sixty-six per cent of the cohort were men and the mean
age at the ﬁrst entry to maintenance treatment was
37 years. Methadone was prescribed to 67% and bupre-
norphine to 33% at the point of entry to the study. Mean
dosage for methadone was 122 mg and 17.6 mg for
buprenorphine. Fifty-one out of 200 (26%) had left
maintenance treatment once or more during the
observation period, while the rest had been in contin-
uous treatment since they were included. Mean age of
ﬁrst use of heroin was 21.1 years, and mean duration of
opioid dependence before OMT was 12.3 years. Thirty-
four per cent reported more than 10 overdoses during
their lifetime, 54% between one and 10, and 12%
reported none. Seventeen per cent had not completed
9 years of compulsory schooling, 50% had completed
9 years and 33% had 12 or more years of education.
Twenty-three per cent had <1 year of employment, 28%
between 1 and 5 years and 49% had more than 5 years of
work experience.
Among the patients who had experienced interruption
of maintenance treatment, 15% were assessed as stable
and drug-free when leaving OMT for the ﬁrst time, while
85% were assessed as unstable and taking drugs.
Changes in hospital-treated somatic disease incidents
Table 1 shows the rates of hospital treatment episodes due
to acute and subacute somatic disease incidents and the
rates for inpatient days and outpatient hospital contacts
for the various categories of episodes before, during and
after OMT. Table 2 displays the statistical signiﬁcance of
these changes by showing the incidence rate ratios
according to different OMT status; before versus during
OMTand after versus during OMT, respectively. A total of
1021 somatic disease incidents were registered: 605
before, 310 during and 106 after OMT.
The rate of all treatment episodes was 37% lower
during compared to the period before treatment (before
versus during OMT incidence rate ratio (IRR) 1.6 (95%
CI 1.3 to 1.9), p<0.001). The rate in the post-OMT
period was 197% higher compared to the period during
OMT (after versus during treatment IRR 2.8 (95% CI 2.1
to 3.9), p<0.001).
During treatment, the rate of all inpatient hospital
treatment days was 38% lower (before versus during
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treatment IRR 1.7 (95% CI 1.1 to 2.4), p¼0.01) and the
overall rate of outpatient hospital treatment contacts was
27% lower (before versus during treatment IRR 1.4
(95% CI 1.0 to 1.8), p¼0.04). After treatment the rate of
inpatient days was 5.1 times higher than during treat-
ment (IRR 5.9 (95% CI 3.6 to 9.6), p<0.001) and the
rate of outpatient hospital treatment was 2.6 times
higher (IRR 2.0 (95% CI 1.1 to 3.8), p¼0.03).
Drug-related disease incidents
The rate of drug-related hospital treatment episodes
was 76% lower during treatment than before (before
versus during IRR 4.2 (95% CI 2.9 to 6.2), p<0.001).
The rate of injecting-related episodes was 83% lower
(IRR 5.9 (95% CI 3.1 to 11.4), p<0.001) and the rate of
overdoses was 64% lower (IRR 2.8 (95% CI 1.6 to 5.0),
p<0.001) than before OMT. Among the injecting-related
episodes, local and systemic bacterial infections were the
most common. The rate of drug-related inpatient days
was 84% lower (IRR 6.3 (95% CI 3.4 to 11.8), p<0.001)
and the rate of outpatient contacts was 79% lower during
treatment compared to the pre-treatment period (IRR
4.8 (95% CI 2.7 to 8.3), p<0.001).
The post-OMT rate for drug-related treatment
episodes was higher than the rate before or during
treatment. Compared to the period during OMT,
the rate was 10.1 times higher (IRR 11.1 (95% CI 6.6 to
18.5), p<0.001). Overdoses after OMT were double
those before OMT and the overdose rate was 5.6 times
higher compared to the period during OMT (IRR 5.8
(95% CI 2.7 to 12.3), p<0.001). The rate of injecting-
related episodes was 14.2 times higher after than during
treatment (IRR 12.6 (95% CI 4.3 to 36.8), p<0.001),
the rate of inpatient days due to drug-related episodes
was 23.8 times higher (IRR 25.2 (95% CI 13.1 to 48.7),
p<0.001) and the rate of outpatient contacts was
10.3 times higher (IRR 10.6 (95% CI 4.7 to 25.9),
p<0.001).
Non-drug-related disease incidents
Non-drug-related treatment episodes were 35% more
frequent during treatment compared to the pre-OMT
Table 1 Acute/subacute hospital-treated somatic disease incidents: incidence rates and rates of inpatient days and outpatient
treatment contacts per 100 patient-years
OMT status
Before During After*
Incidence rates
All acute/subacute incidents 60.5 38.1 113.0
All drug-related incidents 31.9 7.5 75.7
Overdoses 10.4 3.7 20.8
Injecting-related, total** 14.2 2.4 34.0
Deep venous thrombosis/lung embolism 0.6 0.2 1.1
Acute hepatitis B and C 0.9 0.1 1.1
Local bacterial infections 8.5 1.5 19.7
Systemic bacterial infections 3.3 0.5 11.0
Other 0.9 0.1 1.1
Other drug-related, total** 7.3 1.4 20.8
Withdrawal-related 2.7 0.5 4.4
Impaired general condition 1.4 0.2 7.7
Neuromuscular 0.5 0.0 1.1
Other 2.7 0.6 7.7
All non-drug-related incidents 12.4 16.7 21.9
Infections 3.7 4.7 11.0
Other 8.7 12.1 11.0
Injuries 16.2 13.9 15.4
Treatment contact rates
Inpatient days per 100 patient-years 150.7 92.4 472.8
Drug-related 86.9 13.9 331.3
Non-drug-related 31.7 62.9 69.1
Injuries 32.1 15.6 72.4
Outpatient contacts per 100 patient-years 56.4 41.4 107.5
Drug-related 22.9 4.8 49.4
Non-drug-related 12.1 16.9 26.3
Injuries 21.4 19.8 31.8
The rates before and during OMT refer to all patients, while the rates after OMT refer exclusively to patients with interrupted OMT. Patient-years
at risk: 1000 before, 813 during and 91 after OMT. Number of incidents: 605 before, 310 during and 106 after OMT.
*After OMT is deﬁned as time out of treatment (one or more consecutive periods) after ﬁrst admittance to OMT, that is the sum of the time
between treatment periods and time after the last treatment period.
**Subgroups in italic.
OMT, opioid maintenance treatment.
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period (before versus during IRR 0.7 (95% CI 0.6 to 1.0),
p¼0.02) and both infections and other non-drug-related
episodes increased. After treatment there was a 31%
increase for all non-drug-related episodes versus the
period during OMT (IRR 1.4 (95% CI 0.9 to 2.2),
p¼0.15). The rates for inpatient days and outpatient
hospital treatment contacts showed similar changes.
Injuries
The changes in incidence and treatment contact rates
for injuries were minor and non-signiﬁcant.
Interaction between OMT status and patient characteristics
From the data in table 1 it is evident that changes
according to OMT status in the total number of hospital
treatment episodes are associated with changes in drug-
related treatment episodes. In the analysis of how the
effect of OMT status is inﬂuenced by various patient
characteristics, we therefore concentrated on drug-
related episodes alone. Table 3 shows the interaction
between the effect of maintenance treatment (OMT
status) and various patient characteristics, that is the
incidence rate ratio between the periods before and
during OMT for drug-related treatment episodes
adjusted for these characteristics.
In a comparison of patients who received continuous
maintenance treatment throughout the during-OMT
observation period versus those who left treatment once
or more, those with continuous treatment showed
greater incidence rate reduction during treatment than
those with interrupted treatment, although the latter still
showed signiﬁcant reduction versus the pre-treatment
period. After treatment, the group with interrupted
treatment showed an increase, with the incidence rate
ratio between the periods after and during OMT for this
group being 5.4 (3.0 to 9.7) (not shown in the table).
Patients with ongoing illicit drug-taking during OMT
showed less reduction in incidence rate during treat-
ment than patients not using illicit drugs. Even so, the
quartile taking most drugs showed a signiﬁcant reduc-
tion during versus before OMT (before versus during
IRR ratio 3.6 (2.4 to 5.3)).
Among the pre-OMT patient characteristics, only
employment history and years of opioid dependence
before OMT showed a signiﬁcant interaction with OMT
status in the period before versus during OMT. Individ-
uals with less work experience and fewer years of opioid
dependence, respectively, showed less reduction in inci-
dence rates during compared to before treatment.
Interaction was also tested for gender, age at OMT start,
lifetime number of overdoses, years of education and
age at heroin debut without showing any statistically
signiﬁcant interaction (p>0.1).
DISCUSSION
The study shows a substantial reduction in drug-related
hospital-treated incidents of somatic disease during
maintenance treatment compared to the pre-treatment
period. The reduction consists of less overdoses, and
fewer injecting-related and other drug-related treatment
episodes.
Overdoses are the most frequent cause of death among
dependent opioid users,10 and the 64% reduction in
overdoses during treatment is an important ﬁnding.
Several studies have documented reduced mortality
during OMT compared to the pre-OMT period9 26e32
and after leaving OMT,33e35 and the reduction in over-
doses found in the present study supports previous
ﬁndings of reduced mortality during OMT.
Table 2 Acute/subacute hospital-treated somatic disease
incidents: crude incidence rate ratios and treatment contact
rate ratios of inpatient days and outpatient hospital contacts
IRR/TCRR (95% CI) p Value
Before versus during OMT, during OMT as reference
(incidence rate[1)
All incidents 1.6 (1.3 to 1.9) <0.001
Drug-related* 4.2 (2.9 to 6.2) <0.001
Overdoses 2.8 (1.6 to 5.0) <0.001
Injecting-related 5.9 (3.1 to 11.4) <0.001
Other 5.7 (2.8 to 11.9) <0.001
Non-drug-related 0.7 (0.6 to 1.0) 0.02
Injuries 1.2 (0.9 to 1.5) 0.23
Inpatient days
Drug-related 6.3 (3.4 to 11.8) <0.001
Non-drug-related 0.5 (0.3 to 1.0) 0.04
Injuries 2.1 (0.7 to 5.7) 0.17
All 1.7 (1.1 to 2.4) 0.01
Outpatient contacts
Drug-related 4.8 (2.7 to 8.3) <0.001
Non-drug-related 0.7 (0.4 to 1.2) 0.18
Injuries 1.1 (0.7 to 1.6) 0.78
All 1.4 (1.0 to 1.8) 0.04
After versus during OMT, during OMT as reference
(incidence rate[1)
All incidents 2.8 (2.1 to 3.9) <0.001
Drug-related 11.1 (6.6 to 18.5) <0.001
Overdoses 5.8 (2.7 to 12.3) <0.001
Injecting-related 12.6 (4.3 to 36.8) <0.001
Other 16.7 (6.5 to 42.7) <0.001
Non-drug-related 1.4 (0.9 to 2.2) 0.15
Injuries 0.8 (0.3 to 1.8) 0.57
Inpatient days
Drug-related 25.2 (13.1 to 48.7) <0.001
Non-drug-related 1.1 (0.5 to 2.3) 0.78
Injuries 4.6 (0.8 to 28.5) 0.98
All 5.9 (3.6 to 9.6) <0.001
Outpatient contacts
Drug-related 10.6 (4.7 to 25.9) <0.001
Non-drug-related 1.6 (0.7 to 3.7) 0.26
Injuries 1.1 (0.4 to 3.1) 0.87
All 2.0 (1.1 to 3.8) 0.03
The incidence rate ratios indicate the statistical signiﬁcance of the
changes in incidence rates demonstrated in table 1, estimated by
Poisson regression (generalised estimating equations). Patient-
years at risk: 1000 before, 813 during and 91 after OMT. Number of
incidents: 605 before, 310 during and 106 after OMT.
IRR, incidence rate ratios; OMT, opioid maintenance treatment;
TCRR, treatment contact rate ratios.
*Subgroups in italic.
Skeie I, Brekke M, Gossop M, et al. BMJ Open 2011;1:e000130. doi:10.1136/bmjopen-2011-000130 5
Changes in somatic disease incidents during opioid maintenance treatment
group.bmj.com on August 31, 2012 - Published by bmjopen.bmj.comDownloaded from 
Injecting-related treatment episodes were also
substantially reduced (by 83%) during OMT. This may
have been due to those OMT patients who stopped
injecting and to others who continued to inject but at
a less frequent rate than before treatment.28 The
reduction includes all kinds of injecting-related episodes
among which local and systemic bacterial infections are
by far the most frequent. The local skin infections often
require surgical treatment and may give rise to severe
systemic infections as septicaemia, fasciitis, endocarditis,
osteomyelitis, discitis and others. Most of these condi-
tions are rare, but they are much more frequent among
injecting drug users than among the general popula-
tion.36 Such infections may be life-threatening and may
result in severe and permanent health problems, and
often necessitate complex, long-lasting and expensive
hospital treatment. When injecting-related health prob-
lems among drug users are considered, these apparently
less serious conditions are often overshadowed by the
focus on HIV and hepatitis C. However, some studies
indicate that the burden on the healthcare system due to
injecting-related local and systemic bacterial infections
may be even greater than that due to bloodborne
infections.37 The present study found that such bacterial
infections were frequent among dependent opioid users
and that they were substantially reduced during main-
tenance treatment.
Non-drug-related treatment episodes were found
to increase (by 35%) during OMT as compared to the
pre-OMT period. Inpatient days increased by 98% and
outpatient treatment contacts increased by 40%. The
reason for this may be closer contact with health services
during maintenance treatment. Within the OMT
programme, patients may receive healthcare that was not
previously available to them, leading to the diagnosis
and treatment of health problems that were previously
not identiﬁed.38 If so, this increase in non-drug-related
episodes may reﬂect improved access to health services
and not an increase in morbidity. It is theoretically
possible that this increase is due to adverse effects of
OMT, but we have found no evidence of this in our
scrutiny of the hospital records.
Drug-related treatment episodes and related inpatient
days and outpatient hospital contacts were more
frequent in the period after OMT compared to the
periods before OMT and during OMT. These rates apply
only to those patients who had left OMT. Although some
patients may remain drug-free after leaving OMT, it is
likely that many leave OMT, voluntarily or involuntarily,
because of ongoing drug-taking, opposition to
programme rules and control measures, or instability in
taking their OMT medication.10 25 31 Our data show that
only 15% of those who left OMT were assessed as stable
and drug-free at the time of leaving treatment. Patients
with interrupted maintenance treatment may therefore
constitute a patient subgroup with higher levels of risk-
taking behaviour and/or more serious health problems,
and the post-OMT results may be inﬂuenced by selection
bias. We therefore examined the interaction between
OMT status (incidence rates before versus during OMT)
and OMT cessation (having experienced OMT cessation
or not) and found less reduction in drug-related treat-
ment episodes in the cessation group compared to the
group with continuous treatment Nevertheless, even the
cessation group experienced a signiﬁcant reduction in
episodes of about 40%. After OMT cessation, however,
Table 3 Acute/subacute drug-related hospital-treated somatic disease incidents: interaction effect between OMT status
(before versus during OMT) and patient characteristics
Patient characteristics p Value for interaction Adjusted IRR (95% CI)
During-treatment characteristics
Interruption of OMT 0.001
Continuous treatment 6.1 (3.6 to 10.6)
Interrupted treatment 1.7 (1.0 to 2.9)
Drug-use during OMT (illicit opioids, cannabis,
benzodiazepines, central stimulants)
0.07
25th Percentile, quartile without drug use 6.5 (3.5 to 12.0)
75th Percentile, quartile with most drug use 3.6 (2.4 to 5.3)
Pre-treatment characteristics
Employment years 0.02
<1 year 2.6 (1.3 to 5.2)
1e5 years 4.1 (1.8 to 9.2)
>5 years 5.5 (2.7 to 11.2)
Opioid dependence before OMT, years 0.01
8 years (25th percentile) 3.3 (2.0 to 5.5)
16 years (75th percentile) 5.4 (3.1 to 9.4)
Adjusted incidence rate ratios (IRR) estimated by Poisson regression (generalised estimating equations) before versus during OMT, during
OMT as reference (incidence rate¼1). Only characteristics showing signiﬁcant interaction with OMT status are shown. Crude IRR are shown in
table 2. Interaction was also tested for gender, age at OMT start, lifetime number of overdoses, years of education and age at heroin debut
without showing signiﬁcant interaction (p>0.1).
Patient-years at risk: 1000 before, 813 during and 91 after OMT. Number of incidents: 605 before, 310 during and 106 after OMT.
IRR, incidence rate ratio; OMT, opioid maintenance treatment.
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they experienced a more than ﬁvefold increase
compared to the period during OMT. The high post-
OMT incidence rates, therefore, reﬂect an increase in
acute drug-related health problems after OMT cessation
among patients with treatment interruption, and cannot
be fully explained by selection effects. This is an
important ﬁnding that should stimulate increased
efforts to study the health effects of OMT cessation
and to improve responses to minimise the harmful
consequences.
Even the quartile taking most illegal drugs during
OMT showed a signiﬁcant 72% reduction in drug-related
treatment episodes during versus before treatment. This
indicates that not only patients with successful mainte-
nance treatment, but also patients with poor rehabilita-
tion results experience health improvement during OMT.
The present study focuses on acute/subacute hospital
treatment episodes. Injecting drug users experience
increased chronic morbidity that reduces their quality of
life8 39 40 and some studies based on interviews41 and
clinical assessment21 show a reduction in chronic health
problems during OMT. However, considering the high
mortality rate among injecting drug users,10 the often
life-threatening acute disease incidents comprise
a substantialdand perhaps the most importantdpart of
the morbidity pattern within this group.
The study has some limitations. First, the study
assessed acute/subacute hospital-treated disease inci-
dents and not morbidity as such. A key question is
whether changes in incidence and treatment rates
according to OMT status (before, during and after
OMT) reﬂect a change in morbidity; in other words,
whether these rates can be regarded as a proxy indicator
for morbidity. Information on hospital treatment outside
the local area was based on patient recall and some
disease incidents prior to treatment may have been
overlooked. In addition, closer contact with health
services during OMT probably increases patients’ help-
seeking, resulting in hospital treatment for health
problems that would not have been treated before OMT.
Further, the patients were 5 years older during than
before OMT, resulting in an age-dependent increase in
morbidity. Even so, we found a signiﬁcant reduction in
treatment episodes during OMT. Therefore, our ﬁnd-
ings most probably reﬂect a ‘true’ reduction in acute/
subacute incidents of somatic disease, and hence in
acute/subacute somatic morbidity, during compared to
before OMT.
Another limitation is that primary healthcare contacts
were not included in this study. In our previous study,24
however, general practitioner contacts were registered
and we found that about 80% of all acute somatic disease
incidents assessed as severe resulted in hospital treat-
ment both before and during OMT. The focus on
hospital treatment episodes should therefore provide an
adequate assessment of OMT-related changes in severe
acute health problems within the cohort. Also, the
cohort is relatively old, with a mean age at ﬁrst OMT
entry of 37 years and mean duration of opioid depen-
dence before the ﬁrst admission to OMT of 12 years.
This reﬂects the late introduction of OMT to Norway in
1998 with an accumulated demand for maintenance
treatment by older patients at programme start and
a high recommended age limit for OMT admittance
during the ﬁrst years.42 The cohort is typical of Norwe-
gian OMT patients, but the age distribution is no doubt
characterised by speciﬁc historical traits of the Norwe-
gian OMT programme and this might be a possible
limitation to the external validity of the study. However,
we did check the effect modiﬁcation of age at OMTentry
(no signiﬁcant interaction) and duration of opioid
dependence before ﬁrst OMT entry (less reduction
among patients with fewer years of dependence) on the
rates of drug-related treatment episodes before versus
during OMT.
Yet another limitation is that the list of diagnoses to
differentiate whether treatment episodes were drug-
related or not has not been validated by external
researchers and we could ﬁnd no similar list in the
literature. There may be some uncertainty about
whether some episodes were drug-related or not;
however, inter-rater reliability scores were high. There
were also analytical problems due to the fact that the
post-OMT observation period was only 91 years versus
1000 before and 813 during OMT. This is mainly due to
the high retention in OMT in Norway. The relatively few
post-OMT years at risk is a limitation in the study, but
with this design and the given retention in treatment,
the post treatment period will nevertheless be unbal-
anced compared to the periods before and during OMT.
The study also has certain strengths. These include the
high participation rate among patients in as well as out
of maintenance treatment at the time of invitation, the
access to all hospital records and the long observation
period. The overall participation rate was high (71%)
and more than 99% of requested hospital records were
obtained. Hence, selection bias was probably of limited
importance in the study. Further, the evaluation of
morbidity changes is based on in-depth assessment of
full-text hospital records which could be expected to give
more robust data than interview data or register data
alone.
Despite possible limitations in the study design, the
ﬁndings document a substantial reduction in acute and
subacute drug-related disease incidents leading to
hospital treatment during OMT compared to the period
before OMT. This reduction in somatic morbidity during
treatment seems also to be valid for patients with on-
going drug-taking during OMT. However, acute drug-
related health problems show an increase after OMT
cessation, and this is a matter of concern. Further studies
on somatic morbidity after OMT cessation should be
carried out.
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Abstract 
 
Background/aims: Some patients in opioid maintenance treatment (OMT) leave treatment 
temporarily or permanently. This study investigates whether patients interrupting their OMT 
differed from non-interrupters in socio-demographic and drug-use characteristics and 
investigates acute/sub-acute somatic morbidity among the interrupters, prior to, during, and 
after OMT.  
Methods: Cohort design. Observation period: 5 years prior to, up to first 5 years during, and 
up to 5 years after interruption of OMT. Participants: The sample (n=200) comprised 51 OMT 
interrupters and 149 non-interrupters. Data on patient characteristics obtained from interviews 
and OMT register information. Data on somatic morbidity from hospital records. 
Measurements: Key patient characteristics among OMT interrupters and non-interrupters. 
Incidence rates of acute and sub-acute somatic disease incidents leading to hospital treatment 
(drug-related/non-drug-related/injuries) prior to/during/after OMT.  
Results: Interrupters and non-interrupters did not differ in pre-OMT characteristics. 
Interrupters scored significantly higher on drug-taking and overdose during OMT but had a 
significant 49 % reduction in drug-related treatment episodes.  After interruption of treatment 
such episodes increased markedly and were 3.6 times more frequent during the first post-
OMT year compared to the pre-OMT period (p<0.001). This increase was highest during the 
first months after OMT interruption. 2-5 years after interruption there was no significant 
increase.  
Conclusions: Increased somatic morbidity was found among OMT interrupters during the first 
year after OMT, and especially during the immediate post-treatment period.  
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1. Introduction 
Opioid maintenance treatment (OMT) has been the most widely used treatment for opioid 
dependence worldwide during the last decades [1]. Several favourable outcomes for OMT are 
documented in the literature. Reduced mortality during OMT is shown in studies from 
different countries [2-8], and reduction in crime and related costs is well established [9-11], as 
are overall societal economic benefits [9]. Several studies indicate improved health during 
treatment based on self report [12, 13], clinical assessment [14] and reduced inpatient hospital 
treatment [15, 16].  
The favourable outcomes of OMT are primarily in-treatment effects. Less is known 
about the situation after interruption of treatment, although increased mortality after OMT 
interruption has been found in studies from several countries [2, 7, 17-19]. Possible effects of 
OMT interruption on somatic morbidity are yet poorly studied. Although in some high-
threshold programmes a substantial proportion of patients achieve a stable drug-free life after 
planned OMT cessation [15, 20], interruption of maintenance treatment must primarily be 
regarded as an indicator of treatment problems arising from patient and/or programme 
characteristics.  
A significant reduction in total drug-related acute and subacute somatic disease 
leading to hospital treatment for patients who entered OMT was reported in a previous paper 
from our group [21]. This reduction was also found among those who later interrupted their 
OMT, though it was less than among those without interruption of treatment. After OMT 
termination the interrupters had a five-fold increase in drug-related disease episodes compared 
to the in-treatment period. In the present paper we focus on those who had interruptions of 
their opioid maintenance treatment and investigate patient characteristics as well as the 
increase in somatic disease after OMT interruption. The research questions were: Do patients 
with interrupted OMT differ from other OMT patients in terms of problem behaviours? How 
does the incidence of somatic health problems within the interrupter group vary before and 
during OMT and especially throughout the post-OMT period? And, how is the incidence of 
such problems after OMT interruption influenced by patient characteristics? 
 
2. Material and Methods 
2.1 Design, sample and setting                                                                                                          
In Norway OMT was started in 1998 as a public nationwide programme organized in parallel 
with the public hospital catchment area orientation [22]. Thus OMT cohorts from one hospital 
catchment area may be studied, simplifying investigation of hospital treatment among OMT 
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patients. The study cohort was established in 2007/2008 and consisted of patients who started 
OMT from 1998 until end of June 2007 in two counties (Hedmark and Oppland) in Norway. 
Out of a total of 319 patients who started OMT during this period, 38 could not be reached as 
they had no contact with local health- and social services and these were regarded as 
ineligible. Among the 281 eligible, 187 consented to participate, 81 did not. Thirteen who had 
died after their first OMT admittance were included rendering a study cohort of 200 persons. 
Fifty-one of these (26 %) had experienced interruption of OMT at least once and these are the 
focus of this paper. The overall participation rate was 71.2 % (73.7 % among persons not in 
treatment when invited versus 68.8 % among those in treatment).  
Interruption of OMT could be planned or unplanned. Unplanned interruption was 
defined as any unplanned stop of OMT medication (methadone or buprenorphine) lasting for 
more than five days [23]. When patients voluntarily or involuntarily were tapering off OMT 
medication, interruption was defined as the first day without medication. 
  
2.2 Measures and data collection  
Out of the 187 included who were alive, 136 (73 %), 35 with interrupted treatment and 101 
with continuous treatment, underwent a structured interview which provided information on 
personal data, former hospital contacts, drug history as well as education and employment 
history. 
Records from somatic departments in the local hospitals were collected for all 
participants. Based on information from these records and from the interviews, records from 
other hospitals were gathered and more than 99 % of all requested records were collected. The 
number of somatic disease incidents resulting in hospital treatment was counted. Somatic 
disease incidents were defined as any acute or sub-acute somatic health problem leading to 
inpatient or outpatient hospital contact, below referred to as “hospital treatment episodes”. 
Elective hospital treatment due to chronic somatic disorders was not included, but acute 
episodes caused by an underlying chronic disease were registered as new incidents. One 
treatment episode could lead to more than one contact. An episode documented in records 
from several hospitals was counted as one episode only. Psychiatric disease incidents were 
not included unless they caused a somatic condition e.g. due to self harm.  
Incidence rates of these treatment episodes were the primary outcome measure and 
were estimated separately for the periods prior to and during OMT, and for different post-
OMT sub-periods. Incidence rate ratios prior to versus during and after versus during 
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treatment were estimated, as well as post-OMT time sequence comparisons versus the pre-
OMT period.  
Information about ongoing drug use during OMT and interruption of OMT was 
gathered from annual reports on each participant from the national OMT programme. These 
reports separately record the use of illicit opioids, cannabis, benzodiazepines, and central 
stimulants during the previous four weeks based on urine tests and clinical assessment.  A 
combined score for all four substance classes for the whole OMT period was made for each 
patient, based on the annual evaluations. Such scores were obtained for 183 participants (91.5 
%), 47 (92.2 %) with interrupted treatment and 136 (91.3 %) with continuous treatment. 
 
2.3 Observation period 
Hospital record data for each participant were gathered for the five years prior to the first 
admission to OMT, up to the first five years in treatment (one or consecutive periods), and up 
to the first five years after interruption of OMT (one or consecutive periods). Time between 
OMT periods and after the last period was registered as post-OMT. Post-OMT somatic 
treatment episodes were registered according to the end of the preceding treatment period and 
divided into different post-OMT sub-periods: month one, months two and three , months four 
to twelve, and year two to five (”later post-OMT period”). Total pre-OMT observation time 
was 255 years (mean individual observation time=5 years). Total during-OMT observation 
time was 193 years (mean individual observation time=3.8 years). Total post-OMT 
observation time was 91 patient years (mean individual observation time=1.8 years); 50 
patient years the first year post OMT and 41 the second to fifth year post OMT. The study 
end-point for each patient was defined as the date when the record from the local hospital was 
collected during 2008/2009.   
 
2.4 Categories of disease incidents 
Hospital treatment episodes were categorised as drug-related (overdoses, injecting-related, 
other), non-drug-related or injuries. Among injecting-related episodes were deep venous 
thrombosis/lung embolism, acute hepatitis B and hepatitis C, local injection site bacterial 
infections and systemic bacterial infections assessed as related to injecting. Among “other 
drug-related episodes” were withdrawal-related episodes, incidents related to impaired 
general condition due to problem drug use and neuromuscular conditions. Inter-rater 
agreement on whether treatment episodes were drug-related or not (κ =1) and on sub-
categories among drug-related episodes (overdose, injecting-related or other, κ = 0.82) was 
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established in a pilot study [24]. In the present study, IS (first author) examined all full-text 
records. Treatment episodes considered problematic to categorise were discussed between IS 
and ER (co-author) until consensus was reached. 
 
2.5 Statistics 
Patient characteristics in the groups with and without interruption of OMT were compared by 
Pearson Chi-Square-test or Fishers exact test for categorical variables and Independent-
Samples T-test for continuous variables. Incidence rates for treatment episodes were analyzed 
using a Poisson regression model. Incidence rates and incidence rate ratios with 95 % 
confidence intervals were estimated and the significance level was set to 5 %. Dependencies 
in the data, as each participant was measured repeatedly (before – during – after OMT), were 
handled by Generalized Estimating Equations with unstructured working correlation and 
robust variance estimation. Influence of patient characteristics on the health effects of OMT 
interruption was investigated by including an interaction term between OMT status and the 
characteristic in question in the model, one by one. Statistical analysis was performed in SPSS 
ver. 15. 
 
2.6 Ethics 
The study was approved by the Regional Committee for Medical Research Ethics and the 
Norwegian Social Science Data Services. Exemption from professional secrecy duty of 
confidentiality for those dead was given by the Norwegian Directorate of Health.    
 
... Table 1 about here… 
 
3. Results 
3.1 Sample characteristics 
OMT interrupters (N=51) and non-interrupters (N=149) were compared for gender, age at 
admission to OMT, age at first heroin use, years of opioid dependence prior to OMT, lifetime 
number of overdoses as well as for employment and education history. No statistically 
significant differences were found.  Scores for ongoing drug-taking and for overdoses during 
OMT were significantly higher among those who interrupted their treatment. 
 Table 1 compares hospital treatment episodes prior to OMT for interrupters and non-
interrupters. Except for injuries, which were significantly more frequent among interrupters 
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and ”other drug-related episodes” which were found to be significantly more frequent among 
non-interrupters, there were no significant differences between the groups.    
 
… Table 2 about here …. 
 
3.2 Time sequence analysis of somatic disease episodes 
The total number of drug-related treatment episodes showed a statistically significant 
reduction during OMT compared to before OMT (Table 2). When regarded separately, 
overdoses, injecting-related and other drug-related episodes did not show a statistically 
significant reduction.  During the total post-OMT period drug-related episodes were 5.6 times 
more frequent than during OMT and overdoses, injecting-related and other drug-related 
episodes all increased significantly when assessed separately. Non-drug-related treatment 
episodes and injuries did not differ significantly according to OMT status. 
Figure 1 shows rates for the various groups of treatment episodes prior to and during 
treatment and during the post-OMT time sequences for patients with interrupted OMT. Table 
3 shows incidence rate ratios between post-OMT year one and post-OMT years two to five 
respectively, compared to the pre-OMT period. The overall increase in drug-related treatment 
episodes was greatest during the first months after OMT interruption and overdoses were 
especially frequent the first four weeks. Among the injecting-related episodes, local skin 
infections and systemic bacterial infections showed the greatest increase after OMT 
interruption. Treatment contacts due to “impaired general health condition” also increased 
substantially. Non-drug-related episodes showed a significant increase during the first post-
OMT year compared to the pre-OMT period, while injuries showed stable rates throughout 
the whole observation period. With regard to post-OMT years two to five (“later post-OMT 
period”), there was no significant increase in drug-related or non-drug-related episodes 
compared to the pre-OMT period.  
 
… Figure 1 about here … 
 
3.3 Effect modification  
An interaction of borderline statistical significance (p=0.06) within the interrupter group was 
found between gender and OMT status (first post-OMT year versus pre-OMT period): among 
men drug-related episodes were five times more frequent post-OMT (IRR 5.0 (2.8 – 8.9)), 
among women 2.3 times more frequent (IRR 2.3 (1.1 – 4.6)). Age at OMT start, years of 
 
 
8 
employment, years of education and overdoses during lifetime did not interact significantly. 
In-treatment characteristics (drug-taking during OMT, overdoses during OMT and having 
experienced more than one OMT interruption during the observation period) were also tested 
but did not interact significantly with OMT status. For 41 out of the 51 interrupters data on 
drug-taking at first OMT interruption were available. Six out of the 41 (15 %) were described 
as leaving OMT voluntarily and not taking drugs at that time. However, the increase in drug-
related treatment episodes the first year after treatment compared to the pre-treatment period 
was the same among these as among the remaining 35 who left OMT in a non-stabilized 
phase. 
 
… Table 3 about here … 
 
4. Discussion 
4.1 Main findings 
The group with interrupted OMT contact did not differ from the non-interrupters with regard 
to pre-treatment characteristics, including acute somatic health problems prior to the first 
OMT admittance. However, interrupters took more drugs and were more exposed to 
overdoses and experienced less reduction in drug-related health problems during OMT. Only 
15 % of the interrupters were rated as drug-free and stable when leaving treatment, the rest 
left treatment while taking illicit drugs and being in an unstable situation. Interruption of 
OMT was therefore, for the majority, related to problems in treatment.  
The first year after interruption of OMT drug-related morbidity was increased, not 
only when compared to the in-treatment period, but also to the period prior to OMT. The 
increase comprised overdoses, injecting-related problems and other drug-related health 
problems as well as non-drug-related problems. These findings are most likely related to 
relapse to heroin use as opioid dependent persons are known to be at high risk of relapsing 
after leaving OMT [25]. The findings support the view that interruption of maintenance 
treatment is a high-risk situation.  
Among the injecting-related treatment episodes injecting site infections and invasive 
bacterial infections like septicaemia, deep soft-tissue infections and endocarditis were most 
common after exit from OMT. These conditions can be severe, they may cause permanent 
health damage and may sometimes be life-threatening and they often result in complicated, 
expensive and long-lasting hospital treatment [26].  
 
 
9 
Surprisingly, we found no difference between the patients assessed as drug-free when 
leaving OMT (15 %) and those taking drugs. However, as the drug-free group is small, only 
six patients, this result should be interpreted with caution, but it may reflect the difficulties 
achieving a stable drug-free life after OMT cessation.   
 
4.2 Limitations and strengths 
One of the limitations of the study is that hospital-treated somatic disease incidents 
were assessed, and not morbidity as such. However, despite a probable closer contact to 
health- and social services during maintenance treatment, and an expected increased 
morbidity due to increasing age, we found a significant reduction in drug-related treatment 
episodes during OMT among the interrupters. This most probably reflects a substantial 
reduction in drug-related somatic morbidity. The increase in drug-related treatment episodes 
found in the first post-OMT year most certainly reflects a major increase in somatic morbidity 
due to drug taking activities. 
 Another limitation is that the sample includes only 51 OMT interrupters and that the 
overall post-OMT patient years are limited, especially from post-OMT year two on. This 
leads to fewer episodes and lower statistical power, exemplified by the number of drug-
related treatment episodes where the total number of episodes showed a significant reduction 
during OMT, while when examining each specific type of drug-related episodes, no 
significant reductions were found although the estimated effects were equally large. 
Further, only hospital contacts were examined, as the study did not assess less severe 
morbidity not resulting in hospital contact. However, hospital treatment episodes were 
considered sufficient to evaluate changes in severe and potentially life-threatening acute 
morbidity. Finally, the list of disease categories differentiating between drug-related and non-
drug-related episodes, and between injecting-related and non-injecting-related incidents was 
not validated by external researchers.   
Among the strengths of the study are the long pre-, during- and post-OMT observation 
periods that made it possible to study long-term health effects of being in OMT and of leaving 
treatment. The high participation rate makes it probable that the study sample is representative 
for the OMT interrupters in this region. Also, participants were recruited from a particular 
catchment area enabling a comprehensive cohort with defined health service connections.  
This made it possible to trace almost all hospital contacts. And, as evaluation of morbidity 
changes is based on in-depth examination of full-text records, and almost all requested 
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records were obtained, the data should be more robust, specific and reliable than interview 
and register data alone.  
 
4.3 Treatment implications 
Our findings have implications regarding the handling of “problem patients” in OMT 
programmes.  Often, OMT interruption will coincide with a crisis in treatment and any 
problems at that time may continue or deteriorate after leaving treatment. This should draw 
attention to the need for proactive follow-up when treatment crises emerge, in order to prevent 
OMT interruption [27]. Patients should not be subject to involuntary discharge from OMT 
unless continued treatment is considered to increase their mortality and morbidity risks. In 
general, treatment services should seek to retain “problem patients” in treatment [12]. Re-
admittance to OMT should be prompt when patients are ready for it.  
 
 
 
5. Conclusion 
The study shows a significant reduction in drug-related somatic disease incidents during OMT 
compared to the five years before entering OMT in patients who later interrupted their 
maintenance treatment. Interrupters and non-interrupters did not differ in pre-treatment 
characteristics, but interrupters took more illegal drugs and had more overdoses during OMT. 
For the great majority interruption of OMT was closely related to problems in treatment, 
especially ongoing illicit drug-taking. Nevertheless there was a substantial increase in drug-
related somatic health problems during the first year after OMT interruption, compared both 
to the pre- and during-OMT periods. The increase was greatest the first months after leaving 
OMT, and especially the first month. This suggests relapse to extensive drug use and risk-
taking behaviour. Hence, it should generally be a goal to keep “problem patients” in 
treatment.  Patients interrupting OMT should receive special follow-up.   
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Table 1.  Somatic disease incidents treated in hospital: incidence rates per 100 patient 
years (95 % confidence interval) the five years prior to the first admission to OMT 
among patients with and without interruption of OMT.     
        
 
    Interrupted OMT Continuous OMT  P-value 
  (N=51)  (N=149) 
 
All drug-related  27.5  (21.7 – 34.7) 33.4   (29.5 – 37.8)  0.15   
 
Overdoses      11.0   (7.6 – 15.9) 10.2   (8.1 – 12.8)  0.74   
Injecting-related  12.2   (8.6 – 17.3) 14.9   (12.4 – 17.9)  0.32  
Other           4.3   (2.4 – 7.8)   8.3   (6.5 – 10.7)  0.05*  
 
All non-drug-related  12.5   (8.9 – 17.7) 12.3   (10.1 – 15.1)  0.94  
Injuries    21.2   (16.2 – 27.7) 14.5   (12.0 – 17.5)  0.02*  
 
All incidents   61.2   (52.3 – 71.6) 60.3   (54.9 – 66.1)  0.99  
 
 
* Statistically significant difference between the groups with interrupted versus continuous OMT, 
Poisson regression. 
 
Note:  Years at risk before OMT: 1000 years (255 in OMT interrupters).  Number of incidents before 
OMT: 605 (156 in OMT interrupters). Among injecting-related disease incidents were reckoned deep 
venous thrombosis/lung embolism, acute hepatitis B and hepatitis C as well as local and systemic 
infections assessed as related to injecting. 
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Table 2.   Hospital-treated somatic disease incidents in patients with interrupted opioid 
maintenance treatment (N=51): crude incidence rate ratios (IRR) according to OMT 
status (before, during, and after treatment).   
 
 
 
Before versus during OMT:  during treatment as reference (incidence rate=1) 
 
 
    IRR  CI 95 % p-value 
 
All drug-related   1.7 1.0 - 2.9  0.04 
 
Overdoses    2.4 0.9 - 6.1  0.08 
Injecting-related      1.5 0.8 - 2.7  0.18 
Other    2.0 0.5 - 7.5  0.33 
 
Non-drug-related  0.8 0.5 - 1.5  0.54 
 
Injuries       1.1 0.7 - 1.6  0.80 
 
All incidents   1.3 0.9 - 1.8  0.16 
 
 
 
After OMT versus during OMT: during treatment as reference (incidence rate =1) 
 
 
All drug-related   5.6 3.0 – 9.8 <0.001 
 
Overdoses   4.7 1.7 – 12.6 0.003 
Injection-related   4.7 1.9 – 11.2 0.001 
Other                10.3 2.7 – 39.0 0.001 
  
Non-drug-related  1.6 0.8 – 2.8 0.12 
 
Injuries    0.8 0.4 – 1.4 0.41 
 
All incidents   2.5 1.7 – 3.5 <0.001 
 
 
Note: Years at risk: Before OMT 255 years, during OMT 193 years, after OMT 91. Number of incidents: Before 
OMT 156, during OMT 94, after OMT 104.  Poisson regression model (Generalized Estimating Equations). 
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Table 3.  Hospital-treated somatic disease incidents among patients with interrupted 
OMT (N=51): crude incidence rate ratios (IRR) between post-OMT year 1 and  post-
OMT years 2-5 respectively compared to the five last years before the first admittance to
OMT.  
 
 
 
Post-OMT year 1 versus pre-OMT period 
 
 
IRR   CI 95 % p-value 
 
All drug-related   3.6  2.3 - 5.6  <0.001 
 
Overdoses   2.9  1.4 - 6.4  0.006 
Injecting-related   2.6  1.3 - 4.9  0.005 
Other    7.7               3.4- 17.4  <0.001 
 
Non-drug-related  2.6  1.4 - 4.6  <0.001 
 
Injuries    0.6  0.3 - 1.3  0.23 
 
All incidents   2.3  1.7 - 3.2  <0.001 
 
 
 
Post-OMT years 2-5 versus pre-OMT period  
 
 
IRR   CI 95 % p-value 
 
All drug-related   2.0  0.9 – 4.5 0.11 
 
Overdoses   0.7  0.2 – 2.2 0.49 
Injecting-related   2.9  0.9 – 9.4 0.09 
Other    2.3               0.9 – 6.0  0.08 
 
Non-drug-related  1.0  0.4 – 2.3 0.93 
 
Injuries    0.8  0.4 – 1.9 0.66 
 
All incidents   1.4  0.8 – 2.4 0.22 
 
 
Note: IRR estimated by Poisson regression. Patient years at risk: 255 before OMT, 50 the first year post OMT, 
41 the second to fifth year post OMT. Number of incidents: 156 before OMT, 70 the first year post OMT, 34 the 
second to the fifth years post OMT. 
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